


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T13:52:32Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12406664" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12406664</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>aac</setSpec>
        
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Antimicrob Agents Chemother</journal-id><journal-id journal-id-type="iso-abbrev">Antimicrob Agents Chemother</journal-id><journal-id journal-id-type="pmc-domain-id">82</journal-id><journal-id journal-id-type="pmc-domain">aac</journal-id><journal-id journal-id-type="publisher-id">aac</journal-id><journal-title-group><journal-title>Antimicrobial Agents and Chemotherapy</journal-title></journal-title-group><issn pub-type="ppub">0066-4804</issn><issn pub-type="epub">1098-6596</issn><publisher><publisher-name>American Society for Microbiology (ASM)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12406664</article-id><article-id pub-id-type="pmcid-ver">PMC12406664.1</article-id><article-id pub-id-type="pmcaid">12406664</article-id><article-id pub-id-type="pmcaiid">12406664</article-id><article-id pub-id-type="pmid">40772826</article-id><article-id pub-id-type="doi">10.1128/aac.00454-25</article-id><article-id pub-id-type="publisher-id">aac00454-25</article-id><article-id pub-id-type="publisher-id">aac.00454-25</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Pharmacology</subject></subj-group><subj-group subj-group-type="biological-terms"><compound-subject><compound-subject-part content-type="code">antimicrobial-chemotherapy</compound-subject-part><compound-subject-part content-type="label">Antimicrobial Chemotherapy</compound-subject-part></compound-subject></subj-group></article-categories><title-group><article-title>New derivatives of 6-nitrocoumarin-3-thiosemicarbazone exhibit improved antiparasitic activity in the placenta against <italic toggle="yes">Trypanosoma cruzi</italic> and <italic toggle="yes">Toxoplasma gondii</italic></article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Rocha-Valderrama</surname><given-names initials="E">Esteban</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Rost&#225;n</surname><given-names initials="S">Santiago</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Fern&#225;ndez</surname><given-names initials="M">Mercedes</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Liempi</surname><given-names initials="A">Ana</given-names></name><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Castillo</surname><given-names initials="C">Christian</given-names></name><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mahler</surname><given-names initials="G">Graciela</given-names></name><xref rid="aff6" ref-type="aff">
<sup>6</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Galarza-Jarrin</surname><given-names initials="A">Ambar</given-names></name><xref rid="aff7" ref-type="aff">
<sup>7</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9418-6640</contrib-id><name name-style="western"><surname>Costales</surname><given-names initials="JA">Jaime A.</given-names></name><xref rid="aff7" ref-type="aff">
<sup>7</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Pozo-Mart&#237;nez</surname><given-names initials="J">Josu&#233;</given-names></name><xref rid="aff7" ref-type="aff">
<sup>7</sup>
</xref><xref rid="aff8" ref-type="aff">
<sup>8</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Olea-Azar</surname><given-names initials="C">Claudio</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3569-1660</contrib-id><name name-style="western"><surname>Otero</surname><given-names initials="L">Luc&#237;a</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="cor2" ref-type="corresp"/><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><email>luotero@fq.edu.uy</email></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-1733-9126</contrib-id><name name-style="western"><surname>Moncada-Basualto</surname><given-names initials="M">Mauricio</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="cor1" ref-type="corresp"/><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review and editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review and editing</role><email>mmoncadab@utem.cl</email></contrib><aff id="aff1"><label>1</label><institution-wrap><institution>Instituto Universitario de Investigaci&#243;n y Desarrollo Tecnol&#243;gico, Universidad Tecnol&#243;gica Metropolitana</institution><institution-id institution-id-type="ringgold">28092</institution-id><institution-id institution-id-type="ror">https://ror.org/0481m0575</institution-id></institution-wrap>, <city>Santiago</city>, <country>Chile</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution>Inorganic and Analytical Department, Free Radical and Antioxidants Laboratory, Faculty of Chemical and Pharmaceutical Sciences, University of Chile</institution><institution-id institution-id-type="ringgold">14655</institution-id><institution-id institution-id-type="ror">https://ror.org/047gc3g35</institution-id></institution-wrap>, <city>Santiago</city>, <country>Chile</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution>&#193;rea Qu&#237;mica Inorg&#225;nica, DEC, Facultad de Qu&#237;mica, Universidad de la Rep&#250;blica</institution><institution-id institution-id-type="ringgold">201894</institution-id></institution-wrap>, <city>Montevideo</city>, <country>Uruguay</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution>Graduate Program in Chemistry, Facultad de Qu&#237;mica, Universidad de la Rep&#250;blica</institution><institution-id institution-id-type="ringgold">201894</institution-id></institution-wrap>, <city>Montevideo</city>, <country>Uruguay</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution>Programa de Biolog&#237;a Integrativa, Instituto de Ciencias Biom&#233;dicas, Facultad de Medicina, Universidad de Chile</institution><institution-id institution-id-type="ror">https://ror.org/047gc3g35</institution-id></institution-wrap>, <city>Santiago</city>, <country>Chile</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution>Departamento de Qu&#237;mica Org&#225;nica, Laboratorio de Qu&#237;mica Farmac&#233;utica, Facultad de Qu&#237;mica, Universidad de la Rep&#250;blica</institution><institution-id institution-id-type="ringgold">201894</institution-id></institution-wrap>, <city>Montevideo</city>, <country>Uruguay</country></aff><aff id="aff7"><label>7</label><institution-wrap><institution>Centro de Investigaci&#243;n para la Salud en Am&#233;rica Latina, Pontificia Universidad Cat&#243;lica del Ecuador</institution><institution-id institution-id-type="ringgold">27884</institution-id><institution-id institution-id-type="ror">https://ror.org/02qztda51</institution-id></institution-wrap>, <city>Quito</city>, <state>Pichincha</state>, <country>Ecuador</country></aff><aff id="aff8"><label>8</label><institution-wrap><institution>Laboratorio de Qu&#237;mica-M&#233;dica, Facultad de Ciencia y Tecnolog&#237;a, Universidad del Azuay</institution><institution-id institution-id-type="ringgold">27892</institution-id><institution-id institution-id-type="ror">https://ror.org/037xrmj59</institution-id></institution-wrap>, <city>Cuenca</city>, <state>Azuay</state>, <country>Ecuador</country></aff></contrib-group><contrib-group><contrib contrib-type="editor"><role>Editor</role><name name-style="western"><surname>Odom John</surname><given-names initials="A">Audrey</given-names></name><aff><institution-wrap><institution>The Children's Hospital of Philadelphia</institution></institution-wrap>, <city>Philadelphia</city>, <state>Pennsylvania</state>, <country>USA</country></aff></contrib></contrib-group><author-notes><corresp id="cor1">Address correspondence to Mauricio Moncada-Basualto, <email xlink:href="mailto:mmoncadab@utem.cl">mmoncadab@utem.cl</email></corresp><corresp id="cor2">Address correspondence to Luc&#237;a Otero, <email xlink:href="mailto:luotero@fq.edu.uy">luotero@fq.edu.uy</email></corresp><fn fn-type="equal"><p>Esteban Rocha-Valderrama and Santiago Rost&#225;n contributed equally to this article. Author order was determined alphabetically.</p></fn><fn fn-type="COI-statement"><p>The authors declare no conflict of interest.</p></fn></author-notes><pub-date publication-format="electronic" date-type="collection"><month>9</month><year>2025</year></pub-date><pub-date date-type="pub" publication-format="electronic"><day>07</day><month>8</month><year>2025</year></pub-date><volume>69</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">496152</issue-id><elocation-id>e00454-25</elocation-id><history><date date-type="received"><day>20</day><month>3</month><year>2025</year></date><date date-type="accepted"><day>13</day><month>6</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>07</day><month>08</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 10:25:45.023"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2025 Rocha-Valderrama et al.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Rocha-Valderrama et al.</copyright-holder><ali:free_to_read start_date="2025-08-07"/><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International license</ext-link>.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="aac.00454-25.pdf"/><self-uri content-type="pdf" xlink:href="aac.00454-25.pdf"/><abstract abstract-type="primary"><title>ABSTRACT</title><p>Congenital infections by <italic toggle="yes">Trypanosoma cruzi</italic> and <italic toggle="yes">Toxoplasma gondii</italic> pose significant clinical challenges due to the lack of safe and effective treatments. This study evaluates eight novel 6-nitrocoumarin-3-thiosemicarbazone derivatives in an <italic toggle="yes">ex vivo</italic> human placenta model, assessing their antiparasitic activity and impact on tissue integrity. Two therapeutic approaches were tested: pre-infection (preventive) and post-infection (therapeutic). <italic toggle="yes">In vitro</italic> and <italic toggle="yes">ex vivo</italic> assays revealed strong activity trends. Compound <bold>7</bold> was the most effective against <italic toggle="yes">T. cruzi</italic> (IC<sub>50</sub> = 22.4 &#177; 0.8 &#181;M, logP = 2.49), while compound <bold>1</bold> exhibited the highest activity against <italic toggle="yes">T. gondii</italic> (IC<sub>50</sub> = 17.3 &#177; 0.5 &#181;M, logP = 1.44). Unlike current treatments, none of the compounds induced placental tissue damage, preserving trophoblast function. Structure-activity relationship (SAR) analysis identified an inverse correlation between lipophilicity and antiparasitic activity in <italic toggle="yes">T. gondii</italic>, where polar compounds were more effective. In <italic toggle="yes">T. cruzi</italic>, higher lipophilicity favored trypanocidal activity, suggesting differential cell permeability mechanisms. Mechanistic studies using electrochemistry and electron spin resonance (ESR) demonstrated that nitro group bioreduction promotes ROS generation, explaining activity against <italic toggle="yes">T. cruzi</italic>. By contrast, lower ROS levels in <italic toggle="yes">T. gondii</italic> suggest alternative mechanisms. This study validates the <italic toggle="yes">ex vivo</italic> human placenta model as a clinically relevant platform for antiparasitic drug screening. The findings highlight 6-nitrocoumarin-3-thiosemicarbazones as promising early-stage candidates that warrant further optimization to develop safer and more effective therapies for congenital infections.</p></abstract><kwd-group><title>KEYWORDS</title><kwd>6-nitrocoumarin-3-thiosemicarbazone</kwd><kwd><italic toggle="yes">Trypanosoma cruzi</italic></kwd><kwd><italic toggle="yes">Toxoplasma gondii</italic></kwd><kwd><italic toggle="yes">in vitro</italic> and <italic toggle="yes">ex vivo</italic> models</kwd></kwd-group><funding-group specific-use="FundRef"><award-group award-type="grant" id="award-1"><funding-source><institution-wrap><institution>Pontificia Universidad Cat&#243;lica del Ecuador</institution><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100011749</institution-id></institution-wrap></funding-source><award-id>QINV0416-IINV529010300</award-id><principal-award-recipient><name name-style="western"><surname>Costales</surname><given-names>Jaime A.</given-names></name></principal-award-recipient></award-group><award-group award-type="grant" id="award-2"><funding-source><institution-wrap><institution>Agencia Nacional de Investigacion y Desarrollo, ANID</institution></institution-wrap></funding-source><award-id>11220310</award-id><principal-award-recipient><name name-style="western"><surname>Castillo</surname><given-names>Christian</given-names></name></principal-award-recipient></award-group><award-group award-type="grant" id="award-3"><funding-source><institution-wrap><institution>Agencia Nacional de Investigacion y Desarrollo, ANID</institution></institution-wrap></funding-source><award-id>11240973</award-id><principal-award-recipient><name name-style="western"><surname>Moncada-Basualto</surname><given-names>Mauricio</given-names></name></principal-award-recipient></award-group><award-group award-type="grant" id="award-4"><funding-source><institution-wrap><institution>Agencia Nacional de Investigacion y Desarrollo, ANID</institution></institution-wrap></funding-source><award-id>1230644</award-id><principal-award-recipient><name name-style="western"><surname>Olea-Azar</surname><given-names>Claudio</given-names></name></principal-award-recipient></award-group><award-group award-type="grant" id="award-5"><funding-source><institution-wrap><institution>Agencia Nacional de Investigacion y Desarrollo, ANID</institution></institution-wrap></funding-source><award-id>3230385</award-id><principal-award-recipient><name name-style="western"><surname>Pozo-Mart&#237;nez</surname><given-names>Josu&#233;</given-names></name></principal-award-recipient></award-group><award-group award-type="grant" id="award-6"><funding-source><institution-wrap><institution>Agencia Nacional de Investigacion y Desarrollo, ANID</institution></institution-wrap></funding-source><award-id>EQM230118</award-id><principal-award-recipient><name name-style="western"><surname>Moncada-Basualto</surname><given-names>Mauricio</given-names></name></principal-award-recipient></award-group><award-group award-type="grant" id="award-7"><funding-source><institution-wrap><institution>Competition for Research Regular Projects</institution></institution-wrap></funding-source><award-id>LPR22-01</award-id><principal-award-recipient><name name-style="western"><surname>Moncada-Basualto</surname><given-names>Mauricio</given-names></name></principal-award-recipient></award-group></funding-group><counts><count count="0" count-type="supplementary-material"/><count count-type="authors" count="12"/><fig-count count="15"/><table-count count="7"/><equation-count count="0"/><ref-count count="91"/><page-count count="39"/><word-count count="20786"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>September 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><title>INTRODUCTION</title><p>Zoonotic infections caused by protozoa, such as <italic toggle="yes">Trypanosoma cruzi</italic> and <italic toggle="yes">Toxoplasma gondii</italic>, represent important public health problems due to their high morbidity, socioeconomic impact, and the limitations of current treatments. Congenital transmission of both diseases poses a significant challenge, as it affects vulnerable populations such as newborns and their mothers, generating severe complications for both neonatal development and maternal health (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>). Chagas disease, caused by <italic toggle="yes">T. cruzi</italic>, affects more than 6 million people in Latin America, with 70 million individuals at risk of infection. Although traditionally considered an endemic disease, its prevalence has increased in non-endemic regions due to factors such as migration and congenital transmission, the latter responsible for a considerable proportion of cases in developed countries (<xref rid="B3" ref-type="bibr">3</xref>).</p><p>On the other hand, toxoplasmosis, caused by <italic toggle="yes">T. gondii</italic>, affects 30% of the world&#8217;s population, with a significant clinical impact on immunocompromised individuals and pregnant women. Vertical transmission of <italic toggle="yes">T. gondii</italic> can cause spontaneous abortion, congenital malformations, and severe neurological sequelae in the newborn (<xref rid="B4" ref-type="bibr">4</xref>). Both infections share complex transmission mechanisms involving interactions between the parasite, the placental barrier, and maternal-fetal immune responses (<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B6" ref-type="bibr">6</xref>). In this context, human placental explant (HPE) models have emerged as valuable tools to study tissue infection, assess damage to the placental barrier, and analyze the effect of new compounds on placental tissue (<xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B8" ref-type="bibr">8</xref>).</p><p>Current treatments for Chagas disease and toxoplasmosis have significant limitations in efficacy and safety, particularly during pregnancy. In the case of <italic toggle="yes">T. cruzi</italic>, the nitro compounds benznidazole (BNZ) and nifurtimox (NFX) are the main therapeutic options (<xref rid="F1" ref-type="fig">Fig. 1</xref>). These act as prodrugs that generate reactive oxygen species (ROS), inducing oxidative stress in the parasite. However, their efficacy is limited to the acute phase of the disease, and they have significant adverse effects, including teratogenicity, which restricts their use during pregnancy (<xref rid="B9" ref-type="bibr">9</xref><xref rid="B10" ref-type="bibr">&#8211;</xref><xref rid="B12" ref-type="bibr">12</xref>). For <italic toggle="yes">T. gondii</italic>, the combination of pyrimethamine (PMN) and sulfadiazine (SDZ) is the treatment of choice (<xref rid="B13" ref-type="bibr">13</xref>). However, its antifolate activity also affects folate metabolism in humans, limiting its use in the first trimester of pregnancy due to the risk of defects in the development of the fetus&#8217;s central nervous system (<xref rid="B14" ref-type="bibr">14</xref>). Therefore, there is a need for new compounds with selective antiparasitic activity.</p><fig position="float" fig-type="figure" id="F1" orientation="portrait"><label>Fig 1</label><caption><p>Drugs in use for the treatment of <italic toggle="yes">Trypanosoma cruzi</italic> and <italic toggle="yes">Toxoplasma gondii</italic> infections.</p></caption><graphic position="float" orientation="portrait" xlink:href="aac.00454-25.f001.jpg"><alt-text>Chemical structures of four antiparasitic compounds: Nifurtimox (top left), Pyrimethamine (top right), Benznidazole derivative (bottom left), and Sulfadiazine (bottom right), each with distinctive functional groups and aromatic rings.</alt-text></graphic></fig><p>Rojo et al. characterized the differences in the efficacy of NFX and BNZ in HPE infected with <italic toggle="yes">T. cruzi</italic> (<xref rid="B7" ref-type="bibr">7</xref>). Although neither drug completely eradicated the parasitic DNA load under the conditions evaluated, NFX was observed to induce inherent toxicity and tissue damage, possibly related to its mechanism of action. <italic toggle="yes">T. cruzi</italic> displays high genetic variability, and seven major genetic lineages, termed discrete typing units (DTUs), are recognized (<xref rid="B15" ref-type="bibr">15</xref>, <xref rid="B16" ref-type="bibr">16</xref>). These DTUs (TcI-TcVI and Tcbat) are unevenly distributed throughout endemic regions in Latin America. Although no proven correlation exists between <italic toggle="yes">T. cruzi</italic> DTUs and drug sensitivity/effectiveness of treatment, wide variations in susceptibility occur among <italic toggle="yes">T. cruzi</italic> strains belonging to the same DTU in terms of drug resistance (<xref rid="B17" ref-type="bibr">17</xref>).</p><p>Regarding the reference drugs for <italic toggle="yes">T. gondii</italic>, PMN, particularly in combination with sulfadiazine, effectively reduces the infection and proliferation of <italic toggle="yes">T. gondii</italic> in HPE. However, PMN has demonstrated toxicity against trophoblastic cells of the BeWo cell line (<xref rid="B18" ref-type="bibr">18</xref>). Therefore, employing histological and histochemical analyses to evaluate possible tissue damage of new antiparasitic compounds against <italic toggle="yes">T. cruzi</italic> and <italic toggle="yes">T. gondii</italic> is helpful. This approach not only allows for the assessment of the pharmacological effects of the compounds in this biological model but also helps to verify any intrinsic damage these compounds may cause.</p><p>The search and design of new compounds with antiparasitic activity have been based on therapeutic targets present in the parasites, absent in the host, or structurally different from those in the host (<xref rid="B19" ref-type="bibr">19</xref>). In this sense, thiosemicarbazones have been reported as molecules with important antiparasitic activity, and several derivatives of these have been evaluated against both <italic toggle="yes">T. cruzi</italic> and <italic toggle="yes">T. gondii</italic> (<xref rid="B20" ref-type="bibr">20</xref><xref rid="B21" ref-type="bibr">&#8211;</xref><xref rid="B22" ref-type="bibr">22</xref>). The mechanism of action of anti-<italic toggle="yes">T</italic>. <italic toggle="yes">gondii</italic> of these compounds is not precisely known. However, recent studies have suggested that its effect may be due to interference with protein biosynthesis, leading to mitochondrial damage and alterations of the parasitophorous vacuole (<xref rid="B23" ref-type="bibr">23</xref>).</p><p>In addition, computational studies have demonstrated that these structures can potently inhibit certain cathepsins, which are important virulence factors in the cell invasion process of <italic toggle="yes">T. gondii</italic> (<xref rid="B24" ref-type="bibr">24</xref>, <xref rid="B25" ref-type="bibr">25</xref>). An example of a thiosemicarbazone derivative with activity against <italic toggle="yes">T. gondii</italic> is shown in <xref rid="F2" ref-type="fig">Fig. 2</xref> (compound a) (<xref rid="B26" ref-type="bibr">26</xref>). On the other hand, the mechanism of action of thiosemicarbazone derivatives against <italic toggle="yes">T. cruzi</italic> has been related to inhibiting the parasite&#8217;s main cysteine protease, cruzipain, which is crucial in the parasite&#8217;s infection of cells and tissues (<xref rid="B27" ref-type="bibr">27</xref>). We had previously reported the anti-<italic toggle="yes">T</italic>. <italic toggle="yes">cruzi</italic> activity of nitrofuryl-containing thiosemicarbazones (<xref rid="F2" ref-type="fig">Fig. 2</xref>, compound b), in which trypanocidal activity was associated with the generation of oxidative stress through the bioreduction of the nitro moiety as it has been described for NFX (<xref rid="B28" ref-type="bibr">28</xref>).</p><fig position="float" fig-type="figure" id="F2" orientation="portrait"><label>Fig 2</label><caption><p>Representative thiosemicarbazone (a&#8211;b, e) and coumarin (c&#8211;f) derivatives with activity against <italic toggle="yes">T. cruzi</italic> or <italic toggle="yes">T. gondii</italic>. Compound (a) shows potent anti-<italic toggle="yes">T. gondii</italic> activity; (b) is a nitrofuran&#8211;thiosemicarbazone with activity against <italic toggle="yes">T. cruzi</italic>; (c&#8211;d) are coumarins evaluated as trypanocidal agents; (e) is a highly selective coumarin&#8211;thiosemicarbazone hybrid; and (f) is a nitrofuran&#8211;quinolone&#8211;coumarin hybrid active against <italic toggle="yes">T. gondii</italic>. SI = EC&#8325;&#8320; (mammalian cell model) / IC&#8325;&#8320; (parasite).</p></caption><graphic position="float" orientation="portrait" xlink:href="aac.00454-25.f002.jpg"><alt-text>Structures of six antiparasitic compounds with IC&#8325;&#8320; and selectivity index values against T. gondii or T. cruzi, including thiosemicarbazones, nitroaromatics, chromones, and coumarin hybrids, with activity ranging from 1.09&#8239;&#181;M to 137.4&#8239;&#181;M.</alt-text></graphic></fig><p>Coumarins have been described as molecules with diverse biological activities, including anticoagulant, antioxidant, and antiparasitic activity, and they are being evaluated as trypanocidal and antimalarial compounds (<xref rid="B29" ref-type="bibr">29</xref><xref rid="B30" ref-type="bibr">&#8211;</xref><xref rid="B31" ref-type="bibr">31</xref>). Against <italic toggle="yes">T. cruzi</italic>, coumarin derivatives have shown antiparasitic activity, possibly associated with oxidative stress due to imbalances in the mitochondrial membrane potential and the possible inhibition of the parasite&#8217;s glycosomal glyceraldehyde 3-phosphate dehydrogenase (gGAPDH), structurally different from human GAPDH. Some examples are shown in <xref rid="F2" ref-type="fig">Fig. 2</xref> (compounds c and d). Recent studies have shown that the addition of nitro groups to coumarins significantly improves their activity due to the generation of ROS mediated by the reduction of the nitro group (<xref rid="B32" ref-type="bibr">32</xref>, <xref rid="B33" ref-type="bibr">33</xref>). Coumarin&#8217;s activity against <italic toggle="yes">T. gondii</italic> has been assessed in a few instances, and they are being used as substituents for compounds that have demonstrated anti-<italic toggle="yes">T</italic>. <italic toggle="yes">gondii</italic> activity. The works described by D'Ascenzio et al. (<xref rid="B34" ref-type="bibr">34</xref>) (<xref rid="F2" ref-type="fig">Fig. 2</xref>, compound e) and Chimenti et al. (<xref rid="B35" ref-type="bibr">35</xref>) indicate that the addition of a coumarin structure to the basic skeleton of thiazole derivatives increases toxoplasmicidal activity and selectivity against this parasite. Molina et al. (<xref rid="B36" ref-type="bibr">36</xref>) described that 4-thiazolidinone derivatives inhibit the activity of protein kinase 1, altering the infective and reproductive capacity of the parasite. Likewise, the high activity of quinolone-coumarin hybrid compounds has been described (<xref rid="B37" ref-type="bibr">37</xref>). In addition, nitrofurans linked to quinolones have shown high anti-<italic toggle="yes">T</italic>. <italic toggle="yes">gondii</italic> activity (<xref rid="F2" ref-type="fig">Fig. 2</xref>, compound f) (<xref rid="B38" ref-type="bibr">38</xref>).</p><p>Based on the above, including coumarin and thiosemicarbazone moieties in a single molecule could be a good strategy to obtain compounds with improved anti-<italic toggle="yes">T</italic>. <italic toggle="yes">cruzi</italic> and anti-<italic toggle="yes">T</italic>. <italic toggle="yes">gondii</italic> activity and selectivity. In this sense, we had developed new protocols for the preparation of a series of coumarin-thiosemicarbazone hybrid compounds (<xref rid="B39" ref-type="bibr">39</xref>). The prepared compounds were evaluated <italic toggle="yes">in vitro</italic> against the trypomastigote form of <italic toggle="yes">T. cruzi</italic> (Dm28c strain), but most showed negligible activity (<xref rid="B40" ref-type="bibr">40</xref>, <xref rid="B41" ref-type="bibr">41</xref>). Recently, Alves Nunes et al. studied the activity of a series of coumarin-3-thiosemicarbazone hybrids with substituents in the coumarin fraction and without substituents in the thiosemicarbazone fraction (<xref rid="B42" ref-type="bibr">42</xref>). Their study primarily focused on enzymatic inhibition, particularly cruzipain, reporting high inhibitory activity with IC<sub>50</sub> values in the nanomolar range. However, this potent enzymatic inhibition did not translate into strong antiparasitic effects in <italic toggle="yes">T. cruzi</italic>, with IC<sub>50</sub> values not significantly improved compared to reference drugs. However, this suggests their rational design can optimize antiparasitic activity.</p><p>As a strategy for improving the antiparasitic activity of the coumarin-thiosemicarbazone hybrid compounds, a nitro group could be included as a substituent in the coumarin ring. This nitro moiety could be involved in the generation of oxidative stress in the parasites, leading to an enhanced antiparasitic activity, as it has been previously described for other nitro compounds (<xref rid="B28" ref-type="bibr">28</xref>). This study synthesized eight new 6-nitrocoumarin-3-thiosemicarbazone hybrid compounds (<bold>1&#8211;8</bold>), with seven being reported for the first time and fully characterized. The prepared compounds differ by having a hydroxyl group at the 4-position of the coumarin moiety and include substituents with varying lipophilicity in the thiosemicarbazone part (<xref rid="F3" ref-type="fig">Fig. 3</xref>). To evaluate their therapeutic potential, these compounds were thoroughly investigated in <italic toggle="yes">in vitro</italic> and <italic toggle="yes">ex vivo</italic> models relevant to congenital infections, focusing on their effects on <italic toggle="yes">T. cruzi</italic> and <italic toggle="yes">T. gondii</italic> in infected cells and placental tissue. In addition, assessment in human placental explants (HPEs) enabled the analysis of antiparasitic activity in a physiologically relevant setting, providing insights into the compounds' ability to decrease parasitic load without causing noticeable alterations in tissue architecture. The correlation between <italic toggle="yes">in vitro</italic> and ex vivo activity highlights the significance of these models in predicting the therapeutic potential of new agents. Moreover, the relationship between the electrochemical reduction of the nitro group and the formation of reactive oxygen species (ROS) indicates a potential mechanism of action that was investigated in this study.</p><fig position="float" fig-type="figure" id="F3" orientation="portrait"><label>Fig 3</label><caption><p>6-Nitrocoumarin-3-thiosemicarbazone hybrids 1&#8211;8.</p></caption><graphic position="float" orientation="portrait" xlink:href="aac.00454-25.f003.jpg"><alt-text>General structure of eight coumarin&#8211;thiosemicarbazone derivatives with variable R&#185; and R&#178; groups, including hydroxyl, methyl, ethyl, phenyl, and hydrogen substitutions, designed for structure&#8211;activity relationship studies.</alt-text></graphic></fig></sec><sec sec-type="results|discussion" id="s2"><title>RESULTS AND DISCUSSION</title><sec id="s2-1"><title>Study design</title><p>The development of 6-nitrocoumarin-3-thiosemicarbazone hybrids stems from our group&#8217;s continuous interest in exploring the chemical and biological potential of coumarin and thiosemicarbazone derivatives as antiparasitic agents. Previous studies conducted in our laboratory and research from other groups have shown that thiosemicarbazones exhibit significant trypanocidal activity, primarily mediated by cruzipain inhibition and the induction of oxidative stress (<xref rid="B32" ref-type="bibr">32</xref>, <xref rid="B42" ref-type="bibr">42</xref>). In addition, coumarins have demonstrated remarkable potential as inhibitors of key enzymes involved in the metabolism of <italic toggle="yes">T. cruzi</italic> and <italic toggle="yes">T. gondii</italic>. This provides a basis for the rational design of hybrid molecules that combine the antiparasitic properties of both chemical scaffolds (<xref rid="B43" ref-type="bibr">43</xref>, <xref rid="B44" ref-type="bibr">44</xref>).</p><p>Our previous work reported the synthesis and characterization of coumarin-3-thiosemicarbazone hybrids, highlighting their structural diversity and ability to generate reactive oxygen species (ROS) (<xref rid="B39" ref-type="bibr">39</xref><xref rid="B40" ref-type="bibr">&#8211;</xref><xref rid="B41" ref-type="bibr">41</xref>). However, although these compounds exhibited activity against <italic toggle="yes">T. cruzi</italic>, their efficacy against the infective forms of the parasite was limited. These findings suggest that while the non-nitro compounds showed some ability to inhibit parasite proliferation, structural optimization was necessary to enhance their efficacy. In this regard, our previous studies emphasized the importance of structural modifications, such as the incorporation of nitro groups, in improving the biological activity of indazolin-3-ones (<xref rid="B45" ref-type="bibr">45</xref>). Electrochemical analyses further confirmed this strategy, which demonstrated that nitro-functionalized derivatives can enhance ROS production, a critical factor for their antiparasitic efficacy. Moreover, computational and spectroscopic studies provided crucial insights into the Z/E isomerization equilibria of these hybrids (<xref rid="B39" ref-type="bibr">39</xref>).</p><p>Given this background, the present study aims to broaden the scope of our previous research by synthesizing a new series of 6-nitrocoumarin-3-thiosemicarbazone derivatives with varying degrees of lipophilicity. The design of these compounds focuses on optimizing their lipophilicity to enhance membrane permeability and, consequently, improve their antiparasitic activity. The strategic incorporation of functional groups such as hydroxyl and nitro was proposed to investigate their influence on these hybrids&#8217; redox behavior and biological properties. Prior studies informed the introduction of the nitro group at the 6-position on 3-nitrocoumarins, which demonstrated that the positioning of the nitro group within the coumarin structure significantly affects ROS generation and antiparasitic activity (<xref rid="B32" ref-type="bibr">32</xref>). The 6-position was chosen under the hypothesis that it could increase the stabilization of the radical generated during nitro group reduction, thereby enhancing biological activity compared to compounds with the nitro group at the 3-position, where interference from the 4-position substituent hinders efficient delocalization of the unpaired electron, reducing ROS generation and antiparasitic efficacy.</p><p>Since the antiparasitic effect of these compounds depends on their chemical structure and ability to function in a complex biological environment, we assessed their impact using both cellular and infection models. Based on the evidence regarding cruzipain inhibition (<xref rid="B42" ref-type="bibr">42</xref>), we decided to evaluate the antiparasitic activity of these compounds and their effects on tissue infection under two experimental conditions: co-incubation with parasites and post-infection. This evaluation was essential for determining how the compounds influence parasite load in a more physiological context using an <italic toggle="yes">ex vivo</italic> model with human placental explants. This approach allowed us to analyze their effects on extracellular and intracellular parasite forms in a setting that closely resembles the biological reality of infection, providing a solid foundation for future structural optimizations.</p></sec><sec id="s2-2"><title>Chemistry</title><p>Compounds <bold>1&#8211;4</bold> and <bold>5&#8211;8</bold> were obtained by the condensation of the corresponding thiosemicarbazide derivatives with 6-nitro-4-hydroxy-3-acetyl-coumarin (<bold>C1</bold>) or 6-nitro-3-acetyl-coumarin (<bold>C2</bold>), respectively (<xref rid="F4" ref-type="fig">Fig. 4</xref>), using a sealed-vessel reactor (SVR), a methodology previously developed by us for similar compounds (<xref rid="B39" ref-type="bibr">39</xref>). The starting coumarins <bold>C1</bold> and <bold>C2</bold> were prepared, as shown in <xref rid="F4" ref-type="fig">Fig. 4A</xref>. <bold>C1</bold> was prepared from 4-hydroxy-3-acetylcoumarin by nitration reaction with H<sub>2</sub>SO<sub>4</sub> and KNO<sub>3</sub> (<xref rid="B46" ref-type="bibr">46</xref>), while <bold>C2</bold> was prepared by a Knoevenagel reaction between 5-nitrosalicylaldehyde and ethyl acetoacetate (<xref rid="B47" ref-type="bibr">47</xref>). All nitrocoumarin-thiosemicarbazone derivatives were obtained in moderate to very good yields (60%&#8211;86%). They were spectroscopically characterized in solid state by FTIR (see Table S1 at <ext-link xlink:href="https://doi.org/10.5281/zenodo.15694236" ext-link-type="uri">https://doi.org/10.5281/zenodo.15694236</ext-link>) and in solution by <sup>1</sup>H- and <sup>13</sup>C-NMR (see Tables S2 and S3 at <ext-link xlink:href="https://doi.org/10.5281/zenodo.15694236" ext-link-type="uri">https://doi.org/10.5281/zenodo.15694236</ext-link>).</p><fig position="float" fig-type="figure" id="F4" orientation="portrait"><label>Fig 4</label><caption><p>(A) Synthesis of coumarins C1 and C2; (B) synthesis of compounds 1&#8211;8.</p></caption><graphic position="float" orientation="portrait" xlink:href="aac.00454-25.f004.jpg"><alt-text>Synthesis of coumarin&#8211;thiosemicarbazone derivatives 1&#8211;8: formation of nitro-substituted coumarin intermediates C1 and C2; condensation with thiosemicarbazides under acidic conditions yielding final products with varied R&#185; and R&#178; substituents.</alt-text></graphic></fig></sec><sec id="s2-3"><title>Electrochemical characterization</title><p>As previously stated, the potential mode of antiparasitic action of the prepared nitro compounds could be related to the generation of oxidative stress through the bioreduction of the nitro moiety, generating free radical species involved in oxidative stress (<xref rid="B28" ref-type="bibr">28</xref>). To assess the potential of compounds <bold>1&#8211;8</bold> for having this mode of action, their electrochemical characterization in the cathodic direction was performed at room temperature by cyclic voltammetry (CV) in DMSO solutions using a hanging drop mercury electrode (HDME). The electrochemical behavior of these compounds provides insight into their potential bioactivation and ROS generation, which are critical factors in their antiparasitic efficacy.</p><p>Results indicated that compounds <bold>1&#8211;4</bold>, with a hydroxyl group in position 4, presented a similar electrochemical behavior. <xref rid="F5" ref-type="fig">Figure 5A</xref> shows the cyclic voltammogram of compound <bold>1</bold> as a representative example. Three cathodic and one anodic signal were observed. The signals close to &#8722;0.88 and &#8722;0.99 V (Ic<sub>a</sub> and Ic<sub>b</sub>, both irreversible) were attributed to the reduction of the nitro group of the two species involved in the keto-enolic equilibrium of the 4-OH coumarin moiety (<xref rid="B48" ref-type="bibr">48</xref>). The autoprotonation of the nitro group was evidenced by the addition of NaOH (<xref rid="F5" ref-type="fig">Fig. 5B</xref>) (<xref rid="B49" ref-type="bibr">49</xref>). In fact, the third signal near &#8722;1.1 V (IIc, IIa, quasi-reversible) was attributed to the formation of the nitro anion radical. The proposed reduction mechanism is shown in <xref rid="F6" ref-type="fig">Fig. 6</xref>.</p><fig position="float" fig-type="figure" id="F5" orientation="portrait"><label>Fig 5</label><caption><p>Cyclic voltammogram of (A) Compound 1 recorded at different scan rates between 0.05 and 2.50 V/s, (B) Compound 1 recorded at 2.00 V/s scan rate with the addition of different volumes of 0.1 M NaOH, and (C) Compound 5 recorded at different scan rates between 0.05 and 2.50 V/s. All the curves were recorded in DMSO as a solvent and PTBA as a supporting electrolyte.</p></caption><graphic position="float" orientation="portrait" xlink:href="aac.00454-25.f005.jpg"><alt-text>Cyclic voltammograms indicating redox behavior of analytes. Varying scan rates reveal multiple redox peaks with increasing current. Increasing analyte volume enhances peak intensity. Extended scan shows additional peaks at higher potentials.</alt-text></graphic></fig><fig position="float" fig-type="figure" id="F6" orientation="portrait"><label>Fig 6</label><caption><p>Proposed reduction mechanism for 6-nitrocoumarin-thiosemicarbazone hybrids 1&#8211;4.</p></caption><graphic position="float" orientation="portrait" xlink:href="aac.00454-25.f006.jpg"><alt-text>Proposed redox mechanism for nitroaromatic scaffold involving sequential electron transfers (Ica, Icb), radical intermediates, and reversible redox transitions (IIc to IIa), highlighting nitro and hydroxyl group participation in electron delocalization.</alt-text></graphic></fig><p><xref rid="F5" ref-type="fig">Figure 5C</xref> exemplifies the electrochemical behavior of non-hydroxylated compounds <bold>5&#8211;8</bold>. Compound <bold>5</bold> has a quasi-reversible couple close to &#8722;0.94 V (IIa, IIc), which was attributable to the <inline-formula id="ui1"><alternatives><inline-graphic xlink:href="aac.00454-25.im001.jpg"/><mml:math id="u1" display="inline" overflow="scroll"><mml:msub><mml:mrow><mml:mo>-</mml:mo><mml:mi>N</mml:mi><mml:mi>O</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>/</mml:mo><mml:msubsup><mml:mrow><mml:mi>N</mml:mi><mml:mi>O</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mo>.</mml:mo><mml:mo>-</mml:mo></mml:mrow></mml:msubsup><mml:mi/></mml:math></alternatives></inline-formula> couple, the single-electron reduction of the nitro group. The irreversible signal close to &#8722;1.38 V (IIIc) was attributed to the formation of hydroxylamine and the irreversible signal close to &#8722;1.66 V (IVc) to the reduction via two electrons in the imine of the thiosemicarbazone moiety, similar to that described for 5-nitrofuryl containing thiosemicarbazones (<xref rid="B50" ref-type="bibr">50</xref>). <xref rid="F7" ref-type="fig">Figure 7</xref> shows the proposed reduction mechanism.</p><fig position="float" fig-type="figure" id="F7" orientation="portrait"><label>Fig 7</label><caption><p>Proposed reduction mechanism for 6-nitrocoumarin-thiosemicarbazone hybrids 5&#8211;8.</p></caption><graphic position="float" orientation="portrait" xlink:href="aac.00454-25.f007.jpg"><alt-text>Sequential reduction of nitroaromatic derivatives via intermediate states IIc to IVc, involving electron and proton transfers, yields hydroxylamine and hydrazine analogs with water elimination; pathway of redox transformations and R-group substitution.</alt-text></graphic></fig><p>The reduction potentials of all the compounds (<xref rid="T1" ref-type="table">Table 1</xref>) are not affected by the substituent R<sup>2</sup> in the thiosemicarbazone. Related to the reduction of the nitro moiety (couple II), the measured potential of the hybrid derivatives <bold>1&#8211;8</bold> was more negative than that of NFX, which could mean that the bioreduction could be less favorable. However, the measured potentials were similar to those reported for the 5-nitrofuryl thiosemicarbazone derivatives previously studied by the group (<xref rid="B50" ref-type="bibr">50</xref>, <xref rid="B51" ref-type="bibr">51</xref>). For these compounds, the trypanocidal mechanism of action was associated with the generation of oxidative stress. Due to this, the prepared 6-nitrocoumarin-3-thiosemicarbazone hybrids <bold>1&#8211;8</bold> could be active against the infective form of <italic toggle="yes">T. cruzi</italic> through this mode of action.</p><table-wrap position="float" id="T1" orientation="portrait"><label>TABLE 1</label><caption><p>Redox potentials (vs. Ag/AgCl) corresponding to the reduction of hybrids 1&#8211;8, recorded at a rate of 2.00 V/s<xref rid="T1_FN2" ref-type="table-fn"><sup><italic toggle="yes">b</italic></sup></xref></p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" valign="top" colspan="1" rowspan="1">Compound</th><th align="left" valign="top" colspan="1" rowspan="1">E(pIc<sub>a</sub>)</th><th align="left" valign="top" colspan="1" rowspan="1">E(pIc<sub>b</sub>)</th><th align="left" valign="top" colspan="1" rowspan="1">E(pIIc)</th><th align="left" valign="top" colspan="1" rowspan="1">E(pIIIc)</th><th align="left" valign="top" colspan="1" rowspan="1">E(pIVc)</th><th align="left" valign="top" colspan="1" rowspan="1">E(pIIa)</th></tr></thead><tbody><tr><td align="left" valign="top" colspan="1" rowspan="1">1</td><td align="left" valign="top" colspan="1" rowspan="1">&#8722;0.89</td><td align="left" valign="top" colspan="1" rowspan="1">&#8722;0.99</td><td align="left" valign="top" colspan="1" rowspan="1">&#8722;1.08</td><td align="left" valign="top" colspan="1" rowspan="1">&#8211;<xref rid="T1_FN3" ref-type="table-fn"><sup><italic toggle="yes">c</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">&#8211;</td><td align="left" valign="top" colspan="1" rowspan="1">&#8722;0.98</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">2</td><td align="left" valign="top" colspan="1" rowspan="1">&#8722;0.89</td><td align="left" valign="top" colspan="1" rowspan="1">&#8722;0.99</td><td align="left" valign="top" colspan="1" rowspan="1">&#8722;1.08</td><td align="left" valign="top" colspan="1" rowspan="1">&#8211;</td><td align="left" valign="top" colspan="1" rowspan="1">&#8211;</td><td align="left" valign="top" colspan="1" rowspan="1">&#8722;1.01</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">3</td><td align="left" valign="top" colspan="1" rowspan="1">&#8722;0.88</td><td align="left" valign="top" colspan="1" rowspan="1">&#8722;0.99</td><td align="left" valign="top" colspan="1" rowspan="1">&#8722;1.08</td><td align="left" valign="top" colspan="1" rowspan="1">&#8211;</td><td align="left" valign="top" colspan="1" rowspan="1">&#8211;</td><td align="left" valign="top" colspan="1" rowspan="1">&#8722;1.00</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">4</td><td align="left" valign="top" colspan="1" rowspan="1">&#8722;0.62</td><td align="left" valign="top" colspan="1" rowspan="1">&#8722;1.05</td><td align="left" valign="top" colspan="1" rowspan="1">&#8722;1.09</td><td align="left" valign="top" colspan="1" rowspan="1">&#8211;</td><td align="left" valign="top" colspan="1" rowspan="1">&#8211;</td><td align="left" valign="top" colspan="1" rowspan="1">&#8722;1.01</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">5</td><td align="left" valign="top" colspan="1" rowspan="1">&#8211;</td><td align="left" valign="top" colspan="1" rowspan="1">&#8211;</td><td align="left" valign="top" colspan="1" rowspan="1">&#8722;0.94</td><td align="left" valign="top" colspan="1" rowspan="1">&#8722;1.38</td><td align="left" valign="top" colspan="1" rowspan="1">&#8722;1.66</td><td align="left" valign="top" colspan="1" rowspan="1">&#8722;0.90</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">6</td><td align="left" valign="top" colspan="1" rowspan="1">&#8211;</td><td align="left" valign="top" colspan="1" rowspan="1">&#8211;</td><td align="left" valign="top" colspan="1" rowspan="1">&#8722;0.93</td><td align="left" valign="top" colspan="1" rowspan="1">&#8722;1.40</td><td align="left" valign="top" colspan="1" rowspan="1">&#8722;1.68</td><td align="left" valign="top" colspan="1" rowspan="1">&#8722;0.87</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">7</td><td align="left" valign="top" colspan="1" rowspan="1">&#8211;</td><td align="left" valign="top" colspan="1" rowspan="1">&#8211;</td><td align="left" valign="top" colspan="1" rowspan="1">&#8722;0.94</td><td align="left" valign="top" colspan="1" rowspan="1">&#8722;1.40</td><td align="left" valign="top" colspan="1" rowspan="1">&#8722;1.67</td><td align="left" valign="top" colspan="1" rowspan="1">&#8722;0.86</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">8</td><td align="left" valign="top" colspan="1" rowspan="1">&#8211;</td><td align="left" valign="top" colspan="1" rowspan="1">&#8211;</td><td align="left" valign="top" colspan="1" rowspan="1">&#8722;0.94</td><td align="left" valign="top" colspan="1" rowspan="1">&#8722;1.39</td><td align="left" valign="top" colspan="1" rowspan="1">&#8722;1.68</td><td align="left" valign="top" colspan="1" rowspan="1">&#8722;0.86</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">NFX<xref rid="T1_FN1" ref-type="table-fn"><sup><italic toggle="yes">a</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">&#8211;</td><td align="left" valign="top" colspan="1" rowspan="1">&#8211;</td><td align="left" valign="top" colspan="1" rowspan="1">&#8722;0.75</td><td align="left" valign="top" colspan="1" rowspan="1">&#8211;</td><td align="left" valign="top" colspan="1" rowspan="1">&#8211;</td><td align="left" valign="top" colspan="1" rowspan="1">&#8722;0.70</td></tr></tbody></table><table-wrap-foot><fn id="T1_FN1"><label>
<sup>
<italic toggle="yes">a</italic>
</sup>
</label><p>Reference <xref rid="B52" ref-type="bibr">52</xref>.</p></fn><fn id="T1_FN2"><label>
<sup>
<italic toggle="yes">b</italic>
</sup>
</label><p>The potentials obtained in cyclic voltammetry were used to generate free radicals <italic toggle="yes">in situ</italic> electrolytically. ESR spectra were recorded to check the generation of the nitro anion radical for the obtained compounds. For all compounds, a nine-line hyperfine pattern was obtained (<xref rid="F8" ref-type="fig">Fig. 8</xref>), whose hyperfine coupling constants (<xref rid="T2" ref-type="table">Table 2</xref>) were determined by computational simulation of the spectra using the WinSim program.</p></fn><fn id="T1_FN3"><label>
<sup>
<italic toggle="yes">c</italic>
</sup>
</label><p>&#8211; indicates value not observed.</p></fn></table-wrap-foot></table-wrap><p>The comparison with the study of 3-nitrocoumarins reported by Salgado et al. shows key differences in the reduction potentials (<xref rid="B32" ref-type="bibr">32</xref>). While the 3-nitrocoumarins exhibited a more negative reduction potential (approximately &#8722;1.2 V), the 6-nitrocoumarins have less negative reduction potentials, suggesting a more straightforward reduction of these compounds than the 3-nitrocoumarins. This change in reduction potential is consistent with the structural modification at position 6 of the coumarin ring, which could facilitate the bioreduction of the nitro group in a biological environment and generate ROS with greater efficacy.</p><fig position="float" fig-type="figure" id="F8" orientation="portrait"><label>Fig 8</label><caption><p>Experimental and semi-empirically simulated electron paramagnetic resonance spectra of (A) compound 1 and (B) compound 5.</p></caption><graphic position="float" orientation="portrait" xlink:href="aac.00454-25.f008.jpg"><alt-text>Overlay of experimental and simulated EPR spectra across magnetic field range 3440&#8211;3485 G. Spectral patterns reflect close agreement in A, with slight deviations in B, indicating model accuracy and areas for refinement in radical species characterization.</alt-text></graphic></fig><table-wrap position="float" id="T2" orientation="portrait"><label>TABLE 2</label><caption><p>Hyperfine coupling constants of compounds 1&#8211;8 obtained by semi-empirical simulation</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" valign="top" rowspan="2" colspan="1">Compound</th><th align="center" valign="top" colspan="4" rowspan="1">Hyperfine coupling constant (G)</th></tr><tr><th align="left" valign="top" colspan="1" rowspan="1">a<sub>N</sub></th><th align="left" valign="top" colspan="1" rowspan="1">a<sub>H-1</sub></th><th align="left" valign="top" colspan="1" rowspan="1">a<sub>H-2</sub></th><th align="left" valign="top" colspan="1" rowspan="1">a<sub>H-3</sub></th></tr></thead><tbody><tr><td align="left" valign="top" colspan="1" rowspan="1">1</td><td align="left" valign="top" colspan="1" rowspan="1">7.08</td><td align="left" valign="top" colspan="1" rowspan="1">7.54</td><td align="left" valign="top" colspan="1" rowspan="1">3.87</td><td align="left" valign="top" colspan="1" rowspan="1">3.09</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">2</td><td align="left" valign="top" colspan="1" rowspan="1">7.08</td><td align="left" valign="top" colspan="1" rowspan="1">7.61</td><td align="left" valign="top" colspan="1" rowspan="1">3.80</td><td align="left" valign="top" colspan="1" rowspan="1">2.86</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">3</td><td align="left" valign="top" colspan="1" rowspan="1">7.09</td><td align="left" valign="top" colspan="1" rowspan="1">7.56</td><td align="left" valign="top" colspan="1" rowspan="1">3.81</td><td align="left" valign="top" colspan="1" rowspan="1">2.96</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">4</td><td align="left" valign="top" colspan="1" rowspan="1">7.07</td><td align="left" valign="top" colspan="1" rowspan="1">7.74</td><td align="left" valign="top" colspan="1" rowspan="1">4.11</td><td align="left" valign="top" colspan="1" rowspan="1">3.19</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">5</td><td align="left" valign="top" colspan="1" rowspan="1">6.59</td><td align="left" valign="top" colspan="1" rowspan="1">6.87</td><td align="left" valign="top" colspan="1" rowspan="1">4.09</td><td align="left" valign="top" colspan="1" rowspan="1">3.22</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">6</td><td align="left" valign="top" colspan="1" rowspan="1">6.87</td><td align="left" valign="top" colspan="1" rowspan="1">7.21</td><td align="left" valign="top" colspan="1" rowspan="1">4.07</td><td align="left" valign="top" colspan="1" rowspan="1">2.97</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">7</td><td align="left" valign="top" colspan="1" rowspan="1">6.78</td><td align="left" valign="top" colspan="1" rowspan="1">7.21</td><td align="left" valign="top" colspan="1" rowspan="1">3.62</td><td align="left" valign="top" colspan="1" rowspan="1">2.66</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">8</td><td align="left" valign="top" colspan="1" rowspan="1">6.98</td><td align="left" valign="top" colspan="1" rowspan="1">7.36</td><td align="left" valign="top" colspan="1" rowspan="1">4.01</td><td align="left" valign="top" colspan="1" rowspan="1">2.49</td></tr></tbody></table></table-wrap><p>The ESR spectra&#8217;s semi-empirical simulation considers the interaction between the nitrogen atom of the nitro group (aN = 7.05 G) and the three hydrogen atoms of the benzene ring in the coumarin backbone structure. In addition, in a previous study, we described how 3-nitrocoumarins (<xref rid="B32" ref-type="bibr">32</xref>), when reduced, present a less efficient delocalization of the unpaired electron due to the interference of the substituent at position 4, which hinders the efficient generation of ROS and leads to lower trypanocidal activity. By contrast, the compounds with the nitro group at position 6 show better stabilization of the generated radical, which could improve their biological activity.</p><p>The generation of these radical species partially confirms the proposed reduction mechanism for these compounds. These results suggest that the observed reduction potentials allow the bioreduction of these compounds, enabling oxidative stress as a potential mechanism of action. This hypothesis has been more extensively explored in the case of <italic toggle="yes">Trypanosoma cruzi</italic> (<xref rid="B45" ref-type="bibr">45</xref>).</p></sec><sec id="s2-4"><title>Biological evaluation</title><p>The reduction of resazurin sodium salt was used to determine the trypanocidal and toxoplasmicidal activity of the 6-nitrocoumarin-thiosemicarbazone hybrids <bold>1&#8211;8</bold>. For this, treatment with the compounds was carried out for 24 h at a concentration of 100 &#181;M. Most derivatives were, in general, more active against <italic toggle="yes">T. gondii</italic> than against <italic toggle="yes">T. cruzi,</italic> as shown in <xref rid="F9" ref-type="fig">Fig. 9</xref>.</p><fig position="float" fig-type="figure" id="F9" orientation="portrait"><label>Fig 9</label><caption><p>(A) Viability of <italic toggle="yes">T. cruzi</italic> trypomastigotes, Dm28 strain, exposed for 24 h to a concentration of 100 &#181;M of compounds 1&#8211;8. (B) Viability of <italic toggle="yes">T. gondii</italic> tachyzoites, RH strain, exposed for 24 h to a concentration of 100 &#181;M of compounds 1&#8211;8. The significant difference was compared to the negative uninfected control. One-way ANOVA with Dunnett&#8217;s post-test; ****<italic toggle="yes">P</italic> &#8804; 0.0001; ***<italic toggle="yes">P</italic> &#8804; 0.001; **<italic toggle="yes">P</italic> &#8804; 0.01; *<italic toggle="yes">P</italic> &#8804; 0.05.</p></caption><graphic position="float" orientation="portrait" xlink:href="aac.00454-25.f009.jpg"><alt-text>Bar graphs comparing trypomastigote and tachyzoite viability after treatment with hydroxylated and non-hydroxylated compounds. Compounds 4&#8211;8 significantly reduce viability in both forms, with non-hydroxylated variants generally more effective.</alt-text></graphic></fig><p>About the trypanocidal activity, the most active derivatives were those that do not contain a hydroxyl group in the 4 position of the coumarin (<bold>5&#8211;8</bold>), with compound <bold>7</bold> (which has an ethyl group as a substituent in the thiosemicarbazone moiety) being the most active. The hydroxylated compounds showed a marginal activity except for compound <bold>4</bold>, which is the most lipophilic of this series (<xref rid="T3" ref-type="table">Table 3</xref>). The relationship between lipophilicity and trypanocidal activity is unclear for the non-hydroxylated analogs, as the observed activity is quite similar for all of them, independently of the corresponding R<sub>M</sub> values. The inclusion of the nitro moiety in the coumarin skeleton improves the anti-<italic toggle="yes">T</italic>. <italic toggle="yes">cruzi</italic> activity related to the previously reported non-nitrated derivatives (<xref rid="B40" ref-type="bibr">40</xref>, <xref rid="B41" ref-type="bibr">41</xref>).</p><table-wrap position="float" id="T3" orientation="portrait"><label>TABLE 3</label><caption><p>Lipophilicity values (experimental RM and calculated log P) and antiparasitic activity on <italic toggle="yes">T. cruzi</italic> (trypomastigote) and <italic toggle="yes">T. gondii</italic> (tachyzoites) values at 100 &#181;M for compounds <bold>1&#8211;8</bold></p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" valign="bottom" colspan="7" rowspan="1">
<inline-graphic xlink:href="aac.00454-25.inline001.jpg"/>
</th></tr><tr><th align="left" valign="top" colspan="1" rowspan="1">Compound</th><th align="left" valign="top" colspan="1" rowspan="1">R<sup>1</sup></th><th align="left" valign="top" colspan="1" rowspan="1">R<sup>2</sup></th><th align="left" valign="top" colspan="1" rowspan="1">Lipophilicity<xref rid="T3_FN1" ref-type="table-fn"><sup><italic toggle="yes">a</italic></sup></xref><break/>(R<sub>M</sub>)</th><th align="left" valign="top" colspan="1" rowspan="1">Lipophilicity<xref rid="T3_FN2" ref-type="table-fn"><sup><italic toggle="yes">b</italic></sup></xref><break/>(log P)</th><th align="left" valign="top" colspan="1" rowspan="1">Viability<break/><italic toggle="yes">T. cruzi</italic> (%)</th><th align="left" valign="top" colspan="1" rowspan="1">Viability<break/><italic toggle="yes">T. gondii</italic> (%)</th></tr></thead><tbody><tr><td align="left" valign="top" colspan="1" rowspan="1">1</td><td align="left" valign="top" colspan="1" rowspan="1">OH</td><td align="left" valign="top" colspan="1" rowspan="1">H</td><td align="left" valign="top" colspan="1" rowspan="1">0.00</td><td align="left" valign="top" colspan="1" rowspan="1">1.44</td><td align="left" valign="top" colspan="1" rowspan="1">85.5 &#177; 11.3</td><td align="left" valign="top" colspan="1" rowspan="1">24.3 &#177; 10.4</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">2</td><td align="left" valign="top" colspan="1" rowspan="1">OH</td><td align="left" valign="top" colspan="1" rowspan="1">CH<sub>3</sub></td><td align="left" valign="top" colspan="1" rowspan="1">0.13</td><td align="left" valign="top" colspan="1" rowspan="1">1.82</td><td align="left" valign="top" colspan="1" rowspan="1">81.5 &#177; 14.1</td><td align="left" valign="top" colspan="1" rowspan="1">29.1 &#177; 13.5</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">3</td><td align="left" valign="top" colspan="1" rowspan="1">OH</td><td align="left" valign="top" colspan="1" rowspan="1">CH<sub>2</sub>CH<sub>3</sub></td><td align="left" valign="top" colspan="1" rowspan="1">0.33</td><td align="left" valign="top" colspan="1" rowspan="1">2.19</td><td align="left" valign="top" colspan="1" rowspan="1">70.7 &#177; 9.4</td><td align="left" valign="top" colspan="1" rowspan="1">49.6 &#177; 13.5</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">4</td><td align="left" valign="top" colspan="1" rowspan="1">OH</td><td align="left" valign="top" colspan="1" rowspan="1">Ph</td><td align="left" valign="top" colspan="1" rowspan="1">0.85</td><td align="left" valign="top" colspan="1" rowspan="1">2.88</td><td align="left" valign="top" colspan="1" rowspan="1">50.3 &#177; 5.0</td><td align="left" valign="top" colspan="1" rowspan="1">84.4 &#177; 13.7</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">5</td><td align="left" valign="top" colspan="1" rowspan="1">H</td><td align="left" valign="top" colspan="1" rowspan="1">H</td><td align="left" valign="top" colspan="1" rowspan="1">&#8722;0.58</td><td align="left" valign="top" colspan="1" rowspan="1">1.74</td><td align="left" valign="top" colspan="1" rowspan="1">44.6 &#177; 7.1</td><td align="left" valign="top" colspan="1" rowspan="1">65.7 &#177; 14.8</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">6</td><td align="left" valign="top" colspan="1" rowspan="1">H</td><td align="left" valign="top" colspan="1" rowspan="1">CH<sub>3</sub></td><td align="left" valign="top" colspan="1" rowspan="1">&#8722;0.41</td><td align="left" valign="top" colspan="1" rowspan="1">2.11</td><td align="left" valign="top" colspan="1" rowspan="1">49.8 &#177; 5.3</td><td align="left" valign="top" colspan="1" rowspan="1">55.5 &#177; 9.6</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">7</td><td align="left" valign="top" colspan="1" rowspan="1">H</td><td align="left" valign="top" colspan="1" rowspan="1">CH<sub>2</sub>CH<sub>3</sub></td><td align="left" valign="top" colspan="1" rowspan="1">&#8722;0.39</td><td align="left" valign="top" colspan="1" rowspan="1">2.49</td><td align="left" valign="top" colspan="1" rowspan="1">31.3 &#177; 7.4</td><td align="left" valign="top" colspan="1" rowspan="1">53.1 &#177; 8.1</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">8</td><td align="left" valign="top" colspan="1" rowspan="1">H</td><td align="left" valign="top" colspan="1" rowspan="1">Ph</td><td align="left" valign="top" colspan="1" rowspan="1">0.20</td><td align="left" valign="top" colspan="1" rowspan="1">3.17</td><td align="left" valign="top" colspan="1" rowspan="1">45.2 &#177; 6.7</td><td align="left" valign="top" colspan="1" rowspan="1">86.2 &#177; 14.4</td></tr></tbody></table><table-wrap-foot><fn id="T3_FN1"><label>
<sup>
<italic toggle="yes">a</italic>
</sup>
</label><p>TLC, reverse phase-C18, DMSO/phosphate buffer pH 7.4 (70:30 vol/vol) as mobile phase. R<sub>M</sub> = log[(1/R<sub>f</sub>) &#8211; 1].</p></fn><fn id="T3_FN2"><label>
<sup>
<italic toggle="yes">b</italic>
</sup>
</label><p>Obtained through the Molinspiration platform.</p></fn></table-wrap-foot></table-wrap><p>By contrast, our study evaluates the direct antiparasitic activity of new 6-nitrocoumarin-3-thiosemicarbazone hybrids against <italic toggle="yes">T. cruzi</italic> and <italic toggle="yes">T. gondii</italic> in cellular models and placental explants. The results demonstrate effective parasite elimination with a better selectivity profile, showing no significant toxicity in mammalian cells. This highlights the importance of testing compounds in biologically relevant models rather than relying solely on enzymatic assays, as potent enzyme inhibition does not always correlate with efficacy in parasite elimination. Our findings reinforce that while enzymatic inhibition is an important consideration, a more comprehensive evaluation, including cellular and tissue-based assays, is essential to determine the true therapeutic potential of new compounds (<xref rid="B42" ref-type="bibr">42</xref>).</p><p>The differences observed in the activities of both series of compounds (<bold>1&#8211;4</bold> vs. <bold>5&#8211;8</bold>) suggest that the inclusion of the hydroxyl group decreases the trypanocidal activity of this type of compound. This could be related to the potential antioxidant capacity of compound <bold>1&#8211;4</bold> since one of the potential trypanocidal mechanisms proposed for other nitro compounds (<xref rid="B28" ref-type="bibr">28</xref>), including NFX, is associated with the generation of oxidative stress in <italic toggle="yes">T. cruzi</italic>. Furthermore, a hydroxyl group in the structure would quench the radical species formed, reducing oxidative stress and trypanocidal activity.</p><p>Another possible explanation for the low activity displayed by hydroxylated derivatives could be the interaction with the parasite membrane. Compounds with a functional group capable of forming hydrogen bonds can establish a more significant interaction with the components of the cell membrane, preventing them from entering the parasite and efficiently acting on any intracellular target such as enzymes vital for survival or replication of the parasite (<xref rid="B52" ref-type="bibr">52</xref><xref rid="B53" ref-type="bibr">&#8211;</xref><xref rid="B54" ref-type="bibr">54</xref>). This interaction could compete with the increase in lipophilicity of the substituents linked to the thiosemicarbazone fraction, explaining the rise in activity for the most lipophilic compound of this series. Regarding non-hydroxylated compounds (<bold>5&#8211;8</bold>), a trend cannot be established between compound activity and their lipophilicity (<xref rid="T3" ref-type="table">Table 3</xref>) as the possible lipophilic interactions with the parasite cell membrane and, hence, the activity, could be modulated by the overall compound lipophilicity. Slight differences in lipophilicity caused by the substituents linked to the thiosemicarbazone fraction may not significantly impact compound activity.</p><p>On the other hand, a low relationship between trypanocidal activity and the IIc reduction potentials determined was observed. Despite this, a general trend was observed: the compounds with higher trypanocidal activity had lower reduction potentials. This could indicate a potential mechanism of trypanocidal action related to the generation of oxidative stress.</p><p>The toxoplasmicidal activity of all compounds on tachyzoites was also evaluated. <xref rid="F8" ref-type="fig">Figure 8B</xref> shows that the most active compounds contain the hydroxyl group in position 4 of the basic structure of coumarin (<bold>1&#8211;4</bold>). In this parasite, the lipophilicity of the hydroxylated compounds seems to be indirectly proportional to the toxoplasmicidal activity against free tachyzoites, possibly related to differences in components of the parasite&#8217;s cell membrane between <italic toggle="yes">T. cruzi</italic> and <italic toggle="yes">T. gondii</italic> (<xref rid="B55" ref-type="bibr">55</xref>). For compounds <bold>5&#8211;8</bold>, as observed for <italic toggle="yes">T. cruzi</italic>, the changes in lipophilicity do not significantly affect the activity. However, it is evident that for both hydroxylated (<bold>1&#8211;4</bold>) and non-hydroxylated compounds (<bold>5&#8211;8</bold>), introducing a phenyl group in the structure of thiosemicarbazone worsened the toxoplasmicidal activity of the compounds.</p><p>Emami et al. described the toxoplasmicidal activity of a series of coumarin-quinolone derivatives (<xref rid="B37" ref-type="bibr">37</xref>), finding that compounds containing the hydroxylamine group exhibited high activity. However, in our study, we highlight that the thiosemicarbazone fraction plays a more crucial role in the biological activity of the derivatives, particularly in enhancing antiparasitic activity, compared to the coumarin portion, which was critical in the context of coumarin-quinolone derivatives. These results lead us to hypothesize that the thiosemicarbazone fraction plays a more significant role in the biological activity of these derivatives, potentially acting through a different mechanism, such as interference with the parasite&#8217;s metabolic pathways or inhibition of critical enzymes involved in parasite survival.</p><p>The effect of the compounds over intracellular amastigotes of a &#946;-galactosidase-expressing recombinant strain of <italic toggle="yes">T. cruzi</italic> (Tulahuen &#946;-gal) was also evaluated (see Table S4 at <ext-link xlink:href="https://doi.org/10.5281/zenodo.15694236" ext-link-type="uri">https://doi.org/10.5281/zenodo.15694236</ext-link>). Hydroxylated compounds (<bold>1&#8211;4</bold>) did not present activity over intracellular amastigotes, while the non-hydroxylated derivatives (<bold>5&#8211;8</bold>) showed an activity closely associated with their lipophilicity, with compound <bold>8</bold> being the most active. These results indicate that the compounds cross the mammalian cell&#8217;s plasma membrane and exert a trypanocidal effect over intracellular amastigotes. Similarly, intracellular anti-<italic toggle="yes">T</italic>. <italic toggle="yes">gondii</italic> tachyzoite was assessed using quantitative immunocytochemistry targeting the parasite&#8217;s P30 protein (see Table S4 at <ext-link xlink:href="https://doi.org/10.5281/zenodo.15694236" ext-link-type="uri">https://doi.org/10.5281/zenodo.15694236</ext-link>). Similar to what was observed regarding <italic toggle="yes">T. cruzi</italic>, hydroxylated compounds (<bold>1&#8211;4</bold>) exhibited no activity against intracellular parasites, likely due to their inability to traverse mammalian cell membranes. In this case, a modest activity against the intracellular forms of tachyzoites was observed for non-hydroxylated compounds (<bold>5&#8211;8</bold>) (see Table S4 at <ext-link xlink:href="https://doi.org/10.5281/zenodo.15694236" ext-link-type="uri">https://doi.org/10.5281/zenodo.15694236</ext-link>). The complete absence of activity of hydroxylated compounds against intracellular forms of both parasites was confirmed, which could be attributed to their inability to permeate mammalian cell membranes.</p><p>Furthermore, the pharmacokinetic properties of the compounds were evaluated using predictive computational tools from SwissADME (<xref rid="B56" ref-type="bibr">56</xref>), focusing on their potential oral bioavailability and their absorption, distribution, metabolism, and excretion (ADME) profile. The results, presented in Table S5 (see Table S5 at <ext-link xlink:href="https://doi.org/10.5281/zenodo.15694236" ext-link-type="uri">https://doi.org/10.5281/zenodo.15694236</ext-link>), indicate that the compounds have molecular weights ranging from 306.30 to 398.39 Da, with logP values between 0.55 and 2.55, within the range considered suitable for oral absorption according to Lipinski&#8217;s Rule (<xref rid="B57" ref-type="bibr">57</xref>). In addition, the number of hydrogen bond acceptors and donors met the criteria established by this rule (HBA &#8804;10 and HBD &#8804;5), suggesting a favorable profile for oral bioavailability (<xref rid="B58" ref-type="bibr">58</xref>).</p><p>Despite these favorable parameters, the topological polar surface area (TPSA) values ranged from 144.54 to 178.76 &#197;&#178;, exceeding the recommended limit of 140 &#197;&#178;. This could negatively affect intestinal permeability, as reported in previous studies on highly polar drugs (<xref rid="B59" ref-type="bibr">59</xref>). Solubility was evaluated using SwissADME models, which classified the compounds into soluble, moderately soluble, and poorly soluble categories. Compounds <bold>1&#8211;7</bold> were classified as soluble or moderately soluble, whereas compound <bold>8</bold> exhibited limited solubility, which could impact its oral absorption and <italic toggle="yes">in vivo</italic> bioavailability (<xref rid="B60" ref-type="bibr">60</xref>).</p><p>Metabolic interaction analysis indicated that compounds <bold>4</bold> and <bold>8</bold> inhibited the <italic toggle="yes">CYP3A4</italic> enzyme, suggesting a potential risk of pharmacokinetic interactions if co-administered with drugs metabolized by this cytochrome P450 isoform. None of the compounds showed significant inhibition of <italic toggle="yes">CYP1A2, CYP2C19, CYP2C9,</italic> or <italic toggle="yes">CYP2D6</italic>, indicating a lower likelihood of metabolic interactions with these other isoforms. Furthermore, according to the predictive model, the compounds exhibited low gastrointestinal absorption, likely due to their high TPSA values. In addition, none showed the ability to permeate the blood-brain barrier (BBB), suggesting that their action would be limited to the peripheral system, with no significant effects on the central nervous system (<xref rid="B56" ref-type="bibr">56</xref>). These limitations in predicted oral bioavailability and BBB penetration are relevant, particularly in the context of targeting <italic toggle="yes">T. gondii</italic> tissue cysts. However, these compounds are still under early-stage evaluation, and further structural optimization is underway. In addition, future studies will consider alternative delivery strategies, including nanoformulations and exosome-mediated transport, to enhance their pharmacokinetic behavior and tissue-targeting capabilities (<xref rid="B61" ref-type="bibr">61</xref>, <xref rid="B62" ref-type="bibr">62</xref>).</p><p>From a structural perspective, compounds <bold>5&#8211;8</bold>, which lack hydroxyl groups, exhibited lower <italic toggle="yes">TPSA</italic> values and higher lipophilicity. This behavior correlated with greater trypanocidal activity in <italic toggle="yes">in vitro</italic> models, consistent with the hypothesis that greater permeability facilitates the compounds' access to intracellular parasites (<xref rid="B60" ref-type="bibr">60</xref>, <xref rid="B63" ref-type="bibr">63</xref>). However, in <italic toggle="yes">T. gondii</italic>, the trend was different, as the most active compound <bold>1</bold> contained a hydroxyl group, suggesting differences in absorption and metabolism mechanisms between the two parasites.</p><p>On the other hand, compounds <bold>4</bold> and <bold>8</bold>, which inhibited CYP3A4 according to the ADME analysis, demonstrated notable activity, which could be linked to their ability to generate reactive oxygen species (ROS), a mechanism associated with their antiparasitic effect (<xref rid="B64" ref-type="bibr">64</xref>). The generation of ROS by nitro compounds against <italic toggle="yes">T. cruzi</italic> and <italic toggle="yes">T. gondii</italic> suggests that this mechanism may contribute to the observed efficacy (<xref rid="B65" ref-type="bibr">65</xref>, <xref rid="B66" ref-type="bibr">66</xref>). Specifically, <italic toggle="yes">T. gondii</italic> has been shown to induce a state of oxidative stress in infected cells, supporting the hypothesis that ROS-generating compounds can effectively eliminate the parasite (<xref rid="B66" ref-type="bibr">66</xref>). Moreover, recent studies have confirmed that CYP3A4 inhibition can enhance ROS-mediated toxicity in parasitized cells, potentially explaining the differential activity observed in our assays.</p><p>By contrast, hydroxylated compounds (<bold>1&#8211;4</bold>) exhibited higher activity against <italic toggle="yes">T. gondii</italic>, which could be related to the presence of the hydroxyl group at position 4. This group stabilizes reactive species and reduces oxidative stress generation (<xref rid="B67" ref-type="bibr">67</xref>, <xref rid="B68" ref-type="bibr">68</xref>). This suggests that, although oxidative stress may be a relevant mechanism of action, other factors, such as enzyme inhibition or alteration of essential metabolic processes in the parasite, may also contribute to its antiparasitic effect.</p><p>Finally, the physicochemical property profile of the evaluated compounds, presented in Fig. S1 (see Fig. S1 at <ext-link xlink:href="https://doi.org/10.5281/zenodo.15694236" ext-link-type="uri">https://doi.org/10.5281/zenodo.15694236</ext-link>), provides complementary information on their pharmacokinetic behavior and potential for future structural optimizations. These results suggest that additional modifications to the 6-nitrocoumarin-3-thiosemicarbazone hybrids could improve their pharmacokinetic profile and optimize their therapeutic efficacy against <italic toggle="yes">T. cruzi</italic> and <italic toggle="yes">T. gondii</italic>.</p><p>For the most active compounds, <bold>7</bold> and <bold>1</bold> (<xref rid="T3" ref-type="table">Table 3</xref>), the IC<sub>50</sub> values against Dm28 <italic toggle="yes">T. cruzi</italic> trypomastigotes and RH strain <italic toggle="yes">T. gondii</italic> tachyzoites were determined. In addition, CC<sub>50</sub> values were determined on human endothelial cells (EA.hy926) and the trophoblast cell line (BeWo). The last cell line was selected to obtain information regarding the potential application of the compounds in an <italic toggle="yes">ex vivo</italic> infection model (<xref rid="B69" ref-type="bibr">69</xref>). Results are shown in <xref rid="T4" ref-type="table">Table 4</xref>.</p><table-wrap position="float" id="T4" orientation="portrait"><label>TABLE 4</label><caption><p>IC<sub>50</sub> values and selectivity indices for compounds <bold>1</bold> and <bold>7</bold> in human trophoblast cells (BeWo cells), human endothelial cells (EA.hy926), <italic toggle="yes">T. cruzi</italic> trypomastigote parasites of the Dm28 strain, and <italic toggle="yes">T. gondii</italic> tachyzoites of the RH strain</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" valign="bottom" colspan="1" rowspan="1">Compound</th><th align="left" valign="bottom" colspan="1" rowspan="1">IC<sub>50</sub><break/><italic toggle="yes">T. cruzi </italic>(&#956;M)</th><th align="left" valign="bottom" colspan="1" rowspan="1">IC<sub>50</sub><break/><italic toggle="yes">T. gondii</italic> (&#956;M)</th><th align="left" valign="bottom" colspan="1" rowspan="1">CC<sub>50</sub> EA.hy926 cells (&#956;M)</th><th align="left" valign="bottom" colspan="1" rowspan="1">CC<sub>50</sub> BeWo cells (&#956;M)</th><th align="left" valign="bottom" colspan="1" rowspan="1">SI<xref rid="T4_FN1" ref-type="table-fn"><sup><italic toggle="yes">a</italic></sup></xref></th><th align="left" valign="bottom" colspan="1" rowspan="1">SI<xref rid="T4_FN2" ref-type="table-fn"><sup><italic toggle="yes">b</italic></sup></xref></th></tr></thead><tbody><tr><td align="left" valign="bottom" colspan="1" rowspan="1">7</td><td align="left" valign="bottom" colspan="1" rowspan="1">22.4 &#177; 0.8</td><td align="left" valign="bottom" colspan="1" rowspan="1">&#8211;<xref rid="T4_FN3" ref-type="table-fn"><sup><italic toggle="yes">c</italic></sup></xref></td><td align="left" valign="bottom" colspan="1" rowspan="1">128.6 &#177; 0.7</td><td align="left" valign="bottom" colspan="1" rowspan="1">277.9 &#177; 0.4</td><td align="left" valign="bottom" colspan="1" rowspan="1">5.8</td><td align="left" valign="bottom" colspan="1" rowspan="1">12.4</td></tr><tr><td align="left" valign="bottom" colspan="1" rowspan="1">NFX</td><td align="left" valign="bottom" colspan="1" rowspan="1">10 &#177; 0.4<xref rid="T4_FN4" ref-type="table-fn"><sup><italic toggle="yes">d</italic></sup></xref></td><td align="left" valign="bottom" colspan="1" rowspan="1">&#8211;</td><td align="left" valign="bottom" colspan="1" rowspan="1">348.5 &#177; 1.2</td><td align="left" valign="bottom" colspan="1" rowspan="1">&gt;300</td><td align="left" valign="bottom" colspan="1" rowspan="1">34.9</td><td align="left" valign="bottom" colspan="1" rowspan="1">&gt;30</td></tr><tr><td align="left" valign="bottom" colspan="1" rowspan="1">1</td><td align="left" valign="bottom" colspan="1" rowspan="1">&#8211;</td><td align="left" valign="bottom" colspan="1" rowspan="1">17.3 &#177; 0.5</td><td align="left" valign="bottom" colspan="1" rowspan="1">&gt;400</td><td align="left" valign="bottom" colspan="1" rowspan="1">386.9 &#177; 1.0</td><td align="left" valign="bottom" colspan="1" rowspan="1">&gt;23.1</td><td align="left" valign="bottom" colspan="1" rowspan="1">22.3</td></tr><tr><td align="left" valign="bottom" colspan="1" rowspan="1">PMN</td><td align="left" valign="bottom" colspan="1" rowspan="1">&#8211;</td><td align="left" valign="bottom" colspan="1" rowspan="1">20.8 &#177; 1.1</td><td align="left" valign="bottom" colspan="1" rowspan="1">287.5 &#177; 0.9</td><td align="left" valign="bottom" colspan="1" rowspan="1">125.5 &#177; 0.8</td><td align="left" valign="bottom" colspan="1" rowspan="1">13.8</td><td align="left" valign="bottom" colspan="1" rowspan="1">6.03</td></tr></tbody></table><table-wrap-foot><fn id="T4_FN1"><label>
<sup>
<italic toggle="yes">a</italic>
</sup>
</label><p>Selectivity index (SI) = EA.hy926 CC<sub>50</sub> (&#956;M)/parasite IC<sub>50</sub> (&#956;M).</p></fn><fn id="T4_FN2"><label>
<sup>
<italic toggle="yes">b</italic>
</sup>
</label><p>Selectivity index (SI) = BeWo CC<sub>50</sub> (&#956;M)/parasite IC<sub>50</sub> (&#956;M).</p></fn><fn id="T4_FN3"><label>
<sup>
<italic toggle="yes">c</italic>
</sup>
</label><p>&#8211; indicates value not determined.</p></fn><fn id="T4_FN4"><label>
<sup>
<italic toggle="yes">d</italic>
</sup>
</label><p>Reference <xref rid="B70" ref-type="bibr">70</xref>.</p></fn></table-wrap-foot></table-wrap><p>It should be noted that the IC&#8325;&#8320; value reported for pyrimethamine in this table (20.8 &#177; 1.1 &#181;M) was determined using a resazurin-based viability assay applied to extracellular <italic toggle="yes">T. gondii</italic> tachyzoites. This approach differs from the intracellular infection models commonly employed in the literature, which explains the discrepancy with the typically reported nanomolar values. The purpose of this measurement was solely to serve as an internal control under the same experimental conditions applied to the tested compounds. It should not be interpreted as a therapeutic benchmark.</p><p>Neither compound <bold>7</bold> nor compound <bold>1</bold> exhibited toxicity in mammalian cells, indicating good selectivity indexes. Regarding the BeWo cell line, the selectivity index for the <italic toggle="yes">T. cruzi</italic> activity obtained for compound <bold>7</bold> is comparable to the reference drug NFX. It is relevant to note that the inclusion of the nitro group in coumarin-thiosemicarbazone hybrids increased the anti<italic toggle="yes">-T. cruzi</italic> activity without increasing mammalian cell toxicity (<xref rid="B40" ref-type="bibr">40</xref>, <xref rid="B41" ref-type="bibr">41</xref>). In the case of <italic toggle="yes">T. gondii</italic>, the results indicate that compound <bold>1</bold> has high activity against tachyzoites and low cytotoxic activity against BeWo cells, obtaining an SI like that obtained for PMN, considered a potential toxoplasmicidal compound. The CC<sub>50</sub> curves of the compounds and drugs in the different mammalian cell lines are shown in Fig. S2 (see Fig. S2 at <ext-link xlink:href="https://doi.org/10.5281/zenodo.15694236" ext-link-type="uri">https://doi.org/10.5281/zenodo.15694236</ext-link>) and determined IC<sub>50</sub> values on trypomastigotes and tachyzoites are shown in Fig. S3 (see Fig. S3 at <ext-link xlink:href="https://doi.org/10.5281/zenodo.15694236" ext-link-type="uri">https://doi.org/10.5281/zenodo.15694236</ext-link>).</p><p>These data were interpreted considering commonly accepted progression criteria in the antiparasitic drug discovery pipeline for <italic toggle="yes">T. cruzi</italic>, as discussed by Gabald&#243;n-Figueira et al. (<xref rid="B71" ref-type="bibr">71</xref>). According to this framework, compounds with IC<sub>50</sub> values below 5 &#181;M (ideally &lt;1 &#181;M), selectivity index (SI) &gt;10 (ideally &gt;100), and cytotoxicity above 25 &#181;M in mammalian cells are considered potential leads. While the IC&#8325;&#8320; values of our compounds are in the micromolar range, they exhibit low toxicity in both endothelial and placental cells and satisfy selectivity thresholds, particularly in BeWo cells. Their ability to reduce parasite load in both 2D and <italic toggle="yes">ex vivo</italic> placental models supports their potential as chemical scaffolds for further optimization in the hit-to-lead phase.</p><p>It is essential to clarify that the primary objective of this work was not to present fully optimized drug candidates, but rather to explore a novel chemical scaffold with relevant biological activity, low cytotoxicity, and promising behavior in physiologically relevant models.</p><p>While the current potency is still moderate and further optimization will be required to improve efficacy and pharmacokinetic properties, the antiparasitic activity observed <italic toggle="yes">in vitro</italic>, along with the favorable toxicity profile, supports the value of these compounds as chemical starting points for future structure&#8211;activity relationship (SAR) studies.</p><p>The compounds evaluated in this study demonstrate significant antiparasitic activity against <italic toggle="yes">T. cruzi</italic> and <italic toggle="yes">T. gondii</italic>. This approach allows for a comprehensive assessment of their therapeutic potential, evaluating their effectiveness against different forms of parasites. The results highlight the broad-spectrum activity of the compounds, emphasizing their potential as effective therapeutic agents for the treatment of parasitic infections.</p><p>While the evaluated compounds demonstrated relevant activity in cellular models, identifying their mechanism of action is crucial for their optimization as potential therapeutic candidates. One possible mechanism to explain the observed activity is the generation of reactive oxygen species (ROS), as other coumarin derivatives have shown pro-oxidant effects in <italic toggle="yes">T. cruzi</italic> and <italic toggle="yes">T. gondii</italic>. To confirm this hypothesis, specific studies were conducted to quantify ROS formation in parasites treated with the most active compounds.</p></sec><sec id="s2-5"><title>Study of potential mechanisms of action</title><p>To evaluate a potential mechanism of action of the 6-nitrocoumarin-3-thiosemicarbazone hybrids, the formation of intracellular reactive oxygen species (ROS) was determined by quantifying the dichlorofluorescein (DCF) probe. ROS generation was evaluated in <italic toggle="yes">Toxoplasma gondii</italic> tachyzoites and <italic toggle="yes">Trypanosoma cruzi</italic> trypomastigotes, using the most active compounds for each parasite.</p><p>In the case of <italic toggle="yes">T. cruzi</italic>, compound <bold>7</bold> showed a significant increase in ROS generation compared to the untreated control, surpassing the effect observed for menadione (<xref rid="F10" ref-type="fig">Fig. 10A</xref>). This result is consistent with previous studies that demonstrated the formation of intracellular radical species in coumarin-thiosemicarbazone hybrids without a nitro group (<xref rid="B41" ref-type="bibr">41</xref>). The incorporation of the nitro group appears to enhance oxidative stress generation, supporting its pro-oxidant mechanism of action in <italic toggle="yes">T. cruzi</italic> (<xref rid="B32" ref-type="bibr">32</xref>, <xref rid="B43" ref-type="bibr">43</xref>, <xref rid="B45" ref-type="bibr">45</xref>). In addition, electrochemical studies of these compounds revealed a more favorable reduction of the nitro group compared to nitro derivatives at position 3 of the coumarin. This could facilitate the formation of reactive species responsible for oxidative damage to the parasite (<xref rid="B32" ref-type="bibr">32</xref>).</p><fig position="float" fig-type="figure" id="F10" orientation="portrait"><label>Fig 10</label><caption><p>ROS were generated in <italic toggle="yes">T. cruzi</italic> and <italic toggle="yes">T. gondii</italic> after exposure to the evaluated compounds. (<bold>A</bold>) DCF fluorescence kinetics in <italic toggle="yes">T. cruzi</italic> trypomastigotes (strain Dm28) treated with compound 7, menadione (positive control), and untreated control. (<bold>B</bold>) DCF fluorescence kinetics in <italic toggle="yes">T. gondii</italic> tachyzoites (strain RH) treated with compound 1, menadione, and untreated control. (<bold>C</bold>) DCF fluorescence in BeWo cells after exposure to compounds 1 and 7, and menadione. The data represent the mean &#177; SD of three independent experiments (one-way ANOVA with Dunnett&#8217;s post hoc test; ****<italic toggle="yes">P</italic> &#8804; 0.0001; ***<italic toggle="yes">P</italic> &#8804; 0.001; **<italic toggle="yes">P</italic> &#8804; 0.01; *<italic toggle="yes">P</italic> &#8804; 0.05).</p></caption><graphic position="float" orientation="portrait" xlink:href="aac.00454-25.f010.jpg"><alt-text>Bar graphs comparing AUCmeta values indicate that Compound 7 significantly increases oxidative stress, Compound 1 has moderate effect, and neither compound induces significant stress in the presence of Menadione.</alt-text></graphic></fig><p>In <italic toggle="yes">T. gondii</italic>, ROS formation was determined in RH strain tachyzoites using menadione as a positive control. A significant increase in ROS production was observed following exposure to menadione. At the same time, compound <bold>1</bold> also led to an increase in ROS levels, albeit lower than the positive control, but significantly higher than the untreated control (<xref rid="F10" ref-type="fig">Fig. 10B</xref>). However, this compound contains a hydroxyl group at position 4 of the coumarin, which may be modulating its pro-oxidant effect. Hydroxyl groups have been described as antioxidants through the hydrogen atom transfer (HAT) mechanism, stabilizing reactive species and reducing oxidative stress generation (<xref rid="B67" ref-type="bibr">67</xref>, <xref rid="B68" ref-type="bibr">68</xref>).</p><p>This behavior suggests that although oxidative stress may contribute to the antiparasitic activity of these compounds, it is not the sole mechanism involved in their action against <italic toggle="yes">T. gondii</italic>. The literature suggests that <italic toggle="yes">T. gondii</italic> relies on its antioxidant system to counteract oxidative damage induced by drugs (<xref rid="B72" ref-type="bibr">72</xref>). Since compound <bold>1</bold> induces lower ROS levels in <italic toggle="yes">T. gondii</italic> yet retains significant antiparasitic activity, other mechanisms, such as enzyme inhibition or interference with protein biosynthesis, may also be involved (<xref rid="B72" ref-type="bibr">72</xref>). This is consistent with previous studies on thiosemicarbazone compounds, where their activity has been proposed to be mediated by mitochondrial dysfunction and the inhibition of essential proteases required for parasite survival.</p><p>In addition, ROS generation was evaluated in BeWo cells to rule out non-selective cytotoxic effects (<xref rid="F10" ref-type="fig">Fig. 10C</xref>). Unlike in parasites, the compounds did not induce a significant increase in ROS levels in these cells, suggesting a potential selectivity of action. This finding aligns with the low cytotoxicity observed in cell viability assays and supports the hypothesis that nitro group bioactivation occurs preferentially within the intracellular environment of the parasite.</p><p>These findings position the 6-nitrocoumarin-3-thiosemicarbazone hybrids as promising candidates for the treatment of <italic toggle="yes">T. cruzi</italic> and <italic toggle="yes">T. gondii</italic> infections, highlighting oxidative stress as a potential mechanism of action in <italic toggle="yes">T. cruzi</italic>. However, the lower ROS generation in <italic toggle="yes">T. gondii</italic> suggests that oxidative stress is not the exclusive mechanism, and other biological processes may contribute to its antiparasitic effect. The introduction of the nitro group into the coumarin core is a key strategy for enhancing trypanocidal activity. By contrast, the presence of the hydroxyl group at position 4 may modulate toxoplasmicidal activity by conferring antioxidant capacity.</p><p>Future studies should further evaluate the contribution of parasite antioxidant enzyme inhibition and potential interference with the redox machinery of <italic toggle="yes">T. gondii</italic> to validate whether oxidative stress is a complementary mechanism in this parasite or if these compounds act through a different pathway.</p></sec><sec id="s2-6"><title>Study of the generation of radical species by spin trapping</title><p>To characterize the reactive radical species formed and confirm oxidative stress as a possible mechanism of action, the spin-trap technique was used with DMPO in <italic toggle="yes">Trypanosoma cruzi</italic> trypomastigotes and <italic toggle="yes">Toxoplasma gondii</italic> tachyzoites, employing the most active compounds against each parasite.</p><p><xref rid="F11" ref-type="fig">Figure 11A</xref> shows that incubation with menadione under aerobic conditions produced a triplet (aN ~15.5 G) corresponding to a DMPO-derived oxidized paramagnetic compound (DMPOX, 5,5-dimethyl-2-oxopyrroline-1-oxyl), marked with (&#8595;) in the spectrum. This signal is related to the prior formation of hydroxyl radicals, as previously described in our studies (<xref rid="B33" ref-type="bibr">33</xref>, <xref rid="B73" ref-type="bibr">73</xref>, <xref rid="B74" ref-type="bibr">74</xref>).</p><fig position="float" fig-type="figure" id="F11" orientation="portrait"><label>Fig 11</label><caption><p>Electron spin resonance (ESR) spectra in <italic toggle="yes">T. cruzi</italic> and <italic toggle="yes">T. gondii</italic> after exposure to the tested compounds. (<bold>A</bold>) ESR spectrum recorded in <italic toggle="yes">T. cruzi</italic> trypomastigotes (strain Dm28) incubated with compound 7 and DMPO. Signals corresponding to hydroxyl radicals (+), carbon-centered radicals (*), and the oxidized adduct of DMPO (DMPOX; marked with &#8595;) are observed. (<bold>B</bold>) ESR spectrum recorded in <italic toggle="yes">T. gondii</italic> tachyzoites (strain RH) incubated with compound 1 and DMPO. Compared to <italic toggle="yes">T. cruzi</italic>, with carbon-centered radicals (*), DMPOX (&#8595;), lower intensity signals are observed.</p></caption><graphic position="float" orientation="portrait" xlink:href="aac.00454-25.f011.jpg"><alt-text>EPR spectra comparing Compounds 7 and 1 with Menadione and control reveal distinct radical formation. Compound 7 induces strong radical signals, while Compound 1 shows moderate intensity. Controls exhibit negligible signal under magnetic field range.</alt-text></graphic></fig><p>Interestingly, treatment with compound <bold>7</bold> generated a series of complex signals associated with the formation of different free radicals. Among them, signals corresponding to hydroxyl radical generation (aN = aH ~ 14.00 G, marked with (*)) were identified (<xref rid="B74" ref-type="bibr">74</xref>, <xref rid="B75" ref-type="bibr">75</xref>). In addition, signals attributable to the formation of the delocalized nitro radical in the aromatic system were detected, as had been recorded in the electrolytic generation of free radicals, and this was identifiable by hyperfine coupling constants in <xref rid="T2" ref-type="table">Table 2</xref>.</p><p>These signals suggest that compound <bold>7</bold> was reduced by the parasite&#8217;s nitroreductases, leading to the formation of radical species. This indicates a strong link between oxidative stress generation and the parasite&#8217;s antiparasitic mechanism of action. However, this mechanism does not rule out the possible involvement of other pathways, such as interference with key enzymes involved in parasite redox homeostasis.</p><p>The same experiment was conducted on <italic toggle="yes">T. gondii</italic> tachyzoites (<xref rid="F11" ref-type="fig">Fig. 11B</xref>). Treatment with menadione (positive control) resulted in the formation of multiple signals, which were assigned based on their hyperfine coupling constants. A triplet (aN ~15.6 G) corresponding to a DMPO-derived oxidized paramagnetic compound (DMPOX) was detected, marked with (&#8595;) in the spectrum. In addition, a sextet corresponding to the trapping of a carbon-centered radical (aN ~16.00 G, aH ~23.00 G, marked with (+)) was observed. A signal associated with hydroxyl radical generation (aN = aH ~ 14.00 G, marked with (*)) was also detected (<xref rid="B33" ref-type="bibr">33</xref>, <xref rid="B41" ref-type="bibr">41</xref>, <xref rid="B45" ref-type="bibr">45</xref>, <xref rid="B75" ref-type="bibr">75</xref>).</p><p>On the other hand, treatment with compound <bold>1</bold> showed the formation of only two spin adducts, associated with the trapping of a carbon-centered radical and the DMPOX adduct. The lower number of radical species generated compared to <italic toggle="yes">T. cruzi</italic> reinforces the idea that while the toxoplasmicidal activity of these compounds may be related to oxidative stress generation, this may not be the sole mechanism involved.</p><p>The differences observed in the spectra of <italic toggle="yes">T. cruzi</italic> and <italic toggle="yes">T. gondii</italic> indicate variations in their endogenous antioxidant mechanisms (<xref rid="B66" ref-type="bibr">66</xref>, <xref rid="B76" ref-type="bibr">76</xref>). It has been reported that <italic toggle="yes">T. gondii</italic> possesses a highly efficient redox system capable of neutralizing oxidative stress induced by pro-oxidant compounds (<xref rid="B64" ref-type="bibr">64</xref>). However, within the scope of this study, the formation of radical species in both parasites suggests that oxidative stress generation is a potential mechanism of action for these compounds.</p><p>Despite these findings, further studies are necessary to better understand the differences in each parasite&#8217;s response. Future research could focus on evaluating the expression of antioxidant genes in <italic toggle="yes">T. gondii</italic> and <italic toggle="yes">T. cruzi</italic> in response to these compounds and analyzing their enzymatic effect on parasite nitroreductases.</p><p>Based on the results obtained, it is postulated that the trypanocidal mechanism of 6-nitrocoumarin-3-thiosemicarbazone hybrids involves the bioreduction of the nitro group and the subsequent formation of free radicals in the parasite&#8217;s intracellular environment. A viable strategy for developing more effective and less cytotoxic trypanocidal and toxoplasmicidal drugs would be to retain the basic hybrid structure while optimizing its physicochemical properties through the formation of coordination complexes with transition metals, which could enhance its biological effect through additional bioactivation mechanisms.</p></sec><sec id="s2-7"><title>Effect of compounds on the infection of cells</title><p>The studies on ROS generation and electrochemical characterization suggest that the mechanism of action of these compounds may be related to the bioreduction of the nitro group and the induction of oxidative stress in <italic toggle="yes">T. cruzi</italic> and <italic toggle="yes">T. gondii</italic>. However, their impact on cellular and tissue infection was evaluated to confirm whether this effect directly contributes to parasite elimination in a biologically relevant environment. In addition, ADME analyses indicated that the lipophilicity of the compounds could influence their ability to cross cellular membranes and reach intracellular targets. Therefore, infection studies were conducted in trophoblast cells and placental explants to assess the efficacy of the compounds in reducing parasite burden, both in early infection stages and intracellular parasite forms.</p><p>The effect of the compounds on the infection of BeWo trophoblast cells by <italic toggle="yes">T. gondii</italic> and <italic toggle="yes">T. cruzi</italic> was assessed. The DNA of <italic toggle="yes">T. gondii</italic> and <italic toggle="yes">T. cruzi</italic> was quantified in infected BeWo cells treated for 24 hours under two conditions: co-incubation and post-infection treatment. The most active compounds, <bold>1</bold> and <bold>7</bold> for <italic toggle="yes">T. gondii</italic> and <italic toggle="yes">T. cruzi</italic>, respectively, were used at their IC<sub>50</sub> concentrations, previously determined (<xref rid="T4" ref-type="table">Table 4</xref>). Fluorescence microscopy was employed to quantify the number of infected cells. The resulting images were analyzed using ImageJ software to count both infected and uninfected cells.</p><p><xref rid="F12" ref-type="fig">Figure 12</xref> shows the fluorescence microscopy images and parasite DNA levels by real-time qPCR of <italic toggle="yes">T. cruzi-</italic>infected trophoblast cells after different treatments. Co-incubation treatment with compound <bold>7</bold> reduced parasite DNA load by more than 50% compared to the negative control at IC<sub>50</sub> concentration (<xref rid="F10" ref-type="fig">Fig. 10B</xref>). Furthermore, the number of infected cells significantly decreased compared to the control without treatment (<xref rid="T5" ref-type="table">Table 5</xref>). These results are consistent with the activity observed against free parasites. The reduction in the infection rate of trophoblast cells during co-incubation suggests a potential inhibition of virulence factors involved in the parasitic invasion. However, we acknowledge that this observation might also reflect broader effects on parasite viability or energy metabolism. Since invasion is an active process that requires mitochondrial function and ATP availability, it is also possible that the observed inhibition results from impaired energetic processes. While our current data do not allow us to distinguish between these mechanisms, the significant reduction in infection still supports an early antiparasitic effect of compound <bold>7</bold>. Considering the previously documented activities of thiosemicarbazones, it is plausible that this effect is related to the inhibition of cruzipain, as described by Nunes for coumarin-3-thiosemicarbazone derivatives (<xref rid="B42" ref-type="bibr">42</xref>, <xref rid="B77" ref-type="bibr">77</xref>, <xref rid="B78" ref-type="bibr">78</xref>). Similar results had been obtained for the non-nitrated analogs (<xref rid="B41" ref-type="bibr">41</xref>).</p><fig position="float" fig-type="figure" id="F12" orientation="portrait"><label>Fig 12</label><caption><p>(A) Microscopic analysis of BeWo cells exposed to trypomastigotes of the Dm28 strain at a 1:1 ratio and treated with compound <bold>7</bold> and NFX at their IC<sub>50</sub> concentrations. (a and b) Cells exposed to trypomastigotes without treatment, (c and d) co-incubation treatments with compound 7 or (e and f) NFX at the time of infection, (g and h) post-infection treatment with compound 7 or (i and j) NFX. Nuclear staining with DAPI for BeWo cell nuclei and <italic toggle="yes">T. cruzi</italic> kinetoplast (a, c, e, g, i), phase contrast (b, d, f, h, j); arrows indicate areas with amastigotes. The conditions of uninfected cells are shown found in Fig. S4 (see Fig. S4 at <ext-link xlink:href="https://zenodo.org/records/15694236" ext-link-type="uri">https://zenodo.org/records/15694236</ext-link>). Bar scale: 10 &#181;m. (B) Relative quantification (RQ) of <italic toggle="yes">T. cruzi</italic> DNA load in BeWo after co-incubation with compound 7 and NFX at IC<sub>50</sub> concentrations during a 24 hour infection. (C) Relative quantification (RQ) of <italic toggle="yes">T. cruzi</italic> DNA load in BeWo after 24 hour post-infection treatment with compound 7 and NFX at IC<sub>50</sub> concentrations, following an initial 24 hour infection (one-way ANOVA with Dunnett&#8217;s post-test: (****<italic toggle="yes">P</italic> &#8804; 0.0001; **<italic toggle="yes">P</italic> &#8804; 0.01; *<italic toggle="yes">P</italic> &#8804; 0.05).</p></caption><graphic position="float" orientation="portrait" xlink:href="aac.00454-25.f012.jpg"><alt-text>Fluorescence and phase-contrast microscopy reveal reduced T. cruzi presence upon treatment with Compound 7 or NFX. Bar graphs confirm significantly decreased parasite DNA levels in both co-incubation and post-infection assays.</alt-text></graphic></fig><table-wrap position="float" id="T5" orientation="portrait"><label>TABLE 5</label><caption><p>Determination of the effect of derivative 7 and NFX on the infection of BeWo cells by <italic toggle="yes">T. cruzi</italic> at the time of infection (co-incubation) and on the intracellular forms of the parasites (post-infection)<xref rid="T5_FN1" ref-type="table-fn"><sup><italic toggle="yes">a</italic></sup></xref></p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" valign="bottom" colspan="1" rowspan="1">Sample</th><th align="left" valign="bottom" colspan="1" rowspan="1">Treatment</th><th align="left" valign="bottom" colspan="1" rowspan="1">Infected cells (%)</th><th align="left" valign="bottom" colspan="1" rowspan="1">Significance</th></tr></thead><tbody><tr><td align="left" valign="top" colspan="1" rowspan="1">Control</td><td align="left" valign="top" colspan="1" rowspan="1">&#8211;<xref rid="T5_FN2" ref-type="table-fn"><sup><italic toggle="yes">b</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">24 &#177; 3</td><td align="left" valign="top" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">NFX</td><td align="left" valign="top" colspan="1" rowspan="1">Co-inc</td><td align="left" valign="top" colspan="1" rowspan="1">2 &#177; 1</td><td align="left" valign="top" colspan="1" rowspan="1">****</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">7</td><td align="left" valign="top" colspan="1" rowspan="1">Co-inc</td><td align="left" valign="top" colspan="1" rowspan="1">4 &#177; 1</td><td align="left" valign="top" colspan="1" rowspan="1">****</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">NFX</td><td align="left" valign="top" colspan="1" rowspan="1">Post-inf</td><td align="left" valign="top" colspan="1" rowspan="1">23 &#177; 4</td><td align="left" valign="top" colspan="1" rowspan="1">NS</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">7</td><td align="left" valign="top" colspan="1" rowspan="1">Post-inf</td><td align="left" valign="top" colspan="1" rowspan="1">17 &#177; 4</td><td align="left" valign="top" colspan="1" rowspan="1">*</td></tr></tbody></table><table-wrap-foot><fn id="T5_FN1"><label>
<sup>
<italic toggle="yes">a</italic>
</sup>
</label><p>Compound concentrations used correspond to the IC<sub>50</sub> values previously obtained (one-way ANOVA with Dunnett's post-test; ****<italic toggle="yes">P</italic> &#8804; 0.0001; *<italic toggle="yes">P</italic> &#8804; 0.05; NS: non-significant).</p></fn><fn id="T5_FN2"><label>
<sup>
<italic toggle="yes">b</italic>
</sup>
</label><p>&#8211; indicates not applicable (no treatment applied).</p></fn></table-wrap-foot></table-wrap><p>These results suggest that the observed decrease in parasite load could be related to the ability of the compounds to induce oxidative stress and affect parasite viability in the intracellular environment. Since these compounds have been shown to generate ROS, this effect may contribute to the inhibition of parasite proliferation in BeWo cells.</p><p>On the other hand, in the case of post-infection treatment (<xref rid="F12" ref-type="fig">Fig. 12C</xref>), it was observed that compound <bold>7</bold> reduced the parasite DNA load to a lesser extent than during co-incubation, suggesting a lower activity against the intracellular form of <italic toggle="yes">T. cruzi</italic>. <xref rid="T5" ref-type="table">Table 5</xref> shows that compound <bold>7</bold> slightly decreased the number of infected cells, as seen in <xref rid="F12" ref-type="fig">Fig. 12</xref>. It is essential to highlight that these methodologies (DAPI nuclear staining and qPCR) allow quantifying the number of <italic toggle="yes">T. cruzi</italic> nuclei or parasite DNA, but do not discriminate between live or dead parasites. Therefore, these results indicate that compound <bold>7</bold> exhibited activity that decreased the intracellular proliferation of <italic toggle="yes">T. cruzi</italic> compared to the untreated control. The introduction of the nitro group in the coumarin fraction also improved the activity.</p><p>The expected activity was observed for NFX (<xref rid="F12" ref-type="fig">Fig. 12</xref>), based on the fact that this drug usually has significant antiparasitic efficacy during the first weeks after infection, when the predominant form of the parasite is the trypomastigote. However, it shows reduced activity in posterior stages, where the intracellular form predominates. Compound <bold>7</bold> seems to behave similarly in treating both chronic and acute <italic toggle="yes">T. cruzi</italic> infections compared to NFX, with a tendency to perform better for the chronic one (<xref rid="B7" ref-type="bibr">7</xref>).</p><p>Compound concentrations used correspond to the IC<sub>50</sub> values previously obtained (one-way ANOVA with Dunnett&#8217;s post-test; ****<italic toggle="yes">P</italic> &#8804; 0.0001; *<italic toggle="yes">P</italic> &#8804; 0.05; NS: non-significant).</p><p>For the infection of trophoblast cells, the treatment for <italic toggle="yes">T. gondii</italic> infection in co-incubation with compounds <bold>1</bold> and PMN reduced the parasite DNA load (<xref rid="F13" ref-type="fig">Fig. 13A B</xref>). A decrease of around 50% in the parasite DNA load in co-incubation with compound <bold>1</bold> was observed, while the effect of PMN was more significant. These results are consistent with those obtained for the evaluation of toxoplasmicidal compounds using the free parasite and a sensitive redox agent such as resazurin. Likewise, co-incubation with compound <bold>1</bold> also reduced the rate of infection of BeWo cells (<xref rid="T6" ref-type="table">Table 6</xref>). It did not reduce the immunoreactivity for <italic toggle="yes">T. gondii</italic> in the infected cells, which initially demonstrates a disadvantage of this compound against PMN.</p><fig position="float" fig-type="figure" id="F13" orientation="portrait"><label>Fig 13</label><caption><p>(A) Microscopic analysis of BeWo cells exposed to tachyzoites of the RH strain at a 1:1 ratio and treated with compound 1 and PMN at their IC<sub>50</sub> concentrations. (a&#8211;d) cells exposed to tachyzoites without treatment, (e&#8211;h) co-incubation treatments included compound 1 or (i&#8211;l) PMN at the time of infection, (m&#8211;p) post-infection treatments were applied 24 hours later with compound 1 or (q&#8211;t) PMN. Nuclear staining with DAPI for BeWo cell nuclei (a, e, i, m, and q). Immunofluorescence of P30 protein of <italic toggle="yes">T. gondii</italic> (b, f, j, and r). Merged DAPI and immunofluorescence (c, g, k, o, and s). Phase contrast (d, h, l, p, and r). Arrows indicate areas of major immunoreactivity. The conditions of uninfected cells are shown in Fig. S5 (see Fig. S5 at <ext-link xlink:href="https://zenodo.org/records/15694236" ext-link-type="uri">https://zenodo.org/records/15694236</ext-link>). The conditions of uninfected cells and cells not treated with anti-P30 antibody are shown in Fig. S5 (see Fig. S5 at <ext-link xlink:href="https://zenodo.org/records/15694236" ext-link-type="uri">https://zenodo.org/records/15694236</ext-link>). Bar scale: 10 &#181;m. (B) Relative quantification (RQ) of <italic toggle="yes">T. gondii</italic> DNA load in BeWo after co-incubation with compound 1 and PMN at IC<sub>50</sub> concentrations during a 24 hour infection. (C) RQ of <italic toggle="yes">T. gondii</italic> DNA load in BeWo after a 24 hour post-infection treatment with compound 1 and PMN at IC<sub>50</sub> concentrations, following an initial 24 hour infection (one-way ANOVA with Dunnett&#8217;s post-test: (****<italic toggle="yes">P</italic> &#8804; 0.0001; ***<italic toggle="yes">P</italic> &#8804; 0.001; **<italic toggle="yes">P</italic> &#8804; 0.01).</p></caption><graphic position="float" orientation="portrait" xlink:href="aac.00454-25.f013.jpg"><alt-text>Immunofluorescence and phase images show reduced T. gondii signal after treatment with Compound 1 or PMN. Bar graphs confirm significant decrease in parasite DNA during co-incubation and post-infection, with PMN being more effective than Compound 1.</alt-text></graphic></fig><table-wrap position="float" id="T6" orientation="portrait"><label>TABLE 6</label><caption><p>Determination of the effect of compound 1 and PMN on the infection of BeWo cells by <italic toggle="yes">T. gondii</italic> at the time of infection (co-incubation) and the intracellular forms of the parasites (post-infection)<xref rid="T6_FN1" ref-type="table-fn"><sup><italic toggle="yes">a</italic></sup></xref></p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" valign="top" colspan="1" rowspan="1">Sample</th><th align="left" valign="bottom" colspan="1" rowspan="1">Treatment</th><th align="left" valign="top" colspan="1" rowspan="1">Infected cells (%)</th><th align="left" valign="top" colspan="1" rowspan="1">Significance</th></tr></thead><tbody><tr><td align="left" valign="top" colspan="1" rowspan="1">Control</td><td align="left" valign="top" colspan="1" rowspan="1">&#8211;<xref rid="T6_FN2" ref-type="table-fn"><sup><italic toggle="yes">b</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">64 &#177; 6</td><td align="left" valign="top" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">PMN</td><td align="left" valign="top" colspan="1" rowspan="1">Co-inc</td><td align="left" valign="top" colspan="1" rowspan="1">19 &#177; 2</td><td align="left" valign="top" colspan="1" rowspan="1">****</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">1</td><td align="left" valign="top" colspan="1" rowspan="1">Co-inc</td><td align="left" valign="top" colspan="1" rowspan="1">32 &#177; 7</td><td align="left" valign="top" colspan="1" rowspan="1">****</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">PMN</td><td align="left" valign="top" colspan="1" rowspan="1">Post-inf</td><td align="left" valign="top" colspan="1" rowspan="1">16 &#177; 4</td><td align="left" valign="top" colspan="1" rowspan="1">****</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">1</td><td align="left" valign="top" colspan="1" rowspan="1">Post-inf</td><td align="left" valign="top" colspan="1" rowspan="1">52 &#177; 4</td><td align="left" valign="top" colspan="1" rowspan="1">*</td></tr></tbody></table><table-wrap-foot><fn id="T6_FN1"><label>
<sup>
<italic toggle="yes">a</italic>
</sup>
</label><p>Compound concentrations used correspond to the IC<sub>50</sub> values previously obtained (one-way ANOVA with Dunnett's post-test; ****<italic toggle="yes">P</italic> &#8804; 0.0001; *<italic toggle="yes">P</italic> &#8804; 0.05; NS: not significant).</p></fn><fn id="T6_FN2"><label>
<sup>
<italic toggle="yes">b</italic>
</sup>
</label><p>&#8211; indicates not applicable (no treatment applied).</p></fn></table-wrap-foot></table-wrap><p>In the case of post-infection treatment, PMN significantly reduced the parasite DNA load of <italic toggle="yes">T. gondii</italic> (<xref rid="F13" ref-type="fig">Fig. 13C</xref>). However, compound <bold>1</bold> had no activity against the intracellular form.</p><p>Regarding the post-infection treatment, the results obtained through the quantification of intracellular parasites using fluorescence microscopy (<xref rid="F13" ref-type="fig">Fig. 13A</xref>) show a statistical similarity with the values obtained in the quantification by parasite DNA loading in the <italic toggle="yes">in vitro</italic> model, where it is confirmed that compound <bold>1</bold> does not present a toxoplasmicidal activity by reducing infected cells, which is satisfactorily explained by the inability of hydroxylated compounds of permeating the mammalian cell membrane. Hence, they did not have intracellular activity. Despite this, the result highlights the importance of considering this physicochemical characteristic for the rational design of toxoplasmicidal compounds or the possibility of improving bioavailability using drug vehicles that can facilitate the entry of this type of compound into the infected cell, potentially allowing for direct action against <italic toggle="yes">T. gondii</italic>.</p><p>In addition, the limited effect observed for compound <bold>1</bold> in post-infection treatment may reflect a restricted activity window associated with specific stages of the <italic toggle="yes">T. gondii</italic> lytic cycle. Recent studies have demonstrated that thiosemicarbazones can induce a transient, non-genetic adaptation in <italic toggle="yes">T. gondii</italic>, characterized by stress-induced changes in the expression of transporters and ribosomal proteins (<xref rid="B62" ref-type="bibr">62</xref>). Although our data do not support stable resistance, it is possible that compound 1 acts primarily during invasion or early intracellular processes, rather than during sustained replication. Future optimization efforts will focus on structural modifications designed to improve intracellular efficacy and evaluate potential adaptive responses more specifically.</p><p>Our data show compounds <bold>5&#8211;8</bold> were active against intracellular stages of two <italic toggle="yes">T. cruzi</italic> strains belonging to distant genetic lineages: Dm28 (TcI) and Tulahuen (TcVI). It is tempting to speculate that the studied compounds would also be active against other, genetically different, strains of <italic toggle="yes">T. cruzi</italic>. Experimental confirmation of this claim warrants further studies.</p><p>On the other hand, the lower activity observed in the post-infection condition could be related to the difficulty of the compounds crossing cell membranes and reaching their intracellular targets. Furthermore, in <italic toggle="yes">T. cruzi</italic> and <italic toggle="yes">T. gondii</italic>, the presence of antioxidant systems could contribute to the intracellular forms&#8217; resistance to oxidative stress induced by the compounds.</p></sec><sec id="s2-8"><title>Effect of compounds in the infection of HPE</title><p>The infection of HPE by <italic toggle="yes">T. cruzi</italic> and <italic toggle="yes">T. gondii</italic> has revealed differentiated immune responses and defense mechanisms, highlighting the complexity of the pathogen-host interaction in this tissue (<xref rid="B79" ref-type="bibr">79</xref>). Among the primary defense mechanisms observed for both pathogens is the detachment of the trophoblast from the free chorionic villi. However, this mechanism may not stop the progress of the infection, resulting in significant tissue damage (<xref rid="B80" ref-type="bibr">80</xref>, <xref rid="B81" ref-type="bibr">81</xref>). This damage is characterized by the disorganization of the extracellular matrix, evidenced by the loss of integrity in the distribution of key extracellular matrix components such as collagen and fibronectin. Thus, the HPE model has been widely used to study pathogen-host interactions and to evaluate drugs and compounds with antiparasitic activity, especially in the case of <italic toggle="yes">T. gondii</italic> (<xref rid="B8" ref-type="bibr">8</xref>). This model offers an advantage over traditional <italic toggle="yes">in vitro</italic> models by allowing detailed histopathological analysis, providing a more comprehensive view of the effects of drugs in terms of both efficacy and toxicity.</p><p>The effect on HPE infection of compounds <bold>1</bold> and <bold>7</bold> by <italic toggle="yes">Toxoplasma gondii</italic> and <italic toggle="yes">Trypanosoma cruzi</italic>, respectively, was evaluated. To do this, the DNA of the <italic toggle="yes">T. gondii</italic> or <italic toggle="yes">T. cruzi</italic> parasite was quantified by infecting HPE for 24 hours under treatment conditions of co-incubation of compounds with the parasite at the same time of infection, and with a 24 hour post-infection treatment. The compound&#8217;s IC<sub>50</sub> concentration value previously obtained under both conditions was used.</p><p><xref rid="F14" ref-type="fig">Figure 14</xref> shows the effects of compound <bold>7</bold> on the DNA load of the <italic toggle="yes">T. cruzi</italic> parasite in co-incubation and post-infection treatments, respectively, as well as the histological images of the HPE with the different treatments. The co-incubation treatment significantly reduced the parasite DNA load, showing a trend like that observed in the <italic toggle="yes">in vitro</italic> model. However, in this model, a higher parasite load was recorded for co-incubation compared to what was observed in BeWo cells, suggesting that the parasite, when coincubated with the compounds, could have a greater entry capacity to tissue compared to its ability to infect BeWo cells.</p><fig position="float" fig-type="figure" id="F14" orientation="portrait"><label>Fig 14</label><caption><p>(A) Histological analysis of HPE exposed to <italic toggle="yes">T. cruzi</italic>, compound 7, and NFX at their respective IC<sub>50</sub> values. HPE were incubated either in the absence (a and b, e and f, k and l) or presence (c and d, g&#8211;j, m&#8211;p) of 10<sup>5</sup> trypomastigotes/mL of the Dm28 strain for 24 hours. Co-incubation treatments included compound 7 (g and h) or NFX (m and n) at the time of infection. Post-infection treatments were applied 24 hours later with compound 7 (i and j) or NFX (o and p). HPE, in the absence of trypomastigotes, was exposed to compound 7 (e and f) or NFX (k and l) for 24 h to observe the direct effect of the compounds on the HPE. Tissues were processed for routine hematoxylin-eosin histology (a, c, e, g, i, k, m, and o) and Picro Sirius red collagen histochemistry (b, d, f, h, j, l, n, and p). Arrows indicate the areas where the trophoblast is detached, and asterisks indicate the areas where birefringence reduction is present in PRS-stained samples. Bar scale: 20 &#181;m. (B) Relative quantification (RQ) of <italic toggle="yes">T. cruzi</italic> DNA load in HPE after co-incubation with compound 7 and NFX at IC<sub>50</sub> concentrations during a 24 hour infection. (C) Relative quantification (RQ) of <italic toggle="yes">T. cruzi</italic> DNA load in HPE after a 24 hour post-infection treatment with compound 7 and NFX at IC<sub>50</sub> concentrations, following an initial 24 hour infection (one-way ANOVA with Dunnett&#8217;s post-test: (***<italic toggle="yes">P</italic> &#8804; 0.001; **<italic toggle="yes">P</italic> &#8804; 0.01).</p></caption><graphic position="float" orientation="portrait" xlink:href="aac.00454-25.f014.jpg"><alt-text>Histopathology and collagen staining reveal reduced tissue damage and collagen alteration in treated groups. Coincubation with Compound 7 or NFX significantly lowers T. cruzi DNA levels, while post-infection treatments show moderate reductions.</alt-text></graphic></fig><p>Regarding post-infection treatment, no statistically significant activity against the intracellular form was detected neither for compound <bold>7</bold> nor NFX, despite showing a trend that could represent an advantage of compound <bold>7</bold> over NFX. This could be explained because, in this model, the compound must permeate not only the membranes of the host cells but also more complex structures such as the extracellular matrix, which presents collagen, elastic fibers, proteoglycans, and glycoproteins, among others. However, the expected difference in activity between co-incubation and post-infection was observed for NFX, as this drug has weak activity against the intracellular form, similar to what was observed in the <italic toggle="yes">in vitro</italic> model. For compound <bold>7</bold>, results were also similar to those recorded in the <italic toggle="yes">in vitro</italic> model.</p><p>A histopathological study was conducted on the free chorionic villi of HPE under the treatment conditions described in <xref rid="F14" ref-type="fig">Fig. 14</xref>. The co-incubation treatment with compound <bold>7</bold> prevented tissue damage induced by trypomastigotes, avoiding trophoblast detachment (indicated by arrows) and maintaining the structural integrity and collagen detection in the extracellular matrix. In comparison, compound <bold>7</bold> showed advantages over the reference drug NFX. Although NFX, under co-incubation conditions, managed to reduce the parasitic load, it also caused tissue damage under the treatment conditions, and even when explants were incubated only with the drug. By contrast, compound <bold>7</bold> did not induce tissue damage under these conditions. However, despite compound <bold>7</bold> showing a slight reduction in the parasitic load in the post-infection treatment conditions, possibly attributable to an intracellular effect of the compound, no reduction in tissue damage caused by trypomastigotes was observed in this condition, with a decrease in collagen indicating a reduction in the integrity of the extracellular matrix.</p><p>About the above, Masson&#8217;s trichrome staining (see Fig. S6 at <ext-link xlink:href="https://doi.org/10.5281/zenodo.15694236" ext-link-type="uri">https://doi.org/10.5281/zenodo.15694236</ext-link>) and Picro Sirius Red staining revealed damage to the extracellular matrix. The reduction in birefringence observed with the latter indicates disorganization of type I collagen, the main component of the extracellular matrix. Although compound <bold>7</bold> exhibits an anti-<italic toggle="yes">T</italic>. <italic toggle="yes">cruzi</italic> effect, as evidenced by the reduction of parasitic DNA load in the <italic toggle="yes">in vitro</italic> model, tissue damage persists. This damage is associated with the invasion process, suggesting that post-infection treatment does not prevent it. However, the results also show that the integrity of the extracellular matrix is preserved with the co-incubation treatment. This could be explained either by the parasite&#8217;s death before it invades the tissue or by the inhibition of invasion, possibly due to the suppression of the parasite&#8217;s virulence factors. These findings suggest that compound <bold>7</bold> could serve as a scaffold for designing more potent trypanocidal agents, which could be useful in the treatment of Chagas disease.</p><p><xref rid="F15" ref-type="fig">Figure 15B</xref> C shows the effects of compound <bold>1</bold> on the DNA load of the <italic toggle="yes">T. gondii</italic> parasite in co-incubation and post-infection treatments at IC<sub>50</sub> concentration, maintaining a similar trend to that observed in the <italic toggle="yes">in vitro</italic> model. For the 24 hour post-infection treatment, the parasitic DNA load decreased for the PMN treatment and, to a lesser extent, for the derivative <bold>1</bold> treatment, which is not statistically significant, as occurred in the <italic toggle="yes">in vitro</italic> infection model.</p><fig position="float" fig-type="figure" id="F15" orientation="portrait"><label>Fig 15</label><caption><p>(A) Histological analysis of HPE exposed to <italic toggle="yes">T. gondii</italic>, compound 1, and PMN at their respective IC<sub>50</sub> values. HPE were incubated either in the absence (a and b, e and f, k and l) or presence (c and d, g&#8211;j, m&#8211;p) of 10<sup>5</sup> tachyzoites/mL of RH strain for 24 hours. Co-incubation treatments included compound 1 (g and h) or NFX (m and n) at the time of infection. Post-infection treatments were applied 24 hours later with compound 1 (i and j) or PMN (o and p). HPE, in the absence of tachyzoites, was exposed to Comp 1 (e and f) or PMN (k and l) for 24 h to observe the direct effect of the compounds on the HPE. Tissues were processed for routine hematoxylin-eosin histology (a, c, e, i, j, k, m, o) and Picro Sirius red collagen histochemistry (b, d, f, h, j, l, n, p). Arrows indicate the areas where the trophoblast is detached, and asterisks indicate the areas where birefringence reduction is present in PRS-stained samples. Bar scale: 20 &#181;m. (B) Relative quantification (RQ) of <italic toggle="yes">T. gondii</italic> DNA load in HPE after co-incubation with compound one and PMN at IC<sub>50</sub> concentrations during a 24 hour infection. (C) Relative quantification (RQ) of <italic toggle="yes">T. gondii</italic> DNA load in HPE after a 24 hour post-infection treatment with compound one and PMN at IC<sub>50</sub> concentrations, following an initial 24 hour infection (one-way ANOVA with Dunnett&#8217;s post-test; **<italic toggle="yes">P</italic> &#8804; 0.01).</p></caption><graphic position="float" orientation="portrait" xlink:href="aac.00454-25.f015.jpg"><alt-text>Histopathology and collagen staining reveal reduced T. gondii-induced tissue damage and collagen alteration following treatment. Coincubation with Compound 1 or PMN significantly decreases T. gondii DNA load, with PMN notable reduction post-infection.</alt-text></graphic></fig><p>Histopathological analysis was conducted on the free chorionic villi of HPE under the treatment conditions specified in <xref rid="F15" ref-type="fig">Fig. 15A</xref>. Co-incubation treatment with compound <bold>1</bold> prevented tissue damage induced by tachyzoites, avoiding trophoblast detachment (indicated by arrows) and preserving structural integrity and collagen detection in the extracellular matrix according to the observations made by Masson&#8217;s trichrome (see Fig. S6 at <ext-link xlink:href="https://doi.org/10.5281/zenodo.15694236" ext-link-type="uri">https://doi.org/10.5281/zenodo.15694236</ext-link>) and Picro Sirius red staining. In comparison, compound <bold>1</bold> did not demonstrate superiority over the reference drug PMN, effectively reducing the parasitic load under the same co-incubation conditions without causing tissue damage&#8212;neither compound induced tissue damage when incubated with the explants, confirming the low toxicity of compound <bold>1</bold>.</p><p>In the context of post-infection treatment, it was observed that compound <bold>1</bold>, like the <italic toggle="yes">in vitro</italic> model, did not reduce the parasitic load or mitigate tissue damage caused by the parasite. This was reflected in a decrease in the integrity of the extracellular matrix, evidenced by reduced collagen levels and increased trophoblast detachment in the explants. Conversely, post-infection treatment with PMN effectively reduced the explants&#8217; parasitic load and decreased the induced tissue damage. This effect is attributed to PMN, which seems to inhibit the invasion process even 24 hours after infection, resulting in reduced tissue damage and DNA load compared to the untreated control. This phenomenon could explain the slight decrease in DNA load observed in the post-infection treatment with compound <bold>1</bold>, although not statistically significant, in contrast to the results obtained in the <italic toggle="yes">in vitro</italic> model.</p><p>The results obtained in placental explants suggest that oxidative stress may be involved in the antiparasitic effect of these compounds. The reduction in parasite burden observed under co-incubation conditions indicates that the generation of ROS could contribute to parasite inhibition before tissue invasion (<xref rid="B72" ref-type="bibr">72</xref>, <xref rid="B76" ref-type="bibr">76</xref>). However, in the post-infection condition, the lower efficacy of the compounds might be related to limitations in their ability to cross the cell membrane and extracellular matrix of placental tissue. In addition, <italic toggle="yes">T. cruzi</italic> and <italic toggle="yes">T. gondii</italic> possess antioxidant systems that could mitigate the impact of oxidative stress induced by these compounds, potentially explaining the reduced activity observed against intracellular parasite forms. These findings highlight the need for further investigation into the relationship between oxidative stress, tissue permeability, and parasite resistance in this model.</p><p>Our studies on evaluating potential new drugs demonstrate that the <italic toggle="yes">ex vivo</italic> model is a useful tool for the preliminary assessment of tissue damage that compounds may cause. Furthermore, the results show a similar trend in the effects on infection in trophoblast cells and human placental explants, suggesting that the <italic toggle="yes">in vitro</italic> model could effectively predict parasitic load in more complex tissues, such as the placenta. However, utilizing a more accessible and less complex <italic toggle="yes">in vitro</italic> model than human placental explants could be valuable for a broader analysis of compound families. In this regard, 3D models represent an interesting alternative to explore for obtaining an <italic toggle="yes">in vitro</italic> model that accurately reflects placental tissue.</p><p>In this context, although the results obtained in the placental explant model confirm the trends observed in the <italic toggle="yes">in vitro</italic> assays, this consistency should not be viewed as methodological redundancy, but rather as a physiological validation of the simpler model. This coherence enhances the value of the <italic toggle="yes">in vitro</italic> system as an effective initial filter for evaluating antiparasitic compounds. At the same time, the explant model offers the opportunity for more in-depth investigations, including parasite-specific immunolocalization and detailed phenotypic characterization of tissue interactions. This perspective has been incorporated into the study&#8217;s future outlook, focusing on the development and validation of optimized compounds.</p><p>Furthermore, future efforts will include pharmacokinetic and metabolic studies to evaluate compound stability, bioavailability, and systemic exposure. These analyses will be crucial in determining whether therapeutic concentrations can be achieved <italic toggle="yes">in vivo</italic>. In addition, resistance profiling will be crucial in assessing potential parasite adaptation under prolonged exposure, particularly for structurally optimized derivatives with enhanced potency.</p><p>Although <italic toggle="yes">in vivo</italic> evaluation remains a critical step in antiparasitic drug development, we considered that at this early stage, with limited potency and no pharmacokinetic data, such studies would not yield conclusive results. Therefore, future <italic toggle="yes">in vivo</italic> studies will be reserved for structurally optimized compounds with improved biological profiles and predicted drug-like properties, to ensure relevance and translatability of the findings.</p></sec><sec id="s2-9"><title>Conclusion</title><p>Eight new 6-nitrocoumarin-3-thiosemicarbazone hybrids were synthesized and characterized, evaluating their activity against <italic toggle="yes">Trypanosoma cruzi</italic> and <italic toggle="yes">Toxoplasma gondii</italic> in cellular and tissue models. The most active compounds, <bold>1</bold> and <bold>7</bold>, significantly reduced parasite burden, especially under co-incubation conditions. However, their post-infection effectiveness was lower, possibly due to limitations in cellular penetration or resistance mechanisms of the parasites.</p><p>The compounds exhibited low cytotoxicity in mammalian cells and did not cause tissue damage in placental explants, indicating a favorable selectivity profile. Electrochemical and ESR studies suggest that bioreduction of the nitro group and generation of ROS may play roles in their mechanism of action against <italic toggle="yes">T. cruzi</italic>. Additionally, other processes, such as enzymatic inhibition, may be involved in combating <italic toggle="yes">T. gondii</italic>.</p><p>These findings underscore the importance of testing compounds in biologically relevant models and support the potential of 6-nitrocoumarin-3-thiosemicarbazone hybrids as lead-like structures. Although their potency is still moderate, their selectivity and activity in both <italic toggle="yes">in vitro</italic> and <italic toggle="yes">ex vivo</italic> models justify further structure-based optimization efforts to enhance intracellular efficacy and assess pharmacokinetic and resistance profiles in optimized derivatives.</p></sec></sec><sec sec-type="materials|methods" id="s3"><title>MATERIALS AND METHODS</title><sec id="s3-1"><title>General procedures</title><p>All common laboratory chemicals were purchased from commercial sources and used without further purification. 3-Acetyl-4-hydroxycoumarin was synthesized according to a literature procedure (<xref rid="B82" ref-type="bibr">82</xref>). Anton Paar Monowave 50 conventionally heated reactor, provided with sealed vessel heating of 10 mL tubes with 250&#176;C maximum temperature and 20 bar pressures by applying conductive heating principles, was used for carrying out the Sealed Vessel reactions (SVR). All NMR spectra were recorded in DMSO-d<sub>6</sub> at 300 K on a Bruker Avance 400 MHz spectrometer equipped with a 5 mm QXI probe and on an Avance III 400 MHz spectrometer equipped with a 5 mm BBOF plus probe. Chemical shifts (&#948;) are expressed in ppm using tetramethylsilane (TMS) as internal reference, and multiplicities are indicated as s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), and b (broad). The assignments of <sup>1</sup>H and <sup>13</sup>C-NMR resonances were made based on a combination of <sup>1</sup>H, <sup>1</sup>H-COSY, <sup>1</sup>H, <sup>13</sup>C-HSQC, and <sup>1</sup>H, <sup>13</sup>C-HMBC spectra. C, H, N, and S analyses were carried out with a Thermo Scientific Flash 2000 elemental analyzer. The FTIR spectra (4,000&#8211;400 cm<sup>&#8211;1</sup>) were measured as KBr pellets (1%) with a Shimadzu IRPrestige-21 instrument. Electrochemical studies were carried out on a Metrohm Autolab instrument model PGSTAT204, using dimethyl sulfoxide (DMSO) as the solvent (1 mM solutions), tetrabutylammonium perchlorate (0.1 M TBAP) as the supporting electrolyte, a hanging drop mercury electrode (HDME) as the working electrode, Ag/AgCl (3M KCl) as the reference electrode and a graphite rod as the counter electrode. All measurements were performed after bubbling with nitrogen (N<sub>2</sub>) for 10 minutes. ESR studies were conducted on a Bruker ECS 106 X-band (9.85 GHz) spectrometer with a rectangular cavity and a field modulation of 50 kHz. <italic toggle="yes">In situ</italic> reduction of the compounds under study was carried out at potentials determined by cyclic voltammetry (CV) to generate radical species. DMSO was used as the solvent, TBAP as the supporting electrolyte, and a platinum wire as the working electrode. Lipophilicity was studied by reversed-phase TLC experiments. Precoated TLC plates SIL RP-18W/UV254 were used and eluted with DMSO/physiological serum (70:30, vol/vol). Stock solutions were prepared in pure DMSO (Aldrich) prior to use. The plates were developed in a closed chromatographic tank, dried, and the spots were located under UV light. The Rf values were averaged from three determinations and converted into R<sub>M</sub> values via the relationship: R<sub>M</sub> = log [(1/Rf)&#8722;1] (<xref rid="B83" ref-type="bibr">83</xref>).</p></sec><sec id="s3-2"><title>Synthesis of 6-nitro-coumarin-3-thiosemicarbazone</title><sec id="s3-2-1"><title>Synthesis of 3-acetyl-4-hydroxy-6-nitro-2H-chromen-2-one (C1)</title><p>Compound <bold>C1</bold> was obtained using a modified procedure based on a reported procedure (<xref rid="B46" ref-type="bibr">46</xref>). To a stirred solution of KNO<sub>3</sub> (1 mmol) in H<sub>2</sub>SO<sub>4</sub> conc. (1 mmol, 4 mL) was added portion-wise 3-acetyl-4-hydroxy-2H-chromen-2-one (3.5 mmol, 714 mg). The reaction mixture was stirred for 1 h at 0&#176;C and the added ice (50 g) until precipitation of a white solid. The solid is filtered, washed with cold water (50 mL), and dried under vacuum for 48 h to give compound <bold>C1</bold> (448 mg, 53%) as a white solid: <sup>1</sup>H NMR &#948; 8.69 (d, J = 2.7 Hz, <sup>1</sup>H), 8.58 (dd, J = 9.1, 2.8 Hz, 1H), 7.67 (d, J = 9.1 Hz, 1H), 2.69 (s, 3H); <sup>13</sup>C NMR &#948;: 204.99, 176.74, 158.55, 157.60, 143.64, 130.50, 121.05, 118.74, 115.96, 102.24, and 29.46.</p></sec><sec id="s3-2-2"><title>Synthesis of 3-acetyl-6-nitro-2H-chromen-2-one (C2)</title><p>Compound <bold>C2</bold> was obtained using a modified procedure based on a reported procedure (<xref rid="B47" ref-type="bibr">47</xref>). In a sealed vessel, the reactor tube was dissolved 2-hydroxy-5-nitrobenzaldehyde (3.5 mmol, 585 mg) in EtOH (2 mL) and added with stirring ethyl acetoacetate (3.5 mmol, 446 mL) and piperidine (5% mol). The reaction mixture was heated to 50&#176;C for 18 min. The obtained precipitate was filtered, washed with EtOH (2 &#215; 3 mL), and dried for 48 h to yield compound C2 (408 mg, 50% yield) as a with solid: <sup>1</sup>H NMR &#948; 8.94 (d, J = 2.8 Hz, 1H), 8.80 (s, 1H), 8.50 (dd, J = 9.1, 2.8 Hz, 1H), 7.68 (d, J = 9.1 Hz, 1H), 2.59 (s, 3H); <sup>13</sup>C NMR &#948;: 194.70, 158.03, 157.47, 145.81, 143.75, 128.49, 126.45, 126.12, 118.54, 117.70, and 29.92.</p></sec></sec><sec id="s3-3"><title>General procedure for the synthesis of compound 1&#8211;8</title><p>In a vessel reactor tube, the respective coumarin 3-acetyl-4-hydroxy-6-nitrocoumarin (<bold>C1</bold>) or 3-acetyl-6-nitrocoumarin (<bold>C2</bold>) (1 mmol) was poured and suspended in methanol (1 mL). Then the corresponding thiosemicarbazide (1 mmol) suspended in methanol (1 mL) was added to the mixture with stirring. After 1 minute p-TsOH (5%) was added and heated at 70&#176;C for 12 minutes. The reaction was monitored by TLC until the starting material was consumed and cooled to room temperature. The mixture was filtered off, and the solid was washed with methanol (2 &#215; 5 mL), diethylether (2 &#215; 5 mL), and then air-dried. Compound <bold>5</bold> had been previously prepared through a different procedure (<xref rid="B84" ref-type="bibr">84</xref>).</p><p>(E)&#8722;2-(1-(4-hydroxy-6-nitro-2-oxo-2H-chromen-3-yl)ethylidene)hydrazine-1-carbothioamide <bold>Compound 1&#8212;</bold>yellow microcrystalline solid, yield = 68%. Elemental analysis: Calc. (%) for C<sub>12</sub>H<sub>10</sub>N<sub>4</sub>O<sub>5</sub>S C, 44.7; H, 3.1; N, 17.4, found: C, 44.9; H, 3.0; N, 17.5; <sup>1</sup>H NMR, &#948;: 15.25 (s, 1H); 10.74 (s, 1H), 8.67 (d, <italic toggle="yes">J</italic> = 2.8 Hz, 1H), 8.46 (dd, <italic toggle="yes">J</italic> = 9.0, 2.9 Hz, 1H), 7.55 (d, <italic toggle="yes">J</italic> = 9.0 Hz, 1H), and 2.64 (s, 3H). <sup>13</sup>C NMR, &#948;: 181.14, 176.48, 160.44, 156.77, 143.41, 128.72, 121.51, 119.89, 118.30, and 17.49.</p><p>(E)&#8722;2-(1-(4-hydroxy-6-nitro-2-oxo-2H-chromen-3-yl)ethylidene)-N-methylhydrazine-1-carbothioamide <bold>Compound 2</bold>&#8212;brown microcrystalline solid, yield = 79%. Elemental analysis: Calc. (%) for C<sub>13</sub>H<sub>12</sub>N<sub>4</sub>O<sub>5</sub>S: C, 46.4; H, 3.6; N, 16.7, found: C, 46.2; H, 3.7; N, 16.5. <sup>1</sup>H NMR, &#948;: 15.06 (s, 1H), 10.59 (s, 1H), 8.67 (d, <italic toggle="yes">J</italic> = 2.9 Hz, 1H), 8.46 (dd, <italic toggle="yes">J</italic> = 9.0, 2.9 Hz, 1H), 7.55 (d, <italic toggle="yes">J</italic> = 9.1 Hz, 1H), 2.96 (s, 3H), and 2.64 (s, 3H). <sup>13</sup>C NMR, &#948;: 181.32, 176.50, 160.46, 156.79, 143.42, 128.73, 121.54, 119.93, 118.31, 31.36, and 17.54.</p><p>(E)-N-ethyl-2-(1-(4-hydroxy-6-nitro-2-oxo-2H-chromen-3-yl)ethylidene)hydrazine-1-carbothioamide <bold>Compound 3&#8212;</bold>yellow microcrystalline solid, yield = 62%. Elemental analysis: Calc. (%) for (C<sub>14</sub>H<sub>14</sub>N<sub>4</sub>O<sub>5</sub>S): C, 48.0; H, 4.0; N, 16.0, found: C, 48.1; H, 4.1; N, 15.8. <sup>1</sup>H NMR &#948;: 15.16 (s, 1H), 10.52 (s, 1H), 8.67 (d, <italic toggle="yes">J</italic> = 2.9 Hz, 1H), 8.51 (s, 1H), 8.46 (dd, <italic toggle="yes">J</italic> = 9.0, 2.9 Hz, 1H), 7.55 (d, <italic toggle="yes">J</italic> = 9,0 Hz, 1H), 3.60&#8211;3.40 (m, 2H), 2.64 (s, 3H), 1.14 (t, <italic toggle="yes">J</italic> = 7.2 Hz, 3H). <sup>13</sup>C NMR &#948;: 180.20, 176.33, 160.46, 156.78, 143.41, 128.68, 121.51, 119.91, 118.29, 38.20, 17.53, and 13.94.</p><p>(E)&#8722;2-(1-(4-hydroxy-6-nitro-2-oxo-2H-chromen-3-yl)ethylidene)-N-phenylhydrazine-1-carbothioamide <bold>Compound 4</bold>&#8212;orange microcrystalline solid, yield = 74%. Elemental analysis: Calc. (%) for (C<sub>18</sub>H<sub>14</sub>N<sub>4</sub>O<sub>5</sub>S): C, 54.3; H, 3.5; N, 14.1, found: C, 54.1; H, 3.5; N, 14.3. <sup>1</sup>H-NMR &#948;: 15.48 (s, 1H), 10.20 (s, 1H), 8.69 (d, <italic toggle="yes">J</italic> = 2.9 Hz, 1H), 8.45 (dd, <italic toggle="yes">J</italic> = 9.0, 2.9 Hz, 1H), 7.60&#8211;7.56 (m, 2H), 7.54 (d, <italic toggle="yes">J</italic> = 9.1 Hz, 1H), 7.37 (t, <italic toggle="yes">J</italic> = 7.9 Hz, 2H), 7.15 (t, <italic toggle="yes">J</italic> = 7.2 Hz, 1H), and 2.73 (s, 3H).<sup>13</sup>C NMR &#948;: 178.31, 175.99, 160.62, 156.81, 143.34, 139.05, 128.67, 128.41, 124.82, 122.95, 121.51, 120.20, 118.19, and 17.92.</p><p>(E)&#8722;2-(1-(6-nitro-2-oxo-2H-chromen-3-yl)ethylidene)hydrazine-1-carbothioamide <bold>Compound 5</bold>&#8212;yellow microcrystalline solid, yield = 86%. Elemental analysis: Calc. (%) for (C<sub>12</sub>H<sub>10</sub>N<sub>4</sub>O<sub>4</sub>S): C, 47.1; H, 3.3; N, 18.3, found: C, 47.2; H, 3.4; N, 18.5. <sup>1</sup>H NMR &#948;: 10.56 (s, 1H), 8.68&#8211;8.65 (m, 2H), 8.51 (s, 1H), 8.42 (dd, <italic toggle="yes">J</italic> = 9.1, 2.8 Hz, 1H), 7.92 (s, 1H), 7.65 (d, <italic toggle="yes">J</italic> = 9.2 Hz, 1H), and 2.27 (s, 3H). <sup>13</sup>C NMR &#948;: 179.36, 158.15, 156.91, 144.76, 143.63, 140.66, 127.37, 126.68, 124.68, 119.33, 117.52, 15.81.</p><p>(E)-N-methyl-2-(1-(6-nitro-2-oxo-2H-chromen-3-yl)ethylidene)hydrazine-1-carbothioamide <bold>Compound 6</bold>&#8212;yellow microcrystalline solid, yield = 28%. Elemental analysis: Calc. (%) for (C<sub>13</sub>H<sub>12</sub>N<sub>4</sub>O<sub>4</sub>S): C, 48.7; H, 3.8; N, 17.5, found: C, 48.5; H, 3.9; N, 16.9. <sup>1</sup>H NMR &#948;: 10.57 (s, 1H), 8.72 (d, <italic toggle="yes">J</italic> = 2.7 Hz, 1H), 8.56 (s, 1H), 8.49&#8211;8.46 (m, 1H), 8.44 (dd, <italic toggle="yes">J</italic> = 9.1, 2.8 Hz, 1H), 7.67 (d, <italic toggle="yes">J</italic> = 9.1 Hz, 1H), 3.04 (d, <italic toggle="yes">J</italic> = 4.5 Hz, 3H), and 2.27 (s, 3H). <sup>13</sup>C NMR &#948;: 178.94, 158.23, 156.89, 144.65, 143.70, 140.49, 127.79, 126.72, 124.65, 119.26, 117.60, 31.01, 15.85.</p><p>(E)-N-methyl-2-(1-(6-nitro-2-oxo-2H-chromen-3-yl)ethylidene)hydrazine-1-carbothioamide <bold>Compound 7</bold>&#8212;yellow microcrystalline solid, yield = 75%. Elemental analysis: Calc. (%) for (C<sub>14</sub>H<sub>14</sub>N<sub>4</sub>O<sub>4</sub>S): C, 50.3; H, 4.2; N, 16.8, found: C, 50.7; H, 4.4; N, 16.6. <sup>1</sup>H NMR &#948;: 10.50 (s, 1H), 8.74 (d, <italic toggle="yes">J</italic> = 2.8 Hz, 1H), 8.53 (s, 1H), 8.48 (t, <italic toggle="yes">J</italic> = 5.8 Hz, 1H), 8.44 (dd, <italic toggle="yes">J</italic> = 9.1, 2.8 Hz, 1H), 7.67 (d, <italic toggle="yes">J</italic> = 9.1 Hz, 1H), 3.61 (p, <italic toggle="yes">J</italic> = 7.1 Hz, 2H), 2.26 (s, 3H), and 1.16 (t, <italic toggle="yes">J</italic> = 7.1 Hz, 3H). <sup>13</sup>C NMR &#948;: 177.89, 158.14, 156.88, 144.75, 143.68, 140.46, 127.78, 126.72, 124.71, 119.26, 117.58, 38.44, 15.85, 14.39.</p><p>(E)&#8722;2-(1-(6-nitro-2-oxo-2H-chromen-3-yl)ethylidene)-N-phenylhydrazine-1-carbothioamide <bold>Compound 8</bold>&#8212;yellow microcrystalline solid, yield = 83%. Elemental analysis: Calc. (%) for (C<sub>18</sub>H<sub>14</sub>N<sub>4</sub>O<sub>4</sub>S): C, 56.5; H, 3.7; N, 14.6, found: C, 56.7; H, 3.9; N, 14.3. <sup>1</sup>H NMR &#948;: 10.98 (s, 1H), 10.11 (s, 1H), 8.72 (d, <italic toggle="yes">J</italic> = 2.8, 1H) y 8.68 (s, 1H), 8.44 (dd, <italic toggle="yes">J</italic> = 9.1, 2.8 Hz, 1H), 7.67 (d, <italic toggle="yes">J</italic> = 9.1 Hz, 1H), 7.61 (m, 2H), 7.39 (t, <italic toggle="yes">J</italic> = 7.9 Hz, 2H), 7.22 (tt, <italic toggle="yes">J</italic> = 7.1, 1.1 Hz, 1H), and 2.35 (s, 3H). <sup>13</sup>C NMR &#948;: 177.10, 158.03, 156.90, 145.48, 143.67, 140.95, 138.83, 128.27, 127.29, 126.81, 125.50, 125.28, 124.78, 119.28, 117.57, and 15.99.</p></sec><sec id="s3-4"><title>Biological studies</title><p>The trypomastigotes of the Dm28 strain of <italic toggle="yes">T. cruzi</italic>, tachyzoites of the RH strain of <italic toggle="yes">T. gondii,</italic> and mammalian cells were obtained from an in-house collection (Programa de Biolog&#237;a Integrativa, Facultad de Medicina, Universidad de Chile).</p></sec><sec id="s3-5"><title>Cell cultures</title><p>BeWo cells (ATCC CCL-98) were cultured in DMEM/F-12 (Dulbecco&#8217;s Modified Eagle Medium Nutrient Mixture F12) supplemented with 10% inactivated fetal bovine serum (FBSi) and 1% antibiotics (penicillin-streptomycin), incubated at 37&#176;C in a humidified atmosphere with 5% CO<sub>2</sub>. Cells at semi-confluence were harvested by trypsinization and sedimented by centrifugation at 500 &#215; <italic toggle="yes">g</italic> for 5 minutes at room temperature, re-suspended in DMEM-F12 medium, and counted with trypan blue using the JuLI FL Live Cell Analyzer device (<xref rid="B85" ref-type="bibr">85</xref>). EA.hy926 cells (ATCC CRL-2922) were cultured in DMEM high glucose (Dulbecco&#8217;s Modified Eagle Medium) supplemented with 10% FBSi and 1% antibiotics (penicillin-streptomycin). In this, and all cultures described below, cells were incubated at 37&#176;C, with 5% CO<sub>2</sub> and 98% relative humidity. VERO (ATCC CCL-81) cells were cultured in Roswell Park Memorial Institute 1640 medium (RPMI 1640), supplemented with 5% FBSi and 1% antibiotics (penicillin-streptomycin). In this, and all cultures described below, cells were incubated at 37&#176;C, with 5% CO<sub>2</sub> and 98% relative humidity. HFF (ATCC SCRC-1041) cells were cultured in DMEM supplemented with 10% FBSi and 1% antibiotics (penicillin-streptomycin). In this, and all cultures described below, cells were incubated at 37&#176;C, with 5% CO<sub>2</sub> and 98% relative humidity. LLC-MK2 (ATCC CCL-7) monkey kidney cells were cultured in DMEM, supplemented with 10% FBSi and 1% antibiotics (penicillin-streptomycin). In this, and all cultures described below, cells were incubated at 37&#176;C, with 5% CO<sub>2</sub> and 98% relative humidity. Cell passages were performed weekly.</p></sec><sec id="s3-6"><title>Parasite culture and harvesting <italic toggle="yes">Trypanosoma cruzi</italic></title><p>VERO cells at semi-confluence were infected with trypomastigotes from the Dm28 strain and cultured in RPMI 1640 medium supplemented with 5% FBSi and 1% antibiotics (penicillin-streptomycin) at 37&#176;C in a humidified atmosphere with 5% CO<sub>2</sub>. The parasites invaded the cells and replicated intracellularly as amastigotes. After 48 to 72 hours, amastigotes were allowed to differentiate back into trypomastigotes and released by cell lysis. Trypomastigotes were separated from cellular debris by centrifugation at 500 &#215; <italic toggle="yes">g</italic> for 5 minutes and then recovered from the supernatant by centrifugation at 3,500 &#215; <italic toggle="yes">g</italic> for 10 minutes at 4&#176;C, re-suspended in RPMI 1640 medium supplemented (5% FBS and 1% antibiotics), and quantified using a Neubauer chamber (<xref rid="B68" ref-type="bibr">68</xref>).</p><p>The recombinant Tulahuen &#946;-gal strain, expressing &#946;-galactosidase, was employed (<xref rid="B86" ref-type="bibr">86</xref>). Trypomastigotes were obtained by infecting LLC-MK2 cells monolayers in 75 cm<sup>2</sup> culture flasks. Cells were infected for 48 hours with 1.5 &#215; 10<sup>5</sup> trypomastigotes in 10 mL DMEM supplemented with 2% FBSi and 1% antibiotics (penicillin/streptomycin) and incubated. After 48 hours, the cell monolayer was washed with sterile PBS, and the medium was replaced. Trypomastigotes were collected starting at day 5 post-infection, pelleted by centrifugation, and washed 2&#215; in sterile PBS. The number of parasites was determined microscopically, using a hemocytometer.</p></sec><sec id="s3-7"><title>
Toxoplasma gondii
</title><p>HFF cells at semi-confluence were infected with tachyzoites from the RH strain and cultured in DMEM medium supplemented with 1% FBSi and 1% antibiotics at 37&#176;C in a humidified atmosphere with 5% CO<sub>2</sub>. After 48 hours, tachyzoites in the supernatant were collected. Parasites in the culture medium were purified by filtration through a 3 &#181;m polycarbonate membrane (IsoporeTM Membrane Filters, Merck Millipore), eliminating cellular debris. Then, tachyzoites were recovered by centrifugation at 3,500 &#215; <italic toggle="yes">g</italic> for 5 minutes at room temperature, re-suspended in DMEM medium supplemented (1% FBSi and 1% antibiotics), and quantified using a Neubauer chamber (<xref rid="B87" ref-type="bibr">87</xref>).</p></sec><sec id="s3-8"><title>Cytotoxicity on cells</title><p>BeWo or EA.hy926 cells were seeded in 96-well plates, with 5 &#215; 10<sup>4</sup> cells per well, and incubated with the compounds chosen as most active against <italic toggle="yes">T. cruzi</italic> and <italic toggle="yes">T. gondii</italic> (previously dissolved in DMSO) at concentrations ranging from 17 &#956;M to 400 &#181;M for 24 hours at 37&#176;C in a humid atmosphere with 5% CO<sub>2</sub>. Triton X-100 was used as a positive control, and untreated cells served as a negative control. In addition, the maximum concentration of DMSO was used as a control for the method. After the incubation period, cells were washed with PBS, and 100 &#181;L of DMEM-F12 medium with resazurin to a final concentration of 3 mM was added to each well, followed by incubation for 3 hours at 37&#176;C in a humidified atmosphere with 5% CO<sub>2</sub>. After incubation, measurements were taken using a microplate reader (Thermo Scientific Varioskan Flash) at excitation wavelengths of 560 nm and emission wavelengths of 590 nm. The obtained values were expressed as IC<sub>50</sub>(<xref rid="B88" ref-type="bibr">88</xref>).</p></sec><sec id="s3-9"><title>Activity on <italic toggle="yes">T. cruzi</italic> trypomastigotes and <italic toggle="yes">T. gondii</italic> tachyzoites</title><p>Parasites at 10<sup>7</sup> parasites/mL concentration were incubated for 24 hours with the compounds under investigation (previously dissolved in DMSO) at a concentration of 100 &#181;M at 37&#176;C in a humid atmosphere with 5% CO<sub>2,</sub> DMSO concentration did not exceed 0.5% vol/vol. NFX was used as a positive control for <italic toggle="yes">T. cruzi</italic>, and PMN was used for <italic toggle="yes">T. gondii</italic>. Untreated parasites served as a negative control. In addition, considering that the compounds were dissolved in DMSO, a control condition with the maximum possible DMSO concentration was used to verify that this solvent alone has no antiparasitic or cytotoxic activity. Subsequently, parasites with their respective conditions were transferred to a 96-well white fluorescence reading plate, adding resazurin at a final concentration of 3 mM with 0.8 mM phenazine. The plate was incubated for 3 hours at 37&#176;C in a humidified atmosphere with 5% CO<sub>2</sub>, and fluorescence measurements were taken using a microplate reader (Thermo Scientific Varioskan Flash) at excitation wavelengths of 560 nm and emission wavelengths of 590 nm. Once the most active compound against the parasites was identified, the IC<sub>50</sub> value, corresponding to the inhibitory concentration of 50% of the parasite population, was determined (<xref rid="B38" ref-type="bibr">38</xref>, <xref rid="B89" ref-type="bibr">89</xref>).</p></sec><sec id="s3-10"><title>Effect on intracellular parasite</title><p>LLC-MK2 cells (2 &#215; 10<sup>4</sup>/well), suspended in 200 &#181;L DMEM with 10% FBSi and 1% antibiotics (penicillin-streptomycin), were placed in each well of a 96-well plate and incubated for 24 hours. Subsequently, the culture medium was removed, and cell monolayers were infected by placing five trypomastigotes per cell in 200 &#181;L of DMEM 2 for 24 hours under the same incubation conditions. After infection, the culture medium was removed, and cells were washed 4 times with 1&#215; sterile PBS. Finally, 10 twofold serial dilutions (200 &#181;M to 0.39 &#181;M concentration range) of each compound, in DMEM 2 without phenol red, were placed in duplicate wells in a 96-well plate and incubated for 72 hours. Subsequently, inhibition of intracellular parasite multiplication was measured as in Bettiol et al. (<xref rid="B90" ref-type="bibr">90</xref>): 50 &#181;L of a solution containing 100 &#181;M chlorophenol red &#946;-D-galactopyranoside (CPRG) and Triton (0.5%) in PBS was added to each well. Absorbance at 600 nm was read 4 hours later, in a multimodal GloMax microplate reader (Promega).</p><p>VERO cells (5 &#215; 10<sup>4</sup>/well), suspended in 200 &#181;L RPMI with 5% FBS and 1% antibiotics (penicillin-streptomycin), were placed in each well of a 96-well plate and incubated for 24 hours. Subsequently, the culture medium was removed, and cell monolayers were infected by placing one tachyzoite per cell in 200 &#181;L of RPMI for 24 hours under the same incubation conditions. After infection, the culture medium was removed, and the cells were washed with sterile PBS. Then, concentrations of each compound (200 &#181;M to 0.39 &#181;M) in RPMI were placed in triplicate wells in a white 96-well plate and incubated for 24 hours. Finally, the cells were washed with PBS to remove the supernatant, fixed with 90% cold methanol, washed with PBS containing 0.05% Tween, and blocked using 3% BSA for 1 hour at 37&#176;C. Then, they were incubated with the primary monoclonal antibody <italic toggle="yes">Toxoplasma gondii</italic> (TP3): sc-52255 at a dilution of 1:500 with 1% BSA overnight at 4&#176;C. Afterward, the samples were incubated with the FITC anti-mouse IgG secondary antibody at a dilution of 1:100 with 1% BSA for 1 hour at 37&#176;C. Finally, they were washed with PBS containing 0.05% and maintained in PBS. Fluorescence measurements were taken using a microplate reader (Thermo Scientific Varioskan Flash) at excitation wavelengths of 488 nm and emission wavelengths of 519 nm (see Fig. S8 at <ext-link xlink:href="https://doi.org/10.5281/zenodo.15694236" ext-link-type="uri">https://doi.org/10.5281/zenodo.15694236</ext-link>).</p><p>For the microscopic analysis of BeWo cells infected with <italic toggle="yes">T. cruzi</italic>, the cells were washed with PBS to remove the supernatant, fixed with 90% cold methanol, rewashed with PBS, and incubated for 5 minutes with 1 &#181;g/mL&#8212;1 4,6-diamidino-2-phenylindole (DAPI) (Molecular Probes). To analyze BeWo cells infected with <italic toggle="yes">T. gondii</italic>, cells were fixed with 90% cold methanol, washed with PBS containing 0.05% Tween, and blocked using 3% BSA for 1 hour at 37&#176;C. Then, they were incubated with the primary monoclonal antibody <italic toggle="yes">Toxoplasma gondii</italic> (TP3): sc-52255 at a dilution of 1:500 with 1% BSA overnight at 4&#176;C. Afterward, the samples were incubated with the FITC anti-mouse IgG secondary antibody at a dilution of 1:100 with 1% BSA for 1 hour at 37&#176;C. Finally, they were washed with PBS containing 0.05% Tween and incubated for 5 minutes with DAPI. Subsequently, the sections were mounted in Vectashield (ScyTek ACA). Sections for the analysis of cell infection by <italic toggle="yes">T. cruzi</italic> and <italic toggle="yes">T. gondii</italic> were observed under an epifluorescence microscope (Motic BA 310), and images were captured with a Motic 5 camera. <italic toggle="yes">T. cruzi</italic> amastigotes were identified by their morphology, including nuclear size and the presence of a kinetoplast, and were analyzed and quantified using ImageJ. At least 500 cells per condition were analyzed, and infected and non-infected cells were counted for every 100 cells (<xref rid="B35" ref-type="bibr">35</xref>, <xref rid="B70" ref-type="bibr">70</xref>).</p></sec><sec id="s3-11"><title>Intracellular generation of ROS</title><p>ROS detection was performed using the 2&#8242;,7&#8242;-dichlorodihydrofluorescein diacetate (DCFH<sub>2</sub>-DA) method (<xref rid="B45" ref-type="bibr">45</xref>). For the assay, <italic toggle="yes">Dm28c</italic> trypomastigotes and tachyzoites were seeded in 96-well plates at a density of 10&#8310; parasites/mL. In contrast, BeWo cells were seeded at 5 &#215; 10&#8308; cells per well, using the previously described culture medium.</p><p>After incubation with 20 &#181;M DCFH<sub>2</sub>-DA for 15 minutes at 37&#176;C, the parasites were centrifuged at 3,500 &#215; <italic toggle="yes">g</italic>, washed twice with PBS (pH 7.4), and subsequently transferred to Nunc 96-well fluorescence plates. Meanwhile, after 24 hours of incubation at 37&#176;C and 5% CO&#8322;, the culture medium of BeWo cells was replaced, and 20 &#181;M DCFH<sub>2</sub>-DA solution was added, followed by a 15 minute incubation at 37&#176;C. The cells were then washed with PBS at pH 7.4. As a positive control, 20 &#181;M menadione was used, while the negative control consisted of culture medium without compounds.</p><p>Subsequently, the most active compounds were added at the IC<sub>50</sub> concentration, and fluorescence (excitation: 488 nm, emission: 528 nm) was recorded for 40 minutes using a Thermo Scientific Varioskan Lux microplate reader. Over time, the area under the fluorescence increase curve was determined using Origin 8 software (version 9.2), with normalization relative to the control. The results correspond to three independent experiments' mean &#177; standard deviation (SD).</p></sec><sec id="s3-12"><title>Electron spin resonance studies in parasite media</title><p>The free radical production capacity of the most active 6-nitrocoumarin-3-thiosemicarbazone hybrids against each parasite was evaluated using electron spin resonance (ESR) spectroscopy, with 5,5-dimethyl-1-pyrroline-N-oxide (DMPO) as a spin-trapping agent (<xref rid="B41" ref-type="bibr">41</xref>, <xref rid="B45" ref-type="bibr">45</xref>).</p><p>Each tested hybrid was dissolved in spectroscopy-grade DMSO at an approximate concentration of 1 mM and added to a mixture containing <italic toggle="yes">Trypanosoma cruzi</italic> (Dm28c strain) or <italic toggle="yes">Toxoplasma gondii</italic> at a density of 50 &#215; 10&#8310; trypomastigotes or tachyzoites per mL, along with DMPO at a final concentration of 250 mM. Menadione (20 &#181;M) was used as a positive control.</p><p>The mixture was transferred to a 50 &#181;L capillary, and ESR spectra were recorded in the X-band (9.85 GHz) using a Bruker ECS 106 spectrometer with a rectangular cavity and 50 kHz field modulation. All spectra were acquired on the same scale after 15 scans.</p></sec><sec id="s3-13"><title>Obtention of HPE</title><p>Term human placentas were obtained from uncomplicated pregnancies via scheduled cesarean sections. Each patient provided informed consent for the experimental use of the placenta, and the study was approved by the ethics committee of Hospital San Jos&#233;, Servicio Salud Metropolitano Norte (N&#176; 013/2022). Exclusion criteria for placental use included significant fetal anomalies, placental tumors, intrauterine infection, positive serology for Chagas disease, obstetric pathology, and any other maternal disease. Donor patients tested negative for <italic toggle="yes">T. gondii</italic> IgG/IgM antibodies. Organs were collected in sterile, cold PBS and processed within 30 minutes after delivery. Maternal and fetal surfaces of each placenta were discarded, and the villous tissue from the central part of the placental cotyledons was isolated. Isolated chorionic villi were washed with PBS to remove the blood and cut into approximately 0.5 cm<sup>3</sup> pieces, incubated in RPMI medium supplemented with 5% FBS and 1% antibiotics (penicillin-streptomycin) at 37&#176;C in a humid atmosphere with 5% CO<sub>2</sub> overnight (<xref rid="B79" ref-type="bibr">79</xref>). All the experiments were performed in triplicate in at least three different placentas.</p></sec><sec id="s3-14"><title>Effect of compounds on infection in <italic toggle="yes">ex vivo</italic> and <italic toggle="yes">in vitro</italic> model</title><p>Cells or HPE were exposed to parasites. Cells were revealed in a 1:1 relation (cell: parasite), and HPE was exposed to 1 &#215; 10<sup>5</sup> parasites/mL for 24 hours. The following treatment conditions were used in both infection models. (i) Parasites used during infection were co-incubated for 24 hours with the most active nitrocoumarin-thiosemicarbazone derivative against each parasite at the previously obtained IC<sub>50</sub> concentration. (ii) A post-infection treatment condition was applied by treating cells or HPE infected for 24 hours, removing parasites from the medium, and adding the most active nitrocoumarin-thiosemicarbazone derivative for the corresponding parasite at the IC<sub>50</sub> concentration for 24 hours. Untreated cells or HPE served as a negative control, and the compounds&#8217; activity was compared with the reference drugs (NFX and PMN). This approach allowed the observation of the effects of the most active compounds on the infection of BeWo cells and HPE against each of the parasites for both the infective and intracellular proliferative forms.</p></sec><sec id="s3-15"><title>DNA amplification by real-time PCR</title><p>For the parasitic DNA load in the <italic toggle="yes">in vitro</italic> infection model, BeWo cells were seeded in 6-well plates with 5 &#215; 10<sup>5</sup> cells and were allowed to adhere overnight at 37&#176;C in a humidified atmosphere with 5% CO<sub>2</sub>. Subsequently, cells were exposed to parasites at a 1:1 ratio (cell: parasite) for 24 hours. Finally, the cells were washed with PBS and harvested using trypsin. For the parasitic DNA load in the <italic toggle="yes">ex vivo</italic> infection model, HPE was incubated in 24-well plates and exposed to parasites at a concentration of 10<sup>5</sup> parasites/mL for 24 hours. Finally, they were washed with PBS and homogenized using the ultraturrax homogenizer OMNI TipTM. Genomic DNA was extracted from BeWo cells or HPE using the Wizard Genomic DNA Purification Kit (Promega, USA) following the manufacturer&#8217;s instructions. The resulting DNA was quantified using a &#956;Drop Plate DNA quantification system on the Varioskan Flash multimode reader (Thermo Scientific, USA). For the amplification of human DNA and parasitic DNA, three pairs of primers specific for human GAPDH (hGADPH), <italic toggle="yes">T. cruzi</italic> satellite DNA, and <italic toggle="yes">T. gondii</italic> B1 gene DNA were used (<xref rid="T7" ref-type="table">Table 7</xref>). Each reaction mixture contained 0.5 &#181;L of 10 nM of each primer (Forward and reverse), 1 ng of DNA from <italic toggle="yes">T. cruzi</italic> samples, 10 ng of DNA from <italic toggle="yes">T. gondii</italic> samples, 10 &#181;L of SensiFASTTM SYBR Hi-ROX kit (Bioline, Heidelberg, Baden W&#252;rttemberg, Germany), and ultrapure water (Sigma-Aldrich, St. Louis, MO, USA) for a total of 20 &#181;L.</p><table-wrap position="float" id="T7" orientation="portrait"><label>TABLE 7</label><caption><p>Primers for the identification and amplification of <italic toggle="yes">T. cruzi</italic> DNA (Satellite DNA), <italic toggle="yes">T. gondii</italic> DNA (B1 Gene), and human DNA of the GAPDH gene as an endogenous loading control<xref rid="T7_FN1" ref-type="table-fn"><sup><italic toggle="yes">a</italic></sup></xref></p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" valign="top" colspan="1" rowspan="1">qPCR primer</th><th align="left" valign="top" colspan="1" rowspan="1">Forward sequence</th><th align="left" valign="top" colspan="1" rowspan="1">Reverse sequence</th><th align="left" valign="top" colspan="1" rowspan="1">Amplicon length (bp)</th></tr></thead><tbody><tr><td align="left" valign="top" colspan="1" rowspan="1">
<italic toggle="yes">T. cruzi</italic>
</td><td align="left" valign="top" colspan="1" rowspan="1"><named-content content-type="sequence">GCTCTTGCCCCACA</named-content>MGGTGC</td><td align="left" valign="top" colspan="1" rowspan="1">
<named-content content-type="sequence">CAAGCAGCGGATAGTTCAG</named-content>
</td><td align="left" valign="top" colspan="1" rowspan="1">182</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">
<italic toggle="yes">T. gondii</italic>
</td><td align="left" valign="top" colspan="1" rowspan="1">
<named-content content-type="sequence">AGCGTTCGTCCTCAACTATCGATTG</named-content>
</td><td align="left" valign="top" colspan="1" rowspan="1">
<named-content content-type="sequence">TCCCCTCTGCTCGCGAAAAGT</named-content>
</td><td align="left" valign="top" colspan="1" rowspan="1">98</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">hGAPDH</td><td align="left" valign="top" colspan="1" rowspan="1">
<named-content content-type="sequence">TGATGCGTGTACAAGCGTTTT</named-content>
</td><td align="left" valign="top" colspan="1" rowspan="1">
<named-content content-type="sequence">ACATGGTATTCACCACCCCACTAT</named-content>
</td><td align="left" valign="top" colspan="1" rowspan="1">97</td></tr></tbody></table><table-wrap-foot><fn id="T7_FN1"><label>
<sup>
<italic toggle="yes">a</italic>
</sup>
</label><p>Primer sequences are in the 5&#8242; to 3&#8242; direction.</p></fn></table-wrap-foot></table-wrap><p>Amplification was carried out using the CFX96 Touch Deep Well Real-Time PCR Detection System (Biorad, California, USA) with the following cycling program: initial denaturation at 95&#176;C for 3 min, followed by 40 cycles of denaturation at 95&#176;C for 5 s, annealing at 60&#176;C for 30 s, and a dissociation stage ranging from 60&#176;C to 95&#176;C. The relative quantification analysis of the results was expressed as RQ values using the comparative control method (&#8710;&#8710;Ct) (<xref rid="B80" ref-type="bibr">80</xref>).</p></sec><sec id="s3-16"><title>Histological and histochemical techniques</title><p>The HPE was fixed in 10% formaldehyde in 0.1 M phosphate buffer (pH 7.3) for 24 h, dehydrated in alcohol, clarified in xylene, embedded in paraffin, and sectioned at 3 &#181;m. Paraffin histological sections were stained with hematoxylin-eosin for routine histological analysis, Picro Sirius red, and trichromic Masson for collagen histochemistry. Sections for the histological analysis were observed under an optical microscope (Leica DM500) and images were captured with a Leica ICC50 W camera (<xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B91" ref-type="bibr">91</xref>).</p></sec><sec id="s3-17"><title>ADME properties</title><p>The pharmacokinetic properties of the synthesized 6-nitrocoumarin-3-thiosemicarbazone derivatives were evaluated using SwissADME (<ext-link xlink:href="http://www.swissadme.ch" ext-link-type="uri">http://www.swissadme.ch</ext-link>, accessed on February 12, 2025). The analysis included predictions of absorption, distribution, metabolism, and excretion (ADME), as well as an evaluation of drug-likeness based on Lipinski&#8217;s Rule of Five (<xref rid="B56" ref-type="bibr">56</xref>).</p><p>Lipophilicity (logP) was determined using the iLOGP model, which provides a theoretical estimation of the compounds&#8217; permeability across biological membranes. Aqueous solubility was predicted using SwissADME&#8217;s computational algorithms, classifying the compounds as highly soluble, moderately soluble, or poorly soluble. The topological polar surface area (TPSA) was calculated to estimate intestinal absorption and blood-brain barrier (BBB) permeability.</p><p>Metabolic stability was assessed by predicting potential interactions with major cytochrome P450 (CYP) isoforms, including CYP1A2, CYP2C19, CYP2C9, CYP2D6, and CYP3A4, to identify possible metabolic liabilities and drug-drug interactions. In addition, oral bioavailability was evaluated through the bioavailability radar, which provides a graphical representation of key pharmacokinetic parameters.</p><p>Molecular structures were input into SwissADME using the SMILES format, enabling the generation of relevant descriptors for analysis. The computational results were compared with experimental data on lipophilicity (RM values) and antiparasitic activity, allowing for a better understanding of the relationship between physicochemical properties and biological efficacy.</p></sec><sec id="s3-18"><title>Statistics</title><p>Parasites and untreated cells were used as the negative control, corresponding to 100% cell viability. The obtained data were expressed as the mean &#177; standard deviation for each condition and were processed using GraphPad Prism 8 software. For the study of the compound series against parasites and cells, statistical significance was analyzed using a one-way ANOVA test with Dunnett&#8217;s post-test, considering values with <italic toggle="yes">P</italic> &#8804; 0.05 as statistically significant.</p></sec></sec></body><back><ack><title>ACKNOWLEDGMENTS</title><p>This research was funded by Competition for Research Regular Projects, year 2022, LPR22-01 and Agencia Nacional de Investigaci&#243;n y Desarrollo, ANID, project Fondecyt Iniciaci&#243;n N&#176; 11240973 and 11220310, Fondecyt Regular 1230644, Fondecyt Postdoctorado 3230385 and FONDEQUIP EQM230118, project QINV0416-IINV529010300, Pontificia Universidad Cat&#243;lica del Ecuador.</p></ack><sec sec-type="ethics" id="s4-1"><title>ETHICS APPROVAL</title><p>The studies involving humans were approved by Comit&#233; de &#201;tica en Investigaci&#243;n en Seres Humanos, Facultad de Medicina, Universidad de Chile. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.</p></sec><ref-list><title>REFERENCES</title><ref id="B1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Calero-Bernal</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Gennari</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Cano</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Salas-Fajardo</surname><given-names>MY</given-names></string-name>, <string-name name-style="western"><surname>R&#237;os</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>&#193;lvarez-Garc&#237;a</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Ortega-Mora</surname><given-names>LM</given-names></string-name></person-group>. <year>2023</year>. <article-title>Anti-Toxoplasma gondii antibodies in european residents: a systematic review and meta-analysis of studies published between 2000 and 2020</article-title>. <source>Pathogens</source><volume>12</volume>:<elocation-id>1430</elocation-id>. doi:<pub-id pub-id-type="doi">10.3390/pathogens12121430</pub-id><pub-id pub-id-type="pmid">38133313</pub-id><pub-id pub-id-type="pmcid">PMC10745778</pub-id></mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>P&#233;rez-Molina</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Molina</surname><given-names>I</given-names></string-name></person-group>. <year>2018</year>. <article-title>Lancet (London, England)</article-title>. <source>Lancet Publishing Group</source>. doi:<pub-id pub-id-type="doi">10.1016/S0140-6736(17)31612-4</pub-id></mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bonney</surname><given-names>KM</given-names></string-name>, <string-name name-style="western"><surname>Luthringer</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>SA</given-names></string-name>, <string-name name-style="western"><surname>Garg</surname><given-names>NJ</given-names></string-name>, <string-name name-style="western"><surname>Engman</surname><given-names>DM</given-names></string-name></person-group>. <year>2019</year>. <article-title>Pathology and pathogenesis of chagas heart disease</article-title>. <source>Annu Rev Pathol Mech Dis</source><volume>14</volume>:<fpage>421</fpage>&#8211;<lpage>447</lpage>. doi:<pub-id pub-id-type="doi">10.1146/annurev-pathol-020117-043711</pub-id><pub-id pub-id-type="pmcid">PMC7373119</pub-id><pub-id pub-id-type="pmid">30355152</pub-id></mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Flegr</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Prandota</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Sovi&#269;kov&#225;</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Israili</surname><given-names>ZHT</given-names></string-name></person-group>. <year>2014</year>. <article-title>Toxoplasmosis &#8211; a global threat. correlation of latent toxoplasmosis with specific disease burden in a set of 88 countries</article-title>. <source>PLoS ONE</source><volume>9</volume>:<elocation-id>e90203</elocation-id>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0090203</pub-id><pub-id pub-id-type="pmid">24662942</pub-id><pub-id pub-id-type="pmcid">PMC3963851</pub-id></mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Attias</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Teixeira</surname><given-names>DE</given-names></string-name>, <string-name name-style="western"><surname>Benchimol</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Vommaro</surname><given-names>RC</given-names></string-name>, <string-name name-style="western"><surname>Crepaldi</surname><given-names>PH</given-names></string-name>, <string-name name-style="western"><surname>De Souza</surname><given-names>W</given-names></string-name></person-group>. <year>2020</year>. <article-title>The life-cycle of Toxoplasma gondii reviewed using animations</article-title>. <source>Parasit Vectors</source><volume>13</volume>:<elocation-id>588</elocation-id>. doi:<pub-id pub-id-type="doi">10.1186/s13071-020-04445-z</pub-id><pub-id pub-id-type="pmid">33228743</pub-id><pub-id pub-id-type="pmcid">PMC7686686</pub-id></mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Souza</surname><given-names>W</given-names></string-name></person-group>. <year>2002</year>. <article-title>Mammalian placental explants: a tool for studying host-parasite 1265 interactions and placental biology</article-title>. <source>Basic Cell Biology of Trypanosoma Cruzi</source><volume>8</volume>. doi:<pub-id pub-id-type="doi">10.2174/1381612023396276</pub-id></mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rojo</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Castillo</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Duaso</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Liempi</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Droguett</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Galanti</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Maya</surname><given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>L&#243;pez-Mu&#241;oz</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Kemmerling</surname><given-names>U</given-names></string-name></person-group>. <year>2014</year>. <article-title>Toxic and therapeutic effects of Nifurtimox and Benznidazol on Trypanosoma cruzi ex vivo infection of human placental chorionic villi explants</article-title>. <source>Acta Trop</source><volume>132</volume>:<fpage>112</fpage>&#8211;<lpage>118</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.actatropica.2014.01.002</pub-id><pub-id pub-id-type="pmid">24462796</pub-id></mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Castillo</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>D&#237;az-Luj&#225;n</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Liempi</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Fretes</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Kemmerling</surname><given-names>U</given-names></string-name></person-group>. <year>2025</year>. <article-title>Mammalian placental explants: a tool for studying host-parasite interactions and placental biology</article-title>. <source>Placenta</source><volume>166</volume>:<fpage>62</fpage>&#8211;<lpage>70</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.placenta.2024.06.016</pub-id><pub-id pub-id-type="pmid">38910051</pub-id></mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hall</surname><given-names>BS</given-names></string-name>, <string-name name-style="western"><surname>Bot</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Wilkinson</surname><given-names>SR</given-names></string-name></person-group>. <year>2011</year>. <article-title>Nifurtimox activation by trypanosomal type I nitroreductases generates cytotoxic nitrile metabolites</article-title>. <source>J Biol Chem</source><volume>286</volume>:<fpage>13088</fpage>&#8211;<lpage>13095</lpage>. doi:<pub-id pub-id-type="doi">10.1074/jbc.M111.230847</pub-id><pub-id pub-id-type="pmid">21345801</pub-id><pub-id pub-id-type="pmcid">PMC3075655</pub-id></mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>M&#252;ller Kratz</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Garcia Bournissen</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Forsyth</surname><given-names>CJ</given-names></string-name>, <string-name name-style="western"><surname>Sosa-Estani</surname><given-names>S</given-names></string-name></person-group>. <year>2018</year>. <article-title>Clinical and pharmacological profile of benznidazole for treatment of Chagas disease</article-title>. <source>Expert Rev Clin Pharmacol</source><volume>11</volume>:<fpage>943</fpage>&#8211;<lpage>957</lpage>. doi:<pub-id pub-id-type="doi">10.1080/17512433.2018.1509704</pub-id><pub-id pub-id-type="pmid">30111183</pub-id></mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Castro</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>de Mecca</surname><given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>Bartel</surname><given-names>LC</given-names></string-name></person-group>. <year>2006</year>. <article-title>Toxic side effects of drugs used to treat Chagas&#8217; disease (American trypanosomiasis)</article-title>. <source>Hum Exp Toxicol</source><volume>25</volume>:<fpage>471</fpage>&#8211;<lpage>479</lpage>. doi:<pub-id pub-id-type="doi">10.1191/0960327106het653oa</pub-id><pub-id pub-id-type="pmid">16937919</pub-id></mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Buschini</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Ferrarini</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Franzoni</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Galati</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Lazzaretti</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Mussi</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Northfleet de Albuquerque</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Maria Ara&#250;jo Domingues Zucchi</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Poli</surname><given-names>P</given-names></string-name></person-group>. <year>2009</year>. <article-title>Genotoxicity revaluation of three commercial nitroheterocyclic drugs: nifurtimox, benznidazole, and metronidazole</article-title>. <source>J Parasitol Res</source><volume>2009</volume>:<fpage>463575</fpage>. doi:<pub-id pub-id-type="doi">10.1155/2009/463575</pub-id><pub-id pub-id-type="pmid">20981287</pub-id><pub-id pub-id-type="pmcid">PMC2963127</pub-id></mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ben-Harari</surname><given-names>RR</given-names></string-name>, <string-name name-style="western"><surname>Goodwin</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Casoy</surname><given-names>J</given-names></string-name></person-group>. <year>2017</year>. <article-title>Adverse event profile of pyrimethamine-based therapy in toxoplasmosis: a systematic review</article-title>. <source>Drugs R D</source><volume>17</volume>:<fpage>523</fpage>&#8211;<lpage>544</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s40268-017-0206-8</pub-id><pub-id pub-id-type="pmid">28879584</pub-id><pub-id pub-id-type="pmcid">PMC5694419</pub-id></mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Boitel</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Desoubeaux</surname><given-names>G</given-names></string-name></person-group>. <year>2020</year>. <article-title>Antiparasitic treatments in pregnant women: update and recommendations</article-title>. <source>Med Mal Infect</source><volume>50</volume>:<fpage>3</fpage>&#8211;<lpage>15</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.medmal.2018.09.008</pub-id><pub-id pub-id-type="pmid">30361033</pub-id></mixed-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zingales</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Andrade</surname><given-names>SG</given-names></string-name>, <string-name name-style="western"><surname>Briones</surname><given-names>MRS</given-names></string-name>, <string-name name-style="western"><surname>Campbell</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Chiari</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Fernandes</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Guhl</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Lages-Silva</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Macedo</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Machado</surname><given-names>CR</given-names></string-name>, <string-name name-style="western"><surname>Miles</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Romanha</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Sturm</surname><given-names>NR</given-names></string-name>, <string-name name-style="western"><surname>Tibayrenc</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Schijman</surname><given-names>AG</given-names></string-name></person-group>. <year>2009</year>. <article-title>A new consensus for Trypanosoma cruzi intraspecific nomenclature Second revision meeting recommends TcI to TcVI</article-title>. <source>Mem Inst Oswaldo Cruz</source>:<fpage>104</fpage>. doi:<pub-id pub-id-type="doi">10.1590/S0074-02762009000700021</pub-id><pub-id pub-id-type="pmid">20027478</pub-id></mixed-citation></ref><ref id="B16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lima</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Espinosa-&#193;lvarez</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Ortiz</surname><given-names>PA</given-names></string-name>, <string-name name-style="western"><surname>Trejo-Var&#243;n</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Carranza</surname><given-names>JC</given-names></string-name>, <string-name name-style="western"><surname>Pinto</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Serrano</surname><given-names>MG</given-names></string-name>, <string-name name-style="western"><surname>Buck</surname><given-names>GA</given-names></string-name>, <string-name name-style="western"><surname>Camargo</surname><given-names>EP</given-names></string-name>, <string-name name-style="western"><surname>Teixeira</surname><given-names>MMG</given-names></string-name></person-group>. <year>2015</year>. <article-title>Genetic diversity of Trypanosoma cruzi in bats, and multilocus phylogenetic and phylogeographical analyses supporting Tcbat as an independent DTU (discrete typing unit)</article-title>. <source>Acta Trop</source><volume>151</volume>:<fpage>166</fpage>&#8211;<lpage>177</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.actatropica.2015.07.015</pub-id><pub-id pub-id-type="pmid">26200788</pub-id></mixed-citation></ref><ref id="B17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Quebrada Palacio</surname><given-names>LP</given-names></string-name>, <string-name name-style="western"><surname>Gonz&#225;lez</surname><given-names>MN</given-names></string-name>, <string-name name-style="western"><surname>Hernandez-Vasquez</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Perrone</surname><given-names>AE</given-names></string-name>, <string-name name-style="western"><surname>Parodi-Talice</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Bua</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Postan</surname><given-names>M</given-names></string-name></person-group>. <year>2018</year>. <article-title>Phenotypic diversity and drug susceptibility of Trypanosoma cruzi TcV clinical isolates</article-title>. <source>PLoS ONE</source><volume>13</volume>:<elocation-id>e0203462</elocation-id>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0203462</pub-id><pub-id pub-id-type="pmid">30183775</pub-id><pub-id pub-id-type="pmcid">PMC6124804</pub-id></mixed-citation></ref><ref id="B18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>da Silva</surname><given-names>RJ</given-names></string-name>, <string-name name-style="western"><surname>Gomes</surname><given-names>AO</given-names></string-name>, <string-name name-style="western"><surname>Franco</surname><given-names>PS</given-names></string-name>, <string-name name-style="western"><surname>Pereira</surname><given-names>AS</given-names></string-name>, <string-name name-style="western"><surname>Milian</surname><given-names>ICB</given-names></string-name>, <string-name name-style="western"><surname>Ribeiro</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Fiorenzani</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Dos Santos</surname><given-names>MC</given-names></string-name>, <string-name name-style="western"><surname>Mineo</surname><given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>da Silva</surname><given-names>NM</given-names></string-name>, <string-name name-style="western"><surname>Ferro</surname><given-names>EAV</given-names></string-name>, <string-name name-style="western"><surname>de Freitas Barbosa</surname><given-names>B</given-names></string-name></person-group>. <year>2017</year>. <article-title>Enrofloxacin and toltrazuril are able to reduce Toxoplasma gondii growth in human BeWo trophoblastic cells and villous explants from human third trimester pregnancy</article-title>. <source>Front Cell Infect Microbiol</source><volume>7</volume>:<elocation-id>340</elocation-id>. doi:<pub-id pub-id-type="doi">10.3389/fcimb.2017.00340</pub-id><pub-id pub-id-type="pmid">28798905</pub-id><pub-id pub-id-type="pmcid">PMC5526852</pub-id></mixed-citation></ref><ref id="B19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mart&#237;n-Escolano</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Medina-Carmona</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Mart&#237;n-Escolano</surname><given-names>R</given-names></string-name></person-group>. <year>2020</year>. <article-title>Chagas disease: current view of an ancient and global chemotherapy challenge</article-title>. <source>ACS Infect Dis</source><volume>6</volume>:<fpage>2830</fpage>&#8211;<lpage>2843</lpage>. doi:<pub-id pub-id-type="doi">10.1021/acsinfecdis.0c00353</pub-id><pub-id pub-id-type="pmid">33034192</pub-id></mixed-citation></ref><ref id="B20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Carvalho</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Jos&#233;</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Melo</surname><given-names>T</given-names></string-name></person-group>. <year>2018</year>. <article-title>The microbicidal defenses involved in intracellular Toxoplasma gondii, Trypanosoma cruzi and Leishmania amazonensis elimination in the presence of semicarbazones, thiosemicarbazones, and thiazolidinones</article-title>. <source>World Journal of Pharmaceutical Research</source><volume>7</volume>:<fpage>277</fpage>. doi:<pub-id pub-id-type="doi">10.20959/wjpr201818-13610</pub-id></mixed-citation></ref><ref id="B21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ten&#243;rio</surname><given-names>RP</given-names></string-name>, <string-name name-style="western"><surname>Carvalho</surname><given-names>CS</given-names></string-name>, <string-name name-style="western"><surname>Pessanha</surname><given-names>CS</given-names></string-name>, <string-name name-style="western"><surname>de Lima</surname><given-names>JG</given-names></string-name>, <string-name name-style="western"><surname>de Faria</surname><given-names>AR</given-names></string-name>, <string-name name-style="western"><surname>Alves</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>de Melo</surname><given-names>EJT</given-names></string-name>, <string-name name-style="western"><surname>G&#243;es</surname><given-names>AJS</given-names></string-name></person-group>. <year>2005</year>. <article-title>Synthesis of thiosemicarbazone and 4-thiazolidinone derivatives and their in vitro anti-Toxoplasma gondii activity</article-title>. <source>Bioorg Med Chem Lett</source><volume>15</volume>:<fpage>2575</fpage>&#8211;<lpage>2578</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.bmcl.2005.03.048</pub-id><pub-id pub-id-type="pmid">15863319</pub-id></mixed-citation></ref><ref id="B22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cipriani</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Toloza</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Bradford</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Putzu</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Vieites</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Curbelo</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Tomaz</surname><given-names>AI</given-names></string-name>, <string-name name-style="western"><surname>Garat</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Guerrero</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Gancheff</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Maya</surname><given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>Olea Azar</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Gambino</surname><given-names>D</given-names></string-name></person-group>. <year>2014</year>. <article-title>Cruzi activity and mechanism of action of 5-nitrofuryl-containing thiosemicarbazone metal complexes</article-title>. <source>Eur J Inorg Chem</source><volume>27</volume>:<fpage>4677</fpage>&#8211;<lpage>4689</lpage>. doi:<pub-id pub-id-type="doi">10.1002/ejic.201402614</pub-id></mixed-citation></ref><ref id="B23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Semeraro</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Boubaker</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Scaccaglia</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>M&#252;ller</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Vigneswaran</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>H&#228;nggeli</surname><given-names>KPA</given-names></string-name>, <string-name name-style="western"><surname>Amdouni</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Kramer</surname><given-names>LH</given-names></string-name>, <string-name name-style="western"><surname>Vismarra</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Genchi</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Pelosi</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Bisceglie</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Heller</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Uldry</surname><given-names>A-C</given-names></string-name>, <string-name name-style="western"><surname>Braga-Lagache</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Hemphill</surname><given-names>A</given-names></string-name></person-group>. <year>2024</year>. <article-title>Transient adaptation of Toxoplasma gondii to exposure by thiosemicarbazone drugs that target ribosomal proteins is associated with the upregulated expression of tachyzoite transmembrane proteins and transporters</article-title>. <source>Int J Mol Sci</source><volume>25</volume>:<elocation-id>9067</elocation-id>. doi:<pub-id pub-id-type="doi">10.3390/ijms25169067</pub-id><pub-id pub-id-type="pmid">39201756</pub-id><pub-id pub-id-type="pmcid">PMC11354806</pub-id></mixed-citation></ref><ref id="B24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Raghav</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Kaur</surname><given-names>R</given-names></string-name></person-group>. <year>2017</year>. <article-title>A comparative account of sar studies of semicarbazones and thiosemicarbazones on cathepsins H and L</article-title>. <source>Med Chem Res</source><volume>26</volume>:<fpage>1723</fpage>&#8211;<lpage>1734</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00044-017-1826-9</pub-id></mixed-citation></ref><ref id="B25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Larson</surname><given-names>ET</given-names></string-name>, <string-name name-style="western"><surname>Parussini</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Huynh</surname><given-names>MH</given-names></string-name>, <string-name name-style="western"><surname>Giebel</surname><given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>Kelley</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Bogyo</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Merritt</surname><given-names>EA</given-names></string-name>, <string-name name-style="western"><surname>Carruthers</surname><given-names>VB</given-names></string-name></person-group>. <year>2009</year>. <article-title>Toxoplasma gondii cathepsin L is the primary target of the invasion-inhibitory compound morpholinurea-leucyl-homophenyl-vinyl sulfone phenyl</article-title>. <source>J Biol Chem</source><volume>284</volume>:<fpage>26839</fpage>&#8211;<lpage>26850</lpage>. doi:<pub-id pub-id-type="doi">10.1074/jbc.M109.003780</pub-id><pub-id pub-id-type="pmid">19596863</pub-id><pub-id pub-id-type="pmcid">PMC2785372</pub-id></mixed-citation></ref><ref id="B26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ansari</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Montazeri</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Daryani</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Farshadfar</surname><given-names>&#8236;</given-names></string-name>, <string-name name-style="western"><surname>Emami</surname><given-names>S</given-names></string-name></person-group>. <year>2020</year>. <article-title>Synthesis and in vitro anti-Toxoplasma gondii activity of a new series of aryloxyacetophenone thiosemicarbazones</article-title>. <source>Mol Divers</source><volume>24</volume>:<fpage>1223</fpage>&#8211;<lpage>1234</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s11030-019-09986-9</pub-id><pub-id pub-id-type="pmid">31485890</pub-id></mixed-citation></ref><ref id="B27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jasinski</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Salas-Sarduy</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Vega</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Fabian</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Martini</surname><given-names>MF</given-names></string-name>, <string-name name-style="western"><surname>Moglioni</surname><given-names>AG</given-names></string-name></person-group>. <year>2022</year>. <article-title>Thiosemicarbazone derivatives: evaluation as cruzipain inhibitors and molecular modeling study of complexes with cruzain</article-title>. <source>Bioorg Med Chem</source><volume>61</volume>:<fpage>116708</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.bmc.2022.116708</pub-id><pub-id pub-id-type="pmid">35334448</pub-id></mixed-citation></ref><ref id="B28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Aguirre</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Boiani</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Cerecetto</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Fern&#225;ndez</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Gonz&#225;lez</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Denicola</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Otero</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Gambino</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Rigol</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Olea-Azar</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Faundez</surname><given-names>M</given-names></string-name></person-group>. <year>2004</year>. <article-title>In vitro activity and mechanism of action against the protozoan parasite Trypanosoma cruzi of 5-nitrofuryl containing thiosemicarbazones</article-title>. <source>Bioorg Med Chem</source><volume>12</volume>:<fpage>4885</fpage>&#8211;<lpage>4893</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.bmc.2004.07.003</pub-id><pub-id pub-id-type="pmid">15336268</pub-id></mixed-citation></ref><ref id="B29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Vazquez-Rodriguez</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Figueroa-Gu&#237;&#241;ez</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Matos</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Santana</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Uriarte</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Lapier</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Maya</surname><given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>Olea-Azar</surname><given-names>C</given-names></string-name></person-group>. <year>2013</year>. <article-title>Synthesis of coumarin&#8211;chalcone hybrids and evaluation of their antioxidant and trypanocidal properties</article-title>. <source>Med Chem Commun</source><volume>4</volume>:<fpage>993</fpage>. doi:<pub-id pub-id-type="doi">10.1039/c3md00025g</pub-id></mixed-citation></ref><ref id="B30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Vazquez-Rodriguez</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Lama L&#243;pez</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Matos</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Armesto-Quintas</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Serra</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Uriarte</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Santana</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Borges</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Mu&#241;oz Crego</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Santos</surname><given-names>YD</given-names></string-name></person-group>. <year>2015</year>. <article-title>Design, synthesis and antibacterial study of new potent and selective coumarin-chalcone derivatives for the treatment of tenacibaculosis</article-title>. <source>Bioorg Med Chem</source><volume>23</volume>:<fpage>7045</fpage>&#8211;<lpage>7052</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.bmc.2015.09.028</pub-id><pub-id pub-id-type="pmid">26433630</pub-id></mixed-citation></ref><ref id="B31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Borges</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Roleira</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Milhazes</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Santana</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Uriarte</surname><given-names>E</given-names></string-name></person-group>. <year>2005</year>. <article-title>Simple coumarins and analogues in medicinal chemistry: occurrence, synthesis and biological activity</article-title>. <source>Curr Med Chem</source>. doi:<ext-link xlink:href="10.2174/0929867053507315" ext-link-type="doi"> 10.2174/0929867053507315</ext-link><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/0929867053507315</pub-id><pub-id pub-id-type="pmid">15853704</pub-id></mixed-citation></ref><ref id="B32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Salgado</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Moncada-Basualto</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Pozo-Martinez</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Liempi</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Kemmerling</surname><given-names>U</given-names></string-name>, <string-name name-style="western"><surname>Maya</surname><given-names>J-D</given-names></string-name>, <string-name name-style="western"><surname>Jaque</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Borges</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Uriarte</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Matos</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Olea-Azar</surname><given-names>C</given-names></string-name></person-group>. <year>2021</year>. <article-title>Chemical and biological analysis of 4-acyloxy-3-nitrocoumarins as trypanocidal agents</article-title>. <source>Arabian Journal of Chemistry</source><volume>14</volume>:<fpage>102975</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.arabjc.2020.102975</pub-id></mixed-citation></ref><ref id="B33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Robledo-O&#8217;Ryan</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Matos</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Vazquez-Rodriguez</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Santana</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Uriarte</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Moncada-Basualto</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Mura</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Lapier</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Maya</surname><given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>Olea-Azar</surname><given-names>C</given-names></string-name></person-group>. <year>2017</year>. <article-title>Synthesis, antioxidant and antichagasic properties of a selected series of hydroxy-3-arylcoumarins</article-title>. <source>Bioorg Med Chem</source><volume>25</volume>:<fpage>621</fpage>&#8211;<lpage>632</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.bmc.2016.11.033</pub-id><pub-id pub-id-type="pmid">27908757</pub-id></mixed-citation></ref><ref id="B34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>D&#8217;Ascenzio</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Bizzarri</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>De Monte</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Carradori</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Bolasco</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Secci</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Rivanera</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Faulhaber</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Bord&#243;n</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Jones-Brando</surname><given-names>L</given-names></string-name></person-group>. <year>2014</year>. <article-title>Design, synthesis and biological characterization of thiazolidin-4-one derivatives as promising inhibitors of Toxoplasma gondii</article-title>. <source>Eur J Med Chem</source><volume>86</volume>:<fpage>17</fpage>&#8211;<lpage>30</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ejmech.2014.08.046</pub-id><pub-id pub-id-type="pmid">25140751</pub-id></mixed-citation></ref><ref id="B35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chimenti</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Bizzarri</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Bolasco</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Secci</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Chimenti</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Carradori</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Granese</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Rivanera</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Frishberg</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Bord&#243;n</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Jones-Brando</surname><given-names>L</given-names></string-name></person-group>. <year>2009</year>. <article-title>Synthesis and evaluation of 4-acyl-2-thiazolylhydrazone derivatives for anti-Toxoplasma efficacy in vitro</article-title>. <source>J Med Chem</source><volume>52</volume>:<fpage>4574</fpage>&#8211;<lpage>4577</lpage>. doi:<pub-id pub-id-type="doi">10.1021/jm9005862</pub-id><pub-id pub-id-type="pmid">19618935</pub-id></mixed-citation></ref><ref id="B36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Molina</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Ramos</surname><given-names>GA</given-names></string-name>, <string-name name-style="western"><surname>Zamora-V&#233;lez</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Gallego-L&#243;pez</surname><given-names>GM</given-names></string-name>, <string-name name-style="western"><surname>Rocha-Roa</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>G&#243;mez-Marin</surname><given-names>JE</given-names></string-name>, <string-name name-style="western"><surname>Cortes</surname><given-names>E</given-names></string-name></person-group>. <year>2021</year>. <article-title>In vitro evaluation of new 4-thiazolidinones on invasion and growth of Toxoplasma gondii</article-title>. <source>Int J Parasitol Drugs Drug Resist</source><volume>16</volume>:<fpage>129</fpage>&#8211;<lpage>139</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ijpddr.2021.05.004</pub-id><pub-id pub-id-type="pmid">34102589</pub-id><pub-id pub-id-type="pmcid">PMC8187164</pub-id></mixed-citation></ref><ref id="B37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Emami</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Sadeghi</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Shahdin</surname><given-names>S</given-names></string-name></person-group>. <year>2024</year>. <article-title>In vitro evaluation of anti-parasitic activities of quinolone-coumarin hybrids derived from fluoroquinolones and novobiocin against Toxoplasma gondii</article-title>. <source>Acta Parasitol</source><volume>69</volume>:<fpage>1275</fpage>&#8211;<lpage>1283</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s11686-024-00852-9</pub-id><pub-id pub-id-type="pmid">38753101</pub-id></mixed-citation></ref><ref id="B38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sadeghi</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Sarvi</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Emami</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Khalilian</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Hosseini</surname><given-names>SA</given-names></string-name>, <string-name name-style="western"><surname>Montazeri</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Shahdin</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Nayeri</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Daryani</surname><given-names>A</given-names></string-name></person-group>. <year>2022</year>. <article-title>Evaluation of anti-parasitic activities of new quinolones containing nitrofuran moiety against Toxoplasma gondii</article-title>. <source>Exp Parasitol</source><volume>240</volume>:<fpage>108344</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.exppara.2022.108344</pub-id><pub-id pub-id-type="pmid">35931176</pub-id></mixed-citation></ref><ref id="B39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rost&#225;n</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Alvarez</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Veiga</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Otero</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Mahler</surname><given-names>G</given-names></string-name></person-group>. <year>2022</year>. <article-title>New preparation protocols for coumarin-thiosemicarbazone hybrids: solid state characterization, and in silico/NMR studies of the Z/E isomerization equilibria in solution</article-title>. <source>J Mol Struct</source><volume>1251</volume>:<fpage>131980</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.molstruc.2021.131980</pub-id></mixed-citation></ref><ref id="B40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rost&#225;n</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Porto</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Barbosa</surname><given-names>CLN</given-names></string-name>, <string-name name-style="western"><surname>Assis</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Alvarez</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Machado</surname><given-names>FS</given-names></string-name>, <string-name name-style="western"><surname>Mahler</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Otero</surname><given-names>L</given-names></string-name></person-group>. <year>2023</year>. <article-title>A novel palladium complex with a coumarin-thiosemicarbazone hybrid ligand inhibits Trypanosoma cruzi release from host cells and lowers the parasitemia in vivo</article-title>. <source>J Biol Inorg Chem</source><volume>28</volume>:<fpage>711</fpage>&#8211;<lpage>723</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00775-023-02020-2</pub-id><pub-id pub-id-type="pmid">37768364</pub-id></mixed-citation></ref><ref id="B41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rost&#225;n</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Pozo-Mart&#237;nez</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Arcos</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Moncada-Basualto</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Aguilera</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Alvarez</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Olea-Azar</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Mahler</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Otero</surname><given-names>L</given-names></string-name></person-group>. <year>2024</year>. <article-title>Pt(II) and Pd(II) complexes with coumarin-thiosemicarbazone hybrid ligands and triphenylphosphine coligand as potential anti T. cruzi agents</article-title>. <source>J Mol Struct</source><volume>1313</volume>:<fpage>138711</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.molstruc.2024.138711</pub-id></mixed-citation></ref><ref id="B42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Nunes</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Santos-J&#250;nior</surname><given-names>PF da S</given-names></string-name>, <string-name name-style="western"><surname>Gomes</surname><given-names>MC</given-names></string-name>, <string-name name-style="western"><surname>Ferreira</surname><given-names>LAS</given-names></string-name>, <string-name name-style="western"><surname>Padilha</surname><given-names>EKA</given-names></string-name>, <string-name name-style="western"><surname>Teixeira</surname><given-names>TR</given-names></string-name>, <string-name name-style="western"><surname>Stanger</surname><given-names>EJ</given-names></string-name>, <string-name name-style="western"><surname>Kaur</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Silva</surname><given-names>EB da</given-names></string-name>, <string-name name-style="western"><surname>Costa</surname><given-names>CACB</given-names></string-name>, <string-name name-style="western"><surname>Freitas</surname><given-names>JD de</given-names></string-name>, <string-name name-style="western"><surname>Ara&#250;jo-J&#250;nior</surname><given-names>JX de</given-names></string-name>, <string-name name-style="western"><surname>Mendon&#231;a-Junior</surname><given-names>FJB</given-names></string-name>, <string-name name-style="western"><surname>Giardini</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Siqueira-Neto</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Caffrey</surname><given-names>CR</given-names></string-name>, <string-name name-style="western"><surname>Zhan</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Cardoso</surname><given-names>SH</given-names></string-name>, <string-name name-style="western"><surname>Silva-J&#250;nior</surname><given-names>EF da</given-names></string-name></person-group>. <year>2025</year>. <article-title>Nanomolar activity of coumarin-3-thiosemicarbazones targeting Trypanosoma cruzi cruzain and the T. brucei cathepsin L-like protease</article-title>. <source>Eur J Med Chem</source><volume>283</volume>:<fpage>117109</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ejmech.2024.117109</pub-id><pub-id pub-id-type="pmid">39653622</pub-id></mixed-citation></ref><ref id="B43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Moncada-Basualto</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Matsuhiro</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Mansilla</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Lapier</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Maya</surname><given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>Olea-Azar</surname><given-names>C</given-names></string-name></person-group>. <year>2019</year>. <article-title>Supramolecular hydrogels of &#946;-cyclodextrin linked to calcium homopoly-l-guluronate for release of coumarins with trypanocidal activity</article-title>. <source>Carbohydr Polym</source><volume>204</volume>:<fpage>170</fpage>&#8211;<lpage>181</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.carbpol.2018.10.010</pub-id><pub-id pub-id-type="pmid">30366529</pub-id></mixed-citation></ref><ref id="B44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Alvim Jr.</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Dias</surname><given-names>RLA</given-names></string-name>, <string-name name-style="western"><surname>Castilho</surname><given-names>MS</given-names></string-name>, <string-name name-style="western"><surname>Oliva</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Corr&#234;a</surname><given-names>AG</given-names></string-name></person-group>. <year>2005</year>. <article-title>Preparation and evaluation of a coumarin library towards the inhibitory activity of the enzyme GGAPDH from Trypanosoma cruzi</article-title>. <source>J Braz Chem Soc</source><volume>16</volume>:<fpage>763</fpage>&#8211;<lpage>773</lpage>. doi:<pub-id pub-id-type="doi">10.1590/S0103-50532005000500014</pub-id></mixed-citation></ref><ref id="B45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pozo-Mart&#237;nez</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Ar&#225;n</surname><given-names>VJ</given-names></string-name>, <string-name name-style="western"><surname>Z&#250;&#241;iga-Bustos</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Parra-Magna</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Rocha-Valderrama</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Liempi</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Castillo</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Olea-Azar</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Moncada-Basualto</surname><given-names>M</given-names></string-name></person-group>. <year>2024</year>. <article-title>In vitro evaluation of new 5-nitroindazolin-3-one derivatives as promising agents against Trypanosoma cruzi</article-title><source>Int J Mol Sci</source><volume>25</volume>:<fpage>20</fpage>. doi:<pub-id pub-id-type="doi">10.3390/ijms252011107</pub-id><pub-id pub-id-type="pmcid">PMC11508334</pub-id><pub-id pub-id-type="pmid">39456891</pub-id></mixed-citation></ref><ref id="B46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Brawley</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Etter</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Heredia</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Intasiri</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Nennecker</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Welcome</surname><given-names>BM</given-names></string-name>, <string-name name-style="western"><surname>Brizendine</surname><given-names>RK</given-names></string-name>, <string-name name-style="western"><surname>Gould</surname><given-names>TW</given-names></string-name>, <string-name name-style="western"><surname>Bell</surname><given-names>TW</given-names></string-name>, <string-name name-style="western"><surname>Cremo</surname><given-names>C</given-names></string-name></person-group>. <year>2020</year>. <article-title>Synthesis and evaluation of 4-hydroxycoumarin imines as inhibitors of class II myosins</article-title>. <source>J Med Chem</source><volume>63</volume>:<fpage>11131</fpage>&#8211;<lpage>11148</lpage>. doi:<pub-id pub-id-type="doi">10.1021/acs.jmedchem.0c01062</pub-id><pub-id pub-id-type="pmid">32894018</pub-id><pub-id pub-id-type="pmcid">PMC8244571</pub-id></mixed-citation></ref><ref id="B47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bogda&#322;</surname><given-names>D</given-names></string-name></person-group>. <year>1998</year>. <article-title>Coumarins: fast synthesis by knoevenagel condensation under microwave irradiation</article-title>. <source>J Chem Res</source><volume>8</volume>:<fpage>468</fpage>&#8211;<lpage>469</lpage>. doi:<pub-id pub-id-type="doi">10.1039/a801724g</pub-id></mixed-citation></ref><ref id="B48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hu</surname><given-names>X-R</given-names></string-name>, <string-name name-style="western"><surname>He</surname><given-names>J-B</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>Y-W</given-names></string-name>, <string-name name-style="western"><surname>Tian</surname><given-names>J-J</given-names></string-name></person-group>. <year>2011</year>. <article-title>Oxidative spectroelectrochemistry of two representative coumarins</article-title>. <source>Electrochim Acta</source><volume>56</volume>:<fpage>2919</fpage>&#8211;<lpage>2925</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.electacta.2010.12.086</pub-id></mixed-citation></ref><ref id="B49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Olea-Azar</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Cerecetto</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Gerpe</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Gonz&#225;lez</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ar&#225;n</surname><given-names>VJ</given-names></string-name>, <string-name name-style="western"><surname>Rigol</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Opazo</surname><given-names>L</given-names></string-name></person-group>. <year>2006</year>. <article-title>ESR and electrochemical study of 5-nitroindazole derivatives with antiprotozoal activity</article-title>. <source>Spectrochim Acta A Mol Biomol Spectrosc</source>. doi:<pub-id pub-id-type="doi">10.1016/j.saa.2005.04.011</pub-id><pub-id pub-id-type="pmid">16344240</pub-id></mixed-citation></ref><ref id="B50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rigol</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Olea-Azar</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Mendiz&#225;bal</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Otero</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Gambino</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Gonz&#225;lez</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Cerecetto</surname><given-names>H</given-names></string-name></person-group>. <year>2005</year>. <article-title>Electrochemical and ESR study of 5-nitrofuryl-containing thiosemicarbazones antiprotozoal drugs</article-title>. <source>Spectrochim Acta A Mol Biomol Spectrosc</source><volume>61</volume>:<fpage>2933</fpage>&#8211;<lpage>2938</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.saa.2004.11.003</pub-id><pub-id pub-id-type="pmid">16165034</pub-id></mixed-citation></ref><ref id="B51"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Toro</surname><given-names>PM</given-names></string-name>, <string-name name-style="western"><surname>Peralta</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Oyarzo</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wilkinson</surname><given-names>SR</given-names></string-name>, <string-name name-style="western"><surname>Zavala</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Arancibia</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Moncada-Basualto</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Brito</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Cisterna</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Klahn</surname><given-names>AH</given-names></string-name>, <string-name name-style="western"><surname>L&#243;pez</surname><given-names>C</given-names></string-name></person-group>. <year>2021</year>. <article-title>Evaluation of trypanocidal properties of ferrocenyl and cyrhetrenyl N-acylhydrazones with pendant 5-nitrofuryl group</article-title>. <source>J Inorg Biochem</source><volume>219</volume>:<fpage>111428</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jinorgbio.2021.111428</pub-id><pub-id pub-id-type="pmid">33774450</pub-id></mixed-citation></ref><ref id="B52"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cerecetto</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Gonz&#225;lez</surname><given-names>M</given-names></string-name></person-group>. <year>2010</year>. <article-title>Synthetic medicinal chemistry in chagas&#8217; disease: compounds at the final stage of &#8220;hit-to-lead&#8221; phase</article-title>. <source>Pharmaceuticals (Basel)</source><volume>3</volume>:<fpage>810</fpage>&#8211;<lpage>838</lpage>. doi:<pub-id pub-id-type="doi">10.3390/ph3040810</pub-id><pub-id pub-id-type="pmid">27713281</pub-id><pub-id pub-id-type="pmcid">PMC4034012</pub-id></mixed-citation></ref><ref id="B53"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Coimbra</surname><given-names>JTS</given-names></string-name>, <string-name name-style="western"><surname>Feghali</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Ribeiro</surname><given-names>RP</given-names></string-name>, <string-name name-style="western"><surname>Ramos</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Fernandes</surname><given-names>PA</given-names></string-name></person-group>. <year>2020</year>. <article-title>The importance of intramolecular hydrogen bonds on the translocation of the small drug piracetam through a lipid bilayer</article-title>. <source>RSC Adv</source><volume>11</volume>:<fpage>899</fpage>&#8211;<lpage>908</lpage>. doi:<pub-id pub-id-type="doi">10.1039/d0ra09995c</pub-id><pub-id pub-id-type="pmid">35423709</pub-id><pub-id pub-id-type="pmcid">PMC8693363</pub-id></mixed-citation></ref><ref id="B54"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kusumi</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Suzuki</surname><given-names>K</given-names></string-name></person-group>. <year>2005</year>. <article-title>Toward understanding the dynamics of membrane-raft-based molecular interactions</article-title>. <source>Biochimica et Biophysica Acta (BBA) - Molecular Cell Research</source><volume>1746</volume>:<fpage>234</fpage>&#8211;<lpage>251</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.bbamcr.2005.10.001</pub-id><pub-id pub-id-type="pmid">16368465</pub-id></mixed-citation></ref><ref id="B55"><label>55</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Souza</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Attias</surname><given-names>M</given-names></string-name></person-group>. <year>2010</year>. <part-title>Subpellicular microtubules in apicomplexa and trypanosomatids</part-title>, <comment>p</comment><fpage>27</fpage>&#8211;<lpage>62</lpage>. In <person-group person-group-type="editor"><string-name name-style="western"><surname>Souza</surname><given-names>W</given-names></string-name></person-group> (ed), <source>Structures and organelles in pathogenic protists</source>. <publisher-loc>Springer Berlin Heidelberg: Berlin, Heidelberg</publisher-loc>.</mixed-citation></ref><ref id="B56"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Daina</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Michielin</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Zoete</surname><given-names>V</given-names></string-name></person-group>. <year>2017</year>. <article-title>SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules</article-title>. <source>Sci Rep</source><volume>7</volume>:<elocation-id>42717</elocation-id>. doi:<pub-id pub-id-type="doi">10.1038/srep42717</pub-id><pub-id pub-id-type="pmid">28256516</pub-id><pub-id pub-id-type="pmcid">PMC5335600</pub-id></mixed-citation></ref><ref id="B57"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lipinski</surname><given-names>CA</given-names></string-name></person-group>. <year>2004</year>. <article-title>Lead- and drug-like compounds: the rule-of-five revolution</article-title>. <source>Drug Discov Today Technol</source><volume>1</volume>:<fpage>337</fpage>&#8211;<lpage>341</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ddtec.2004.11.007</pub-id><pub-id pub-id-type="pmid">24981612</pub-id></mixed-citation></ref><ref id="B58"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Veber</surname><given-names>DF</given-names></string-name>, <string-name name-style="western"><surname>Johnson</surname><given-names>SR</given-names></string-name>, <string-name name-style="western"><surname>Cheng</surname><given-names>H-Y</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname><given-names>BR</given-names></string-name>, <string-name name-style="western"><surname>Ward</surname><given-names>KW</given-names></string-name>, <string-name name-style="western"><surname>Kopple</surname><given-names>KD</given-names></string-name></person-group>. <year>2002</year>. <article-title>Molecular properties that influence the oral bioavailability of drug candidates</article-title>. <source>J Med Chem</source><volume>45</volume>:<fpage>2615</fpage>&#8211;<lpage>2623</lpage>. doi:<pub-id pub-id-type="doi">10.1021/jm020017n</pub-id><pub-id pub-id-type="pmid">12036371</pub-id></mixed-citation></ref><ref id="B59"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ertl</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Rohde</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Selzer</surname><given-names>P</given-names></string-name></person-group>. <year>2000</year>. <article-title>Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties</article-title>. <source>J Med Chem</source><volume>43</volume>:<fpage>3714</fpage>&#8211;<lpage>3717</lpage>. doi:<pub-id pub-id-type="doi">10.1021/jm000942e</pub-id><pub-id pub-id-type="pmid">11020286</pub-id></mixed-citation></ref><ref id="B60"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Valli</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>D&#246;ring</surname><given-names>TH</given-names></string-name>, <string-name name-style="western"><surname>Marx</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Ferreira</surname><given-names>LLG</given-names></string-name>, <string-name name-style="western"><surname>Medina-Franco</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Andricopulo</surname><given-names>AD</given-names></string-name></person-group>. <year>2024</year>. <article-title>Neglected tropical diseases: a chemoinformatics approach for the use of biodiversity in anti-trypanosomatid drug discovery</article-title>. <source>Biomolecules</source><volume>14</volume>:<elocation-id>1033</elocation-id>. doi:<pub-id pub-id-type="doi">10.3390/biom14081033</pub-id><pub-id pub-id-type="pmid">39199420</pub-id><pub-id pub-id-type="pmcid">PMC11352992</pub-id></mixed-citation></ref><ref id="B61"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Liao</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Du</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Pan</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Yao</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Peng</surname><given-names>Q</given-names></string-name></person-group>. <year>2019</year>. <article-title>Exosomes: the next generation of endogenous nanomaterials for advanced drug delivery and therapy</article-title>. <source>Acta Biomater</source><volume>86</volume>:<fpage>1</fpage>&#8211;<lpage>14</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.actbio.2018.12.045</pub-id><pub-id pub-id-type="pmid">30597259</pub-id></mixed-citation></ref><ref id="B62"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Semeraro</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Boubaker</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Scaccaglia</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>M&#252;ller</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Vigneswaran</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>H&#228;nggeli</surname><given-names>KPA</given-names></string-name>, <string-name name-style="western"><surname>Amdouni</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Kramer</surname><given-names>LH</given-names></string-name>, <string-name name-style="western"><surname>Vismarra</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Genchi</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Pelosi</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Bisceglie</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Heller</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Uldry</surname><given-names>AC</given-names></string-name>, <string-name name-style="western"><surname>Braga-Lagache</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Hemphill</surname><given-names>A</given-names></string-name></person-group>. <year>2024</year>. <article-title>Transient adaptation of Toxoplasma gondii to exposure by thiosemicarbazone drugs that target ribosomal proteins is associated with the upregulated expression of tachyzoite transmembrane proteins and transporters</article-title>. <source>Int J Mol Sci</source><volume>25</volume>:<fpage>16</fpage>. doi:<pub-id pub-id-type="doi">10.3390/ijms25169067</pub-id><pub-id pub-id-type="pmcid">PMC11354806</pub-id><pub-id pub-id-type="pmid">39201756</pub-id></mixed-citation></ref><ref id="B63"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Santos</surname><given-names>VC</given-names></string-name>, <string-name name-style="western"><surname>Leite</surname><given-names>PG</given-names></string-name>, <string-name name-style="western"><surname>Santos</surname><given-names>LH</given-names></string-name>, <string-name name-style="western"><surname>Pascutti</surname><given-names>PG</given-names></string-name>, <string-name name-style="western"><surname>Kolb</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Machado</surname><given-names>FS</given-names></string-name>, <string-name name-style="western"><surname>Ferreira</surname><given-names>RS</given-names></string-name></person-group>. <year>2023</year>. <article-title>Structure-based discovery of novel cruzain inhibitors with distinct trypanocidal activity profiles</article-title>. <source>Eur J Med Chem</source><volume>257</volume>:<fpage>115498</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ejmech.2023.115498</pub-id><pub-id pub-id-type="pmid">37290182</pub-id></mixed-citation></ref><ref id="B64"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gomez</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Coll</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Guarise</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Cifuente</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Masone</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Tello</surname><given-names>PF</given-names></string-name>, <string-name name-style="western"><surname>Pi&#241;eyro</surname><given-names>MD</given-names></string-name>, <string-name name-style="western"><surname>Robello</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Reta</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Sosa</surname><given-names>M&#193;</given-names></string-name>, <string-name name-style="western"><surname>Barrera</surname><given-names>P</given-names></string-name></person-group>. <year>2024</year>. <article-title>New insights into the pro-oxidant mechanism of dehydroleucodine on Trypanosoma cruzi</article-title>. <source>Sci Rep</source><volume>14</volume>:<elocation-id>18875</elocation-id>. doi:<pub-id pub-id-type="doi">10.1038/s41598-024-69201-0</pub-id><pub-id pub-id-type="pmid">39143185</pub-id><pub-id pub-id-type="pmcid">PMC11324952</pub-id></mixed-citation></ref><ref id="B65"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Patterson</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Wyllie</surname><given-names>S</given-names></string-name></person-group>. <year>2014</year>. <article-title>Nitro drugs for the treatment of trypanosomatid diseases: past, present, and future prospects</article-title>. <source>Trends Parasitol</source><volume>30</volume>:<fpage>289</fpage>&#8211;<lpage>298</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.pt.2014.04.003</pub-id><pub-id pub-id-type="pmid">24776300</pub-id><pub-id pub-id-type="pmcid">PMC4045206</pub-id></mixed-citation></ref><ref id="B66"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Paraboni</surname><given-names>MLR</given-names></string-name>, <string-name name-style="western"><surname>Manfredini</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Schreiner</surname><given-names>GE</given-names></string-name>, <string-name name-style="western"><surname>Gon&#231;alves</surname><given-names>IL</given-names></string-name>, <string-name name-style="western"><surname>Silveira</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Commodaro</surname><given-names>AG</given-names></string-name>, <string-name name-style="western"><surname>Belfort Jr</surname><given-names>R</given-names></string-name></person-group>. <year>2022</year>. <article-title>Comparative study of oxidative stress and antioxidative markers in patients infected with Toxoplasma gondii</article-title>. <source>Parasitol Int</source><volume>91</volume>:<fpage>102645</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.parint.2022.102645</pub-id><pub-id pub-id-type="pmid">35977613</pub-id></mixed-citation></ref><ref id="B67"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pozo-Mart&#237;nez</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>V&#225;zquez-Rodr&#237;guez</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Olea-Azar</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Moncada-Basualto</surname><given-names>M</given-names></string-name></person-group>. <year>2022</year>. <article-title>Evaluation of ORAC methodologies in determination of antioxidant capacity of binary combinations of quercetin and 3-(3,4,5-trihydroxybenzoyl) coumarin derivatives</article-title>. <source>Arabian Journal of Chemistry</source><volume>15</volume>:<fpage>104298</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.arabjc.2022.104298</pub-id></mixed-citation></ref><ref id="B68"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pozo-Mart&#237;nez</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Salgado</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Liempi</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Kemmerling</surname><given-names>U</given-names></string-name>, <string-name name-style="western"><surname>Mera-Adasme</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Olea-Azar</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Moncada-Basualto</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Borges</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Uriarte</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Matos</surname><given-names>MJ</given-names></string-name></person-group>. <year>2022</year>. <article-title>Synthesis and study of the trypanocidal activity of catechol-containing 3-arylcoumarins, inclusion in &#946;-cyclodextrin complexes and combination with benznidazole</article-title>. <source>Arabian Journal of Chemistry</source><volume>15</volume>:<fpage>103641</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.arabjc.2021.103641</pub-id></mixed-citation></ref><ref id="B69"><label>69</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Droguett</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Carrillo</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Castillo</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>G&#243;mez</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Negrete</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Liempi</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Mu&#241;oz</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Galanti</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Maya</surname><given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>Kemmerling</surname><given-names>U</given-names></string-name></person-group>. <year>2017</year>. <article-title>Trypanosoma cruzi induces cellular proliferation in the trophoblastic cell line BeWo</article-title>. <source>Exp Parasitol</source><volume>173</volume>:<fpage>9</fpage>&#8211;<lpage>17</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.exppara.2016.12.005</pub-id><pub-id pub-id-type="pmid">27939813</pub-id></mixed-citation></ref><ref id="B70"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Veas</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Rojas-Pirela</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Castillo</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Olea-Azar</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Moncada</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ulloa</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Rojas</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Kemmerling</surname><given-names>U</given-names></string-name></person-group>. <year>2020</year>. <article-title>Microalgae extracts: potential anti-Trypanosoma cruzi agents?</article-title><source>Biomedicine &amp; Pharmacotherapy</source><volume>127</volume>:<fpage>110178</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.biopha.2020.110178</pub-id><pub-id pub-id-type="pmid">32371317</pub-id></mixed-citation></ref><ref id="B71"><label>71</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gabald&#243;n-Figueira</surname><given-names>JC</given-names></string-name>, <string-name name-style="western"><surname>Martinez-Peinado</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Escabia</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Ros-Lucas</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Chatelain</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Scandale</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Gascon</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Pinazo</surname><given-names>M-J</given-names></string-name>, <string-name name-style="western"><surname>Alonso-Padilla</surname><given-names>J</given-names></string-name></person-group>. <year>2023</year>. <article-title>State-of-the-art in the drug discovery pathway for chagas disease: a framework for drug development and target validation</article-title>. <source>Res Rep Trop Med</source><volume>14</volume>:<fpage>1</fpage>&#8211;<lpage>19</lpage>. doi:<pub-id pub-id-type="doi">10.2147/RRTM.S415273</pub-id><pub-id pub-id-type="pmid">37337597</pub-id><pub-id pub-id-type="pmcid">PMC10277022</pub-id></mixed-citation></ref><ref id="B72"><label>72</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Szewczyk-Golec</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Paw&#322;owska</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Weso&#322;owski</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Wr&#243;blewski</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Mila-Kierzenkowska</surname><given-names>C</given-names></string-name></person-group>. <year>2021</year>. <article-title>Oxidative stress as a possible target in the treatment of toxoplasmosis: perspectives and ambiguities</article-title>. <source>Int J Mol Sci</source><volume>22</volume>:<fpage>11</fpage>. doi:<pub-id pub-id-type="doi">10.3390/ijms22115705</pub-id><pub-id pub-id-type="pmcid">PMC8198901</pub-id><pub-id pub-id-type="pmid">34071892</pub-id></mixed-citation></ref><ref id="B73"><label>73</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Aguilera-Venegas</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Olea-Azar</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Ar&#225;n</surname><given-names>VJ</given-names></string-name>, <string-name name-style="western"><surname>Speisky</surname><given-names>H</given-names></string-name></person-group>. <year>2013</year>. <article-title>Indazoles: a new top seed structure in the search of efficient drugs against Trypanosoma cruzi</article-title>. <source>Future Med Chem</source><volume>5</volume>:<fpage>1843</fpage>&#8211;<lpage>1859</lpage>. doi:<pub-id pub-id-type="doi">10.4155/fmc.13.144</pub-id><pub-id pub-id-type="pmid">24144415</pub-id></mixed-citation></ref><ref id="B74"><label>74</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Barriga-Gonz&#225;lez</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Olea-Azar</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Zu&#241;iga-L&#243;pez</surname><given-names>MC</given-names></string-name>, <string-name name-style="western"><surname>Folch-Cano</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Aguilera-Venegas</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Porcal</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Gonz&#225;lez</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Cerecetto</surname><given-names>H</given-names></string-name></person-group>. <year>2015</year>. <article-title>Spin trapping: an essential tool for the study of diseases caused by oxidative stress</article-title>. <source>Curr Top Med Chem</source><volume>15</volume>:<fpage>484</fpage>&#8211;<lpage>495</lpage>. doi:<pub-id pub-id-type="doi">10.2174/1568026615666150206155108</pub-id><pub-id pub-id-type="pmid">25658802</pub-id></mixed-citation></ref><ref id="B75"><label>75</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Moncada-Basualto</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Lapier</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Maya</surname><given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>Matsuhiro</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Olea-Azar</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Delogu</surname><given-names>GL</given-names></string-name>, <string-name name-style="western"><surname>Uriarte</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Santana</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Matose</surname><given-names>MJ</given-names></string-name></person-group>. <year>2018</year>. <article-title>Evaluation of trypanocidal and antioxidant activities of a selected series of 3-amidocoumarins</article-title>. <source>MC</source><volume>14</volume>:<fpage>573</fpage>&#8211;<lpage>584</lpage>. doi:<pub-id pub-id-type="doi">10.2174/1573406414666180419113437</pub-id><pub-id pub-id-type="pmid">29669503</pub-id></mixed-citation></ref><ref id="B76"><label>76</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Machado-Silva</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Cerqueira</surname><given-names>PG</given-names></string-name>, <string-name name-style="western"><surname>Grazielle-Silva</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Gadelha</surname><given-names>FR</given-names></string-name>, <string-name name-style="western"><surname>Peloso</surname><given-names>E de F</given-names></string-name>, <string-name name-style="western"><surname>Teixeira</surname><given-names>SMR</given-names></string-name>, <string-name name-style="western"><surname>Machado</surname><given-names>CR</given-names></string-name></person-group>. <year>2016</year>. <article-title>How Trypanosoma cruzi deals with oxidative stress: antioxidant defence and DNA repair pathways</article-title>. <source>Mutat Res Rev Mutat Res</source><volume>767</volume>:<fpage>8</fpage>&#8211;<lpage>22</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.mrrev.2015.12.003</pub-id><pub-id pub-id-type="pmid">27036062</pub-id></mixed-citation></ref><ref id="B77"><label>77</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Braga</surname><given-names>SFP</given-names></string-name>, <string-name name-style="western"><surname>Santos</surname><given-names>VC</given-names></string-name>, <string-name name-style="western"><surname>Vieira</surname><given-names>RP</given-names></string-name>, <string-name name-style="western"><surname>Silva</surname><given-names>EB da</given-names></string-name>, <string-name name-style="western"><surname>Monti</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Krake</surname><given-names>SH</given-names></string-name>, <string-name name-style="western"><surname>Martinez</surname><given-names>PDG</given-names></string-name>, <string-name name-style="western"><surname>Dias</surname><given-names>LC</given-names></string-name>, <string-name name-style="western"><surname>Caffrey</surname><given-names>CR</given-names></string-name>, <string-name name-style="western"><surname>Siqueira-Neto</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>de Oliveira</surname><given-names>RB</given-names></string-name>, <string-name name-style="western"><surname>Ferreira</surname><given-names>RS</given-names></string-name></person-group>. <year>2022</year>. <article-title>From rational design to serendipity: discovery of novel thiosemicarbazones as potent trypanocidal compounds</article-title>. <source>Eur J Med Chem</source><volume>244</volume>:<fpage>114876</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ejmech.2022.114876</pub-id><pub-id pub-id-type="pmid">36343429</pub-id></mixed-citation></ref><ref id="B78"><label>78</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jasinski</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Salas-Sarduy</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Vega</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Fabian</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Florencia Martini</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Moglioni</surname><given-names>AGD</given-names></string-name></person-group>. <year>2023</year>. <article-title>Design, synthesis and biological evaluation of novel thiosemicarbazones as cruzipain inhibitors</article-title>. <source>Eur J Med Chem</source><volume>254</volume>:<fpage>115345</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ejmech.2023.115345</pub-id><pub-id pub-id-type="pmid">37054562</pub-id></mixed-citation></ref><ref id="B79"><label>79</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Castillo</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Mu&#241;oz</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Carrillo</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Liempi</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Gallardo</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Galanti</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Maya</surname><given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>Kemmerling</surname><given-names>U</given-names></string-name></person-group>. <year>2017</year>. <article-title>Ex vivo infection of human placental chorionic villi explants with Trypanosoma cruzi and Toxoplasma gondii induces different Toll-like receptor expression and cytokine/chemokine profiles</article-title>. <source>Am J Reprod Immunol</source><volume>78</volume>:<elocation-id>e12660</elocation-id>. doi:<pub-id pub-id-type="doi">10.1111/aji.12660</pub-id><pub-id pub-id-type="pmid">28328108</pub-id></mixed-citation></ref><ref id="B80"><label>80</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Duaso</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Rojo</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Cabrera</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Galanti</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Bosco</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Maya</surname><given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>Morello</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Kemmerling</surname><given-names>U</given-names></string-name></person-group>. <year>2010</year>. <article-title>Trypanosoma cruzi induces tissue disorganization and destruction of chorionic villi in an ex vivo infection model of human placenta</article-title>. <source>Placenta</source><volume>31</volume>:<fpage>705</fpage>&#8211;<lpage>711</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.placenta.2010.05.007</pub-id><pub-id pub-id-type="pmid">20541804</pub-id></mixed-citation></ref><ref id="B81"><label>81</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Liempi</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Castillo</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Medina</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Rojas</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Maya</surname><given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>Parraguez</surname><given-names>VH</given-names></string-name>, <string-name name-style="western"><surname>Kemmerling</surname><given-names>U</given-names></string-name></person-group>. <year>2019</year>. <article-title>Ex vivo infection of human placental explants with Trypanosoma cruzi and Toxoplasma gondii: differential activation of NF kappa B signaling pathways</article-title>. <source>Acta Trop</source><volume>199</volume>:<fpage>105153</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.actatropica.2019.105153</pub-id><pub-id pub-id-type="pmid">31469971</pub-id></mixed-citation></ref><ref id="B82"><label>82</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Eisenhauer</surname><given-names>HR</given-names></string-name>, <string-name name-style="western"><surname>Link</surname><given-names>KP</given-names></string-name></person-group>. <year>1953</year>. <article-title>Studies on 4-hydroxycoumarins. XIII. the mechanism for the reaction of 4-hydroxycoumarin with aliphatic acid chlorides 1</article-title> . <source>J Am Chem Soc</source><volume>75</volume>:<fpage>2044</fpage>&#8211;<lpage>2045</lpage>. doi:<pub-id pub-id-type="doi">10.1021/ja01105a006</pub-id></mixed-citation></ref><ref id="B83"><label>83</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pagano</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Demoro</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Toloza</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Boiani</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Gonz&#225;lez</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Cerecetto</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Olea-Azar</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Norambuena</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Gambino</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Otero</surname><given-names>L</given-names></string-name></person-group>. <year>2009</year>. <article-title>Effect of ruthenium complexation on trypanocidal activity of 5-nitrofuryl containing thiosemicarbazones</article-title>. <source>Eur J Med Chem</source><volume>44</volume>:<fpage>4937</fpage>&#8211;<lpage>4943</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ejmech.2009.08.008</pub-id><pub-id pub-id-type="pmid">19783078</pub-id></mixed-citation></ref><ref id="B84"><label>84</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>KhanYusufzai</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Osman</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Khan</surname><given-names>MS</given-names></string-name>, <string-name name-style="western"><surname>Mohamad</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Sulaiman</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Parumasivam</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Gansau</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Johansah</surname><given-names>N</given-names></string-name></person-group>. <year>2017</year>. <article-title>Design, characterization, in vitro antibacterial, antitubercular evaluation and structure&#8211;activity relationships of new hydrazinyl thiazolyl coumarin derivatives</article-title>. <source>Med Chem Res</source><volume>26</volume>:<fpage>1139</fpage>&#8211;<lpage>1148</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00044-017-1820-2</pub-id></mixed-citation></ref><ref id="B85"><label>85</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Liempi</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Castillo</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Cerda</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Droguett</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Duaso</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Barahona</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Hern&#225;ndez</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>D&#237;az-Luj&#225;n</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Fretes</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>H&#228;rtel</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Kemmerling</surname><given-names>U</given-names></string-name></person-group>. <year>2015</year>. <article-title>Trypanosoma cruzi infectivity assessment in &#8220;in vitro&#8221; culture systems by automated cell counting</article-title>. <source>Acta Trop</source><volume>143</volume>:<fpage>47</fpage>&#8211;<lpage>50</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.actatropica.2014.12.006</pub-id><pub-id pub-id-type="pmid">25553972</pub-id></mixed-citation></ref><ref id="B86"><label>86</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Buckner</surname><given-names>FS</given-names></string-name>, <string-name name-style="western"><surname>Verlinde</surname><given-names>CL</given-names></string-name>, <string-name name-style="western"><surname>La Flamme</surname><given-names>AC</given-names></string-name>, <string-name name-style="western"><surname>Van Voorhis</surname><given-names>WC</given-names></string-name></person-group>. <year>1996</year>. <article-title>Efficient technique for screening drugs for activity against Trypanosoma cruzi using parasites expressing beta-galactosidase</article-title>. <source>Antimicrob Agents Chemother</source><volume>40</volume>:<fpage>2592</fpage>&#8211;<lpage>2597</lpage>. doi:<pub-id pub-id-type="doi">10.1128/AAC.40.11.2592</pub-id><pub-id pub-id-type="pmid">8913471</pub-id><pub-id pub-id-type="pmcid">PMC163582</pub-id></mixed-citation></ref><ref id="B87"><label>87</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Liempi</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Castillo</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Medina</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Rojas-Pirela</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Araneda</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Maya</surname><given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>Parraguez</surname><given-names>VH</given-names></string-name>, <string-name name-style="western"><surname>Kemmerling</surname><given-names>U</given-names></string-name></person-group>. <year>2021</year>. <article-title>Ex vivo infection of canine and ovine placental explants with Trypanosoma cruzi and Toxoplasma gondii: differential activation of NF kappa B signaling pathways</article-title>. <source>Acta Trop</source><volume>214</volume>:<fpage>105766</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.actatropica.2020.105766</pub-id><pub-id pub-id-type="pmid">33245906</pub-id></mixed-citation></ref><ref id="B88"><label>88</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rodr&#237;guez-Corrales</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Josan</surname><given-names>JS</given-names></string-name></person-group>. <year>2017</year>. <article-title>Resazurin live cell assay: setup and fine-tuning for reliable cytotoxicity results</article-title>. <source>Methods Mol Biol</source><volume>1647</volume>:<fpage>207</fpage>&#8211;<lpage>219</lpage>. doi:<pub-id pub-id-type="doi">10.1007/978-1-4939-7201-2_14</pub-id><pub-id pub-id-type="pmid">28809005</pub-id></mixed-citation></ref><ref id="B89"><label>89</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rol&#243;n</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Vega</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Escario</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>G&#243;mez-Barrio</surname><given-names>A</given-names></string-name></person-group>. <year>2006</year>. <article-title>Development of resazurin microtiter assay for drug sensibility testing of Trypanosoma cruzi epimastigotes</article-title>. <source>Parasitol Res</source><volume>99</volume>:<fpage>103</fpage>&#8211;<lpage>107</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00436-006-0126-y</pub-id><pub-id pub-id-type="pmid">16506080</pub-id></mixed-citation></ref><ref id="B90"><label>90</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bettiol</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Samanovic</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Murkin</surname><given-names>AS</given-names></string-name>, <string-name name-style="western"><surname>Raper</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Buckner</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Rodriguez</surname><given-names>A</given-names></string-name></person-group>. <year>2009</year>. <article-title>Identification of three classes of heteroaromatic compounds with activity against intracellular Trypanosoma cruzi by chemical library screening</article-title>. <source>PLoS Negl Trop Dis</source><volume>3</volume>:<elocation-id>e384</elocation-id>. doi:<pub-id pub-id-type="doi">10.1371/journal.pntd.0000384</pub-id><pub-id pub-id-type="pmid">19238193</pub-id><pub-id pub-id-type="pmcid">PMC2639639</pub-id></mixed-citation></ref><ref id="B91"><label>91</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fern&#225;ndez-Moya</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Oviedo</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Liempi</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Guerrero-Mu&#241;oz</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Rivas</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Arregui</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Araneda</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Cornet-Gomez</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Maya</surname><given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>M&#252;ller</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Osuna</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Castillo</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Kemmerling</surname><given-names>U</given-names></string-name></person-group>. <year>2024</year>. <article-title>Trypanosoma cruzi-derived exovesicles contribute to parasite infection, tissue damage, and apoptotic cell death during ex vivo infection of human placental explants</article-title>. <source>Front Cell Infect Microbiol</source><volume>14</volume>:<fpage>1437339</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fcimb.2024.1437339</pub-id><pub-id pub-id-type="pmid">39469456</pub-id><pub-id pub-id-type="pmcid">PMC11513395</pub-id></mixed-citation></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>